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ABSTRACT 
 
Effects of Chronic Nicotine Exposure and Lack of High Affinity Nicotinic Receptors on 
Cortico-Hippocampal Areas in the Aging Mouse Brain. (May 2012) 
Pei-San Huang, B.V.M., National Taiwan University, Taiwan 
Co-Chairs of Advisory Committee: Dr. Louise C. Abbott 
                                                                                   Dr. Ursula H. Winzer-Serhan 
 
Nicotine, the major psychoactive ingredient of tobacco smoke, underlies 
numerous effects by activating neuronal nicotinic acetylcholine receptors. Both in vitro 
and in vivo studies suggest that nicotine is neuroprotective and improves cognitive 
performance. Epidemiology studies show that smoking is negatively correlated with the 
incidence of Parkinson’s disease and Alzheimer’s disease. Postmortem research and 
neuroimaging studies show that loss of nicotinic binding sites in the brain is the major 
feature of neurodegenerative diseases related to dementia and cognitive impairment. 
Caloric restriction, a regimen that extends the lifespan in all mammalian species studied 
so far including rodents and primates, is a highly regulated response to food deprivation. 
It is believed that the longevity effect of caloric restriction is mediated by SIRT1, a 
NAD-dependent deacetylase, and its related genes. Nicotine’s effect on body weight 
could also lead to weight loss by decreasing caloric absorption consumption. The goal of 
this study was to find the possible correlation between nicotine’s effects and the 
activation of SIRT1 and its related genes. Using 2-/- mice that lack high affinity 2 
nicotinic acetylcholine receptors (nAChRs), we first demonstrated that 2* nAChRs do 
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not directly regulate expression of survival genes. However, we found that loss of 2* 
nAChRs could result in augmented cellular stress, which indirectly increased expression 
of SIRT1, Nampt, and Ku70, possibly as an adaptive response to provide protection 
against neurodegeneration. We also found that loss of endogenous activation of 2* 
nAChRs had less effect on synaptic connections but strongly impaired survival of 
hippocampal GABAergic neurons. To activate 2* nAChRs in normal mice, we 
administered nicotine through drinking water. In a short-term exposure study, we 
determined the dose of nicotine to be used in young adult mice, and found that chronic 
nicotine treatment was anxiolytic, decreased caloric consumption, increased nAChR 
binding sites, and most importantly, increased expression of SIRT1 and its related genes. 
Finally, we compared long-term nicotine treatment with caloric restriction in middle-
aged mice to examine their effects to brain aging, and our results indicated that in mice 
long term caloric restriction and nicotine treatment both tend to improve memory in 
aging mice, but appear to act through different mechanisms.   
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NOMENCLATURE 
 
A -amyloid 
AD Alzheimer’s disease 
ADHD  Attention-deficit hyperactivity disorder 
ANOVA Analysis of variance 
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MRI Magnetic resonance imaging 
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nAChR Nicotinic acetylcholine receptor 
NAD Nicotinamide adenine dinucleotide 
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NT-3 Neurotrophin-3 
PD Parkinson’s disease 
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PSD95 Postsynaptic density protein 95 
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CHAPTER I 
INTRODUCTION  
 
NICOTINE AND NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS 
Nicotine is the major bioactive ingredient in tobacco leaves where it acts as a 
botanical insecticide (Soloway, 1976; Tomizawa and Casida, 2003). Nicotine is not the 
direct cause of most tobacco related negative health consequences, but it is highly 
addictive (Benowitz, 1999; Balfour, 2002). The addictiveness of nicotine is the reason 
for continued use of tobacco products. On average, about 1.0 to 1.5 mg of nicotine is 
absorbed systemically during smoking one cigarette, and high levels of nicotine reach 
the brain in 10 to 20 seconds, producing rapid behavioral reinforcement through the 
activation of the dopaminergic reward system (Benowitz and Jacob, 1984). There are 
various formulations of nicotine replacement therapy (NRT), such as nicotine gum, 
transdermal patch, nasal spray, inhaler, and sublingual lozenges. Absorption of nicotine 
from these NRTs is slower and the increase in nicotine blood levels more gradual than 
from smoking (Hukkanen et al., 2005). For example, oral nicotine administration is a 
common exposure method in animal experiments, and peak concentrations of nicotine 
are achieved in about 1 hour (Benowitz et al., 1991; Zins et al., 1997). The oral 
bioavailability of nicotine is about 20 to 45% (Benowitz et al., 1991; Compton et al., 
1997; Zins et al., 1997). 
 
____________ 
This dissertation follows the style of Neuroscience. 
 2 
Oral bioavailability of nicotine is incomplete because of hepatic first-pass 
metabolism. The slow delivery of nicotine in NRT also results in a lower brain nicotine 
levels than experienced with smoking, and the gradual rise in levels of nicotine in the 
central nervous system (CNS) allows for development of considerable tolerance to 
pharmacologic effects (Henningfield and Keenan, 1993). After absorption, nicotine 
enters the bloodstream. Based on human autopsy samples taken from smokers, the 
highest affinity for nicotine is in the liver, kidney, spleen, and lung and the lowest 
affinity is found in adipose tissue (Urakawa et al., 1994). Nicotine also binds to brain 
tissues with high affinity, and the receptor binding capacity is increased in smokers 
compared to nonsmokers (Benwell et al., 1988; Breese et al., 1997; Perry et al., 1999).  
The major metabolite of nicotine in mammalian species is cotinine. In humans, 
about 70 to 80% of nicotine is converted to cotinine (Benowitz and Jacob, 1994). 
However, the elimination half-life of cotinine (700-1130 min in human) is much longer 
than nicotine (100-150 min in humans) (Hukkanen et al., 2005). This fact makes blood 
cotinine concentrations fluctuate less throughout the day compared to blood nicotine 
levels, so cotinine is commonly used as a biomarker for nicotine intake (Benowitz, 
1996). The clearance of nicotine is also affected by age. In humans, clearance of nicotine 
is decreased in the elderly (age > 65) compared to young adults (Molander et al., 2001). 
The total nicotine clearance is lower by 23% and renal clearance lower by 49% in the 
elderly compared with young adults. Neonates have diminished nicotine metabolism 
such that the nicotine half-life in newborns is 3 to 4 times longer than observed in adults 
(Dempsey et al., 2000).  
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In the brain, nicotine binds to nicotinic acetylcholine receptors (nAChRs) with 
high affinity. Nicotinic AChRs are ligand-gated pentameric cation channels. They are 
composed of 5 subunits organized around a central pore and are further divided into two 
categories or types: 1) muscle type nAChRs, which are found in vertebrate skeletal 
muscle, where they mediate neuromuscular transmission at the neuromuscular junction 
(NMJ), and 2) neuronal type nAChRs, found mainly throughout the peripheral nervous 
system (PNS) and CNS, but neuronal nAChRs are also found in some non-neuronal 
tissues such as lymphocytes, monocytes, macrophages, dendritic cell, adipocytes, 
keratinocytes, endothelial cells, and epithelial cells of the intestine and lung (Kalamida 
et al., 2007). The embryonic form of muscle type nAChRs are formed by 1, 1, , and 
 subunits, in a ratio of 2:1:1:1, respectively.  In adults, muscle type nAChRs are formed 
by the combination of 1, 1, , and , in a ratio of 2:1:1:1, respectively. Neuronal 
nAChRs have nine identified possible  subunits (2-10) and three possible  subunits 
(2-4), each encoded by a difference gene (Picciotto et al., 2001) (Fig. I-1). The 2, 
3, 4 and 6 subunits form heteromeric receptors with 2, 3 or 4 (Couturier et al., 
1990). The 7, 8, 9, and 10 subunits form homomeric receptors (Le Novere and 
Changeux, 1995) (Fig. I-2). These multiple combinations of nAChRs subunits possess 
distinct pharmacological and physiological properties and show different affinities for 
ligands, as well as variability in the permeability for cations and rate of desensitization 
(Changeux et al., 1998).  The binding site for acetylcholine is located where  subunits 
form junctions with neighboring subunits. Thus more than one molecule of acetylcholine 
could bind simultaneously to one nAChR.  
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Muscular type nAChRs are an important autoantigen involved in myasthenia 
gravis, which is caused by failure of neuromuscular transmission as a result of the 
binding of autoantibodies to muscular nAChRs and leading to defective signaling at the 
NMJ. Myasthenia gravis is therefore characterized by clinical fatigable weakness that 
muscles become weaker during periods of activity, and the muscles that control eye and 
eyelid movement, facial expressions, chewing, talking, and swallowing are especially 
susceptible (Lindstrom, 2000). 
 
 
 
Figure I-1. Acetylcholine receptors can be divided into muscarinic type and nicotinic 
type, which can be further categorized as muscular type and neuronal type. 
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Figure I-2. Homomeric and heteromeric nAChRs subunit composition. 
 
 
Neuronal nAChRs are located in both the CNS and PNS. In the CNS, 42 
heteromeric and 7 homomeric receptors are the most widely distributed. The 4 and 2 
subunits are present in the entire nervous system, and expression of the 7 mRNA is 
robustly expressed in certain layers of the cerebral cortex, hippocampus, hypothalamus, 
and some brain stem nuclei (Wada et al., 1989; Seguela et al., 1993). The 2 subunit is 
expressed at very low levels and only in restricted brain regions such as hippocampus 
(Wada et al., 1989). The 5 subunit is expressed at high levels in the subiculum, pre- 
and parasubiculum, substantia nigra, ventral tegmental area, and weakly expressed in the 
cerebral cortex (Wada et al., 1990). The 3 and 4 subunits are highly expressed in the 
medial habenula and are the main nAChR responsible for acetylcholine transmission in 
autonomic ganglia (Le Novere and Changeux, 1995). The 6 and 3 subunits are 
selectively enriched in catecholaminergic nuclei such as the dopaminergic neurons of the 
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substantia nigra, and the norepinephric neurons of the locus coeruleus (Le Novere and 
Changeux, 1995). The 8 subunit has been found only in the chick nervous system as 
homopentamers or in combination with the 7 subunit, while the 9 subunit is mainly 
expressed in the cochlea and sensory ganglia of the nervous system (Elgoyhen et al., 
1994). Lastly, the 10 subunit appears in the cochlear mechanosensory hair cells 
(Elgoyhen et al., 2001; Plazas et al., 2005). In the PNS, autonomic ganglia express 3 
and 4 at high levels, but they also contain transcript for the 4, 5, 7, and 2 
subunits. These autonomic nAChRs control the activities of the cardiac system, enteric 
movement, urinary tract activities and more (De Biasi, 2002).     
Once the subunits are synthesized, they must assemble into pentameric channels 
and be transported from the endoplasmic reticulum (ER) through the Golgi apparatus 
and then transported to the cell surface. nAChRs that have not been properly assembled 
are targeted to go to the proteasome for degradation (Kalamida et al., 2007). NAChRs 
are found in pre-, peri- and postsynaptic areas (Lena et al., 1993; Wonnacott, 1997) (Fig. 
I-3). Peri- and presynaptic nAChRs act as autoreceptors regulating the release of 
acetylcholine (Tani et al., 1998), serotonin, dopamine, norepinephrine (Summers and 
Giacobini, 1995), glutamate (Gray et al., 1996), and gamma-aminobutyric acid (GABA) 
(Ji and Dani, 2000). Presynaptic nAChRs modulate neurotransmitter release by 
promoting exocytosis either through activation of voltage-gated Ca
2+
 channels (VGCCs) 
or by direct alteration of the intracellular Ca
2+
 concentration (Kalamida et al., 2007). In 
addition to Ca
2+
 dependent exocytosis, nAChRs modulate neurotransmitter release 
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through second messenger pathways as well, which allow nAChRs to exert more subtle 
regulatory actions (Kalamida et al., 2007).  
Postsynaptic nAChRs mediate fast excitatory transmission in the CNS. The 42 
nAChR binds nicotine with a high affinity, while the 7 nAChR binds nicotine with a 
low affinity, but has higher Ca
2+
 permeability than 42 nAChR (Lena and Changeux, 
1998). When ligands bind to nAChRs, the receptor undergoes a conformational change, 
which allows the central channel pore the open. Functionally, the nAChR complex exist 
three conformational states: closed, open, and desensitized. Activation of nAChRs 
occurs when acetylcholine or nicotine binds at the interface between an  and a 
neighboring  or  subunit, causing a conformational change and opening of the channel 
pore. A fundamental property of nAChRs is their susceptibility to desensitization and 
inactivation that follows. In the desensitization state, the channel does not respond to 
further stimulation, being functionally inactivated (Romanelli et al., 2007; Picciotto et 
al., 2008). 
Neuronal nAChRs also regulate intracellular Ca
2+
 concentration primarily from 
direct permeation of the nAChR pore. Ca
2+
 influx causes membrane depolarization and 
subsequent activation of VGCCs or triggers Ca
2+
 release from intracellular stores, 
generating prolonged Ca
2+
 signals (Rathouz and Berg, 1994; Brain et al., 2001; Shoop et 
al., 2001; Dajas-Bailador et al., 2002; Beker et al., 2003). The most Ca
2+
 permeable 
homomeric 7 nAChRs mainly induce Ca2+ currents, which subsequently trigger the 
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Neurotransmitter input 
Neurotransmitter vesicles 
Preterminal neuronal nAChRs 
Presynaptic neuronal nAChRs 
Postsynaptic neuronal nAChRs 
 
Figure I-3. Neuronal nAChRs can be found at perisynaptic, presynaptic and 
postsynaptic areas. 
 
 
release of Ca
2+
 intracellular store (Tsuneki et al., 2000; Sharma and Vijayaraghavan, 
2001; Dajas-Bailador et al., 2002). The 42 nAChRs operate primarily through Ca2+ 
signals coupled with the opening of VGCCs (Tsuneki et al., 2000; Shoop et al., 2001; 
Dajas-Bailador et al., 2002).   
Chronic nicotine exposure (CNE) has been shown to lead to robust nAChR 
upregulation in both human and animal models. In humans, increased high affinity 
nAChR binding has been observed in several CNS regions including the cortex, 
hippocampus and striatum in post-mortem studies as well as in a single-photon emission 
computed tomography imaging study (Benwell et al., 1988; Perry et al., 1999; Staley et 
al., 2006). Animal studies, which also show nAChRs upregulation after CNE, indicate 
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that both 7- and 2-containing nAChRs are up regulated, although 2 containing 
nAChRs appear to be more consistently up regulated, and 2 subunit knockout mice do 
not show upregulation of nicotinic binding sites (Marks et al., 1983; Schwartz and 
Kellar, 1985; McCallum et al., 2006). A maturational enhancer model has been proposed 
to explain the possible mechanism of high affinity nAChRs upregulation after CNE 
proposing that intracellular nAChR precursors are the pharmacological target of 
nicotine. Nicotine binds to the standard nicotinic binding site at the / interface, and in 
addition to that, nicotine also binds to intracellular nAChRs precursors to trigger a key 
step in receptor maturational process in the ER (Corringer et al., 2006).  
 
NEUROPROTECTION PROVIDED BY ACTIVATION OF NACHRS  
It is believed that nicotine exerts its neuroprotective effects mostly through 
neuronal nAChRs, although some effects of nicotine may be independent from binding 
to nAChRs (Picciotto and Zoli, 2008b). Clinically, neuronal nAChRs are associated with 
a wide range of neurological diseases such as Alzheimer’s diseases (AD), schizophrenia, 
attention-deficit hyperactivity disorder (ADHD), Parkinson’s disease (PD), epilepsy, and 
autism. In AD, the cholinergic hypothesis is based on the observation that AD patients 
have pronounced loss of cholinergic function (Terry and Buccafusco, 2003). Studies 
have reported reduced numbers of central nAChRs in aged and AD patients. It has been 
hypothesized that this reduction might be caused by loss of nAChRs located on 
degenerating presynaptic projection neurons (Whitehouse et al., 1986). Activation of 
nAChRs and treatment with nicotinic agonists has been proven to protect neurons from 
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loss in AD and also ameliorate memory and attention deficits in AD patients (Kihara et 
al., 2001; Newhouse et al., 2001). Nicotine has been shown to inhibit the development of 
cellular toxicity induced by -amyloid (A) (Wang et al., 2000). Both 42-amino acid A 
peptide, the predominant form of A in amyloid plaques, and 7 nAChRs are present in 
neuritic plaques, and they colocalize in cortical neurons as detected by 
coimmunoprecipitation (Wang et al., 2000). In addition, there is evidence that smokers 
have a reduced risk of developing AD (Lee, 1994). This observation correlates with the 
fact that, acetylcholinesterase inhibitors have been widely used in AD patients to slow 
their loss of cognition (Kalamida et al., 2007).  
Epidemiological studies show a negative correlation between the incidence of PD 
and smoking (Tanner et al., 2002), and an animal study using monkeys, has 
demonstrated beneficial effects of an 42 nAChRs agonist in this animal model of PD 
(Schneider et al., 1998). Also, acute i.v. administration of nicotine has been shown to 
improve reaction time, speed of processing and reduce tracking errors in PD patients 
(Fratiglioni and Wang, 2000). The incident of smoking in schizophrenic patients (80-
90%) is higher than the general population (25-30%) (de Leon et al., 1995). 
Studies have shown that tobacco use can at least transiently restore cognitive 
deficits of schizophrenic patients, and smoking cessation can exacerbate the disease 
symptoms (Adler et al., 1993). Post-mortem binding study shows decreased numbers of 
hippocampal nAChRs and a higher prevalence of promoter mutations in 7 nAChRs in 
brains of people diagnosed with schizophrenia (Freedman et al., 1995; Leonard et al., 
2002). It has been noted that the incidence of smoking in ADHA patients (40%) also is 
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higher than for the general population (25-30%) (Pomerleau et al., 1995). 42 nAChRs 
activation has been shown to improve attention and reduce memory deficits in rat model 
of ADHD (Ueno et al., 2002). NAChRs agonists improve clinical symptoms and reduce 
hyperactivity and attention deficits in ADHD patients (Wilens et al., 1999; Levin and 
Rezvani, 2000). Significantly reduced numbers of 3 and 42 nAChRs have been 
found in autistic patients, and an increase in 7 subunits has also been observed (Lee et 
al., 2002; Martin-Ruiz et al., 2004). Finally, some forms epilepsy has been associated 
with mutations in the 4 nAChR gene (Steinlein et al., 1995).  
If one examines the literature that goes beyond that which discusses 
neurodegenerative diseases and other neurological disorders, it is noted that many 
additional studies have analyzed the effect of nAChR agonists on cognitive performance 
in a variety of behavioral tests in rats, non-human primates and humans. Nicotine has 
specifically been shown to improve learning and memory in normal humans (Warburton 
et al., 1986). A great amount of information has been published on the specific 
involvement of NAChRs in cognition, including attention, learning, sensory perception, 
memory consolidation and arousal (Levin and Simon, 1998).  Administration of nAChR 
agonists improves cognition in non-human primates and in rodents, and by contrast, 
nAChR antagonists impairs memory function (Levin and Rezvani, 2000; Gould and 
Higgins, 2003; Buccafusco et al., 2005). Working memory and attention tasks are also 
improved by nicotine administration (Gioanni et al., 1999; Levin et al., 2002). 
Epibatidine has been found to induce long-term potentiation, improve memory and 
learning in human and animal models and to also be neuroprotective (Jonnala et al., 
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2002). The nicotinic agonist SIB-1508Y, which is selective for 42 nAChRs, and SIB-
1553A, which is selective for 4 nAChRs, are able to improve cognition and learning in 
a variety of experimental models (Vernier et al., 1999). Nicotinic agonists protect against 
neocortical neuronal loss induced by nucleus magnocellularis lesions in rats and delayed 
hippocampal CA1 subregion neuronal death by ischemia and against septal cholinergic 
neuronal death following fimbrial transaction (Nanri et al., 1998; Martin et al., 2004). 
CNE protects against neurodegeneration of dopaminergic neurons in the 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) and the methamphetamine mouse model of 
PD (Janson et al., 1988; Maggio et al., 1998).  
There also are model systems in which nicotine has shown protective effects in 
vitro, including exposure to cytotoxic insults of glutamate or 6-OHDA (Ryan et al., 
2001). Nicotine rescues PC12 cells from death induced by NGF deprivation (Jonnala et 
al., 2002).  Nicotine has been observed to prevent A toxicity in hippocampal neurons as 
well as cortical neurons (Shimohama and Kihara, 2001; Zamani and Allen, 2001) and it 
appears to specifically inhibit A aggregation by preventing conversion of A from the 
-helix conformation to the -sheet conformation (Salomon et al., 1996). Nicotine 
induces protection of cultured cortical and striatal neurons against cytotoxicity mediated 
by NMDA and AMPA receptor activation and it also protects cultured hippocampal and 
cerebellar neurons against kainic acid induced neurotoxicity (Semba et al., 1996; Kaneko 
et al., 1997).  
Potential mechanisms underlying nicotine mediated neuroprotection are still not 
well defined. Thus far, several directions have been suggested for the possible 
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mechanisms of neuroprotection provided by nAChR activation, and they can be either 
direct or indirect (Picciotto and Zoli, 2008b). With respect to the direct mechanism(s), 
nAChR activation regulates Ca
2+
 entry either by direct entry of Ca
2+
 or depolarization 
leading to opening of VGCCs as mentioned previously. These actions decrease the 
ability of glutamate or other excitotoxic agents to increase Ca
2+
 levels through VGCCs 
or from intracellular stores in the ER. Nicotine can also modulate apoptosis signaling 
pathways by decreasing the levels of pro-apoptotic factors such as caspases, JNK kinase 
or cytochrome c, and increasing the levels of anti-apoptotic factors such as Bcl-2 
(Garrido et al., 2000; Toborek et al., 2000; Garrido et al., 2001; Kihara et al., 2001; 
Onoda et al., 2001; Liu and Zhao, 2004). Nicotine increases the synthesis and release of 
growth factors such as NGF and FGF-2 and increases the levels of their receptors like 
TrkA and TrkB (Maggio et al., 1998; French et al., 1999; Jonnala et al., 2002). 
Indirectly, nicotine regulates neurotransmitter release that in turn, decreases neuronal 
excitability. One such example is nicotine regulation of GABA. 
 
2 KNOCK-OUT MICE 
2 knock-out (2-/-) mice were first generated in 1995 (Picciotto et al., 1995). 
These mutant mice survive, eat and mate normally, and the brains of these animals 
exhibit normal organization and morphology (Lena and Changeux, 1999). The binding 
of nicotine, cytisine and epibatidine is dramatically decreased in most brain regions of 
2-/- mice, while binding of -bungarotoxin, which corresponds to 7-containing 
nAChRs, is not changed in these mutant mice (Orr-Urtreger et al., 1997; Lena and 
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Changeux, 1999). No high-affinity nicotine binding has been observed in any brain 
region. The epibatidine binding activity persists in a few brain regions including the 
habenulo-interpeduncular system, dorsal medulla oblongata, and dorsal cortex of the 
inferior colliculus. This pattern largely overlaps with the pattern of expression of the 4 
subunit and it is thought to correspond to the binding activity of 4-containing nAChRs 
(Zoli et al., 1995; Lena and Changeux, 1999). 2-/- mice have been tested for memory 
retention using a passive avoidance task, which is widely used to measure cognitive 
effects, and 2-/- mice showed marked differences compared to non-mutant siblings; 
wild type mice consistently increased the delay time to enter the dark chamber after 
nicotine administration while 2-/- mice were completely unresponsive to nicotine 
treatment (Picciotto et al., 1995). These data suggest that 2-containing nAChRs are the 
major target of nicotine’s actions in passive avoidance learning. The effects of nicotine 
in the dopaminergic system have also been tested in 2-/- mice. Nicotine significantly 
increased the discharge frequency in the mesencephalic dopaminergic neurons in normal 
mice while this effect disappeared in 2-/- mice, when examined in electrophysiology 
experiments (Picciotto et al., 1998). Microdialysis of the striatum showed that nicotine 
produces a dose-dependent increase in the extracellular dopamine concentration in wild 
type mice but not in 2-/- mice (Picciotto et al., 1998). Increased neurodegeneration 
during aging also has been reported for 2-/- mice. These mutant mice exhibit neural 
tissue atrophy and neuronal loss with accompanying gliosis in the somatosensory cortex 
during aging, and deficits in spatial learning when tested using the Morris water maze 
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(Zoli et al., 1999). Aged 2-/- mice are impaired in both contextual and tone-conditioned 
fear in fear conditioning and latent inhibition tasks, while young 2-/- mice do not differ 
in either tests compared to age-matched wild type mice (Caldarone et al., 2000). 
The olfactory bulb granule cell layer in 2-/- mice displays nearly 50% more 
newborn neurons and significantly fewer apoptotic cells than do wild type mice. 
Conversely, in vivo chronic nicotine exposure significantly decreases the number of 
newborn granule cells in wild type but not 2-/- adult mice in the olfactory bulb, 
confirming that the survival of newborn neurons can be controlled by the activation of 
2-containing nAChRs. However, when investigating the behavioral consequence of an 
increased number of granule cells in 2-/- mice, it has been noted that these animals 
have a less robust short-term olfactory memory than their wild-type counterparts 
(Mechawar et al., 2004). 2-/- mice also display increased vulnerability to excitotoxic 
lesions and decreased positive effects that can be observed from experiencing an 
enriched environment (Zanardi et al., 2007).  
 
HIPPOCAMPUS AND NEOCORTEX ANATOMY 
The hippocampus plays an important role in memory formation. Human imaging 
studies show involvement of the hippocampal region when healthy subjects perform 
memory tasks (Eldridge et al., 2000; Burgess et al., 2002). Patients with confirmed 
hippocampal damage have long been known to suffer from memory deficits (Vargha-
Khadem et al., 1997; Tulving and Markowitsch, 1998; Corkin, 2002; Langston et al., 
2010). The hippocampus is part of the limbic system and is composed of a curved and 
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recurved sheet of cortex that is folded into the medial surface of the temporal lobe. 
Transverse sections reveal that the hippocampus has three distinct zones:  1) the dentate 
gyrus (DG); 2) the hippocampal proper (also called the Ammon’s horn or cornu 
ammonis (CA)); and 3) the subiculum. In each section, the DG and the hippocampal 
proper have the form of two interlocking “C”s. The hippocampal proper is made up of 
three regions: CA1, CA2 and CA3. The subiculum is a transitional zone continuous with 
the hippocampal proper at one of its edges and the cortex of the parahippocampal gyrus 
at the other edge. The hippocampal proper and the DG consist of three layers of neurons, 
that include a superficial molecular layer and a deep polymorphic layer. The middle 
layer consists of the granular cell layer in the DG and the pyramidal cell layer in the 
hippocampal proper. The subiculum, as a transition zone, changes gradually from the 
three layers of neurons seen in the hippocampus proper to the six layers of neurons that 
are characteristic of the neocortex.  
The entire hippocampus receives inputs from the entorhinal cortex (EC) and 
outputs via the subiculum and fimbria/fornix. The EC receives projections from the 
cingulate gyrus, orbital cortex, amygdala, olfactory cortex, and other areas of the 
temporal lobe, such that almost all types of sensory information have access to the 
hippocampus (Nolte, 2002). The fornix is a prominent output pathway of the 
hippocampus, through which fibers reach an assortment of anteriorly situated forebrain 
structures. In addition, many fibers pass directly from the subiculum to the EC and 
amygdala, or backward along the cingulate gyrus (Nolte, 2002). Within the 
hippocampus, there are at least two routes of information flow (Langston et al., 2010). 
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The first is the indirect pathway (trisynaptic circuit) in which information primarily from 
layer II of the EC is projected to the DG, then to CA3 via the mossy fiber pathway, and 
finally reaching CA1 via the Schaffer collateral connections. The second pathway is the 
direct pathway – a monosynaptic connection between EC layer III and CA1 (Witter et 
al., 1989; Langston et al., 2010).  
The cerebral cortex that is visible on the surface of the brain is called the 
neocortex, and pyramidal cells are the most numerous neocortical neurons. These 
neurons have a conical cell body from which a series of spine-studded dendrites emerge 
including a long apical dendrite that leaves the top of each cell and ascends vertically 
toward the cortical surface. Neocortical pyramidal neurons also exhibit a series of basal 
dendrites that emerge closer to the base of the cell and spread out horizontally. 
Neocortical pyramidal cells range in size from 10 m in diameter up to 70 to 100 m. 
Most neocortical pyramidal cells have long axons that leave the cortex to reach either 
other cortical areas or various subcortical sites, where they make excitatory synapses. 
The dendritic spines of pyramidal cells are sites of synaptic contact. Cells of neocortex 
are arranged is a series of six layers. Most superficial is a cell-poor molecular layer 
(layer I), and the deepest is the polymorphic layer (layer VI).  In between these two are 
the external granular layer (layer II), external pyramidal layer (layer III), internal 
granular layer (layer IV), and internal pyramidal layer (layer V) from outside to inside, 
and they are all variously populated by small (granular) cells or large pyramidal cells. 
The six neocortical cell layers are not equally prominent throughout the neocortex 
(Nolte, 2002).  
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NORMAL AGING BRAIN 
As the normal brain ages it changes structurally and functionally. Functionally, 
deficits in memory that are un-related to any specific neuropathology are associated with 
age (Lister and Barnes, 2009). Aged rats and mice demonstrate impairments in spatial 
memory testing by the Morris water maze and the Barnes circular platform task despite 
the continued presence of normal visual perception and motivation (Barnes, 1979; Rapp 
et al., 1987; Bach et al., 1999). Consistent with rodent studies, spatial memory deficits 
are also seen in aged humans when they experience an analog of the Morris water maze 
(Lister and Barnes, 2009). Structurally, the aging brain declines in volume with the 
frontal cortex more severely affected compared to the temporal, parietal and occipital 
cortices (Haug, 1983; Haug and Eggers, 1991). Longitudinal studies using structural 
magnetic resonance imaging (MRI) in humans from age 3 to 70 years  show an increase 
in cortical gray matter volume until age 5 followed by a gradual decline in volume until 
age 70 (Pfefferbaum et al., 1994). Several other studies also have indicated significant 
gray matter tissue volume loss with age (Blatter et al., 1995; Thompson et al., 2003; 
Sullivan et al., 2004), while still other studies have shown greater white matter loss in 
aging (Guttmann et al., 1998; Jernigan et al., 2001). Studies using diffusion tensor 
imaging have shown that age-related changes in white matter are greatest in the anterior 
regions, and it has been suggested that the myelinated fibers in this region are more 
susceptible to breakdown (Bartzokis, 2004; Head et al., 2004). Volume-based imaging 
studies also show that age-related decline in gray matter is also greatest in frontal 
regions (Raz et al., 1997).  
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The hippocampus, which is involved in memory processes as previously 
mentioned, also shows structural changes in normal aging.  Studies have reported that 
hippocampal atrophy and volume loss is associated with memory loss in the normal 
aging brain, although the degree and importance of specific neuronal loss in the 
hippocampus has been debated (Morrison and Hof, 1997; Raz et al., 1998; Raz et al., 
2005; Persson et al., 2006; Head et al., 2008). In the DG of hippocampus, quantification 
of synapse number using stereological methods has revealed reductions of about 24% of 
axospinous synapses in the dentate gyrus molecular layer of aged  rats compared with 
young rats (Geinisman et al., 1992). Compared to the hippocampus, the surrounding 
entorhinal cortex, which is consistently targeted by early AD pathology, remains 
relatively unaffected during the normal aging process (Raz, 2005).  
In general, brain volume changes are not linear across the life span; brain 
volumes decline minimally in younger adults and the loss of volume accelerates with age 
(Raz et al., 2005). Another measure of brain atrophy is ventricular expansion, which 
occurs at an annual rate of 0.43% in young adults, but increases to an annual rate of 
4.25% after the age of 70 (Raz, 2005). Normal aging brains also exhibit decreases in 
resting blood flow, the metabolic rate of oxygen consumption, and vascular reactivity of 
cerebral vessels to various chemical modulators (Gazzaley and D'Esposito, 2005). A 
study using MRI in rhesus monkeys reveals a significant inverse correlation between 
cerebral blood volume and age, and a significant correlation between cerebral blood 
volume and performance on the delayed non-matching to sample task, which is a 
hippocampal dependent task of memory function (Small et al., 2004).  In this study DG 
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showed the most changes compared to the CA1 of the hippocampus, the subiculum, and 
the entorhinal cortex (Small et al., 2004).  Another cellular compartment analysis of 
temporal activity using fluorescent in situ hybridization (catFISH) study also showed a 
significant age-related reduction in the percentage of Arc-positive cells, that was 
restricted to the DG but not CA1 or CA3 of the hippocampus (Small et al., 2004). Arc is 
an immediate early gene whose expression is induced following behavioral relevant 
neural activity (Small et al., 2004).  
Several hypotheses have been proposed for the mechanism of normal brain aging 
(Drag and Bieliauskas, 2010). The dopamine hypothesis of aging posits that age-related 
dysregulation in the dopamine system mediates the cognitive deficits associated with 
normal aging (Backman et al., 2006). In support of this hypothesis, several studies have 
demonstrated that dopamine markers can be used as predictors of cognitive performance 
in normal aging (Volkow et al., 1998; Backman et al., 2000; Erixon-Lindroth et al., 
2005; Cropley et al., 2006). There also is evidence suggesting that normal aging is 
accompanied by dopamine dysregulation in multiple areas including the striatum and 
frontal cortex (Suhara et al., 1991; Mozley et al., 2001; Reeves et al., 2002; van Dyck et 
al., 2002; Stark and Pakkenberg, 2004) and fluctuations in dopamine levels can 
significantly affect cognition (Luciana et al., 1998). Anatomically, the frontal lobes are 
especially sensitive to the aging process and the declines in frontal lobe functional 
efficiency can account for many of the cognitive deficits associated with cognitive aging, 
such as executive function, language, and memory (West, 1996; Raz et al., 1997).  
Another possible explanation for normal brain aging comes from the speed of processing 
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hypothesis, which suggests that age-related cognitive decline can be accounted for 
through a decrease in the speed to process information (Salthouse, 1996).  Finally, the 
inhibitory control hypothesis proposes that decreases in the ability to inhibit or suppress 
task-irrelevant stimuli, which is also is especially relevant to frontal lobe function, can 
explain age-related changes in cognitive function (Hasher and Zachs, 1988). 
 
CALORIC RESTRICTION AND SIRT1 
Epidemiology studies have reported an inverse relationship between caloric 
intake and risk of AD and PD (Luchsinger et al., 2002; Mattson et al., 2002; Mattson, 
2003). These findings fit well within the context of the beneficial effects of the caloric 
restriction (CR) paradigm, one of the most robust in gerontology (Weindruch and Sohal, 
1997; Masoro, 2005; Piper and Bartke, 2008). As demonstrated using numerous animal 
models, CR has proven to be the most effective means to significantly delay or slow 
brain aging. Reducing intake of a caloric consumption by 20-50% can increase lifespan, 
reduce incidence and slow onset of chronic disease, enhance stress protection, and 
maintain youthful behavioral function (Weindruch and Sohal, 1997; Masoro, 2005; Piper 
and Bartke, 2008). Recent studies in mouse models of AD confirm that restricting 
caloric intake by 30 to 40% from normal levels can markedly slow pathogenesis of the 
disease (Qin et al., 2006b; Halagappa et al., 2007). Short-term CR substantially 
decreases the accumulation of A plaques and gliosis marked by astrocytic activation in 
two AD mouse models (Patel et al., 2005). A CR dietary regimen prevents A peptide 
generation and neuritic plaque deposition in the brain of Tg2576 mice, which are a 
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mouse model of AD (Wang et al., 2005). A deposition in monkeys on a CR regimen is 
also reduced (Qin et al., 2006a). Similarly, long-term studies of monkeys conducted at 
the National Institute on Aging and the University of Wisconsin have produced data 
indicating that 30% CR animals are healthier than fully fed counterparts based on 
reduced incidence of various diseases, exhibition of better indices of predisposition to 
disease, and slower rates of aging based on analysis of several biomarkers (Ramsey et 
al., 2000; Roth et al., 2004; Mattison et al., 2007; Raman et al., 2007). CR monkeys in 
these studies exhibited relative preservation of volume in the mid-cingulate cortex, 
lateral temporal cortex bilaterally, and the right dorsolateral frontal cortex as well as 
various subcortical regions, when grey matter volume measured in vivo by MRI.  In 
contrast, grey matter volume generally declined in the frontal and temporal cortex during 
the third decade of the life of non CR monkeys (Colman et al., 2009). Diffusion tensor 
imaging shows preservation of white matter in CR monkeys in the fronto-occipital 
fasciculus, superior longitudinal fasciculus, external capsule, and brainstem (Bendlin et 
al., 2011). In addition, while both CR and control monkeys showed iron deposition in 
the globus pallidus and substantia nigra, the CR animals had significantly less iron in 
these regions and they also exhibited less iron deposition in the red nucleus and parietal, 
temporal, and perirhinal cortices (Kastman et al., 2010). A recent report also indicates a 
significant increase in survival in CR monkeys as well as attenuation of age-related 
declines in brain volume in selected regions (Colman et al., 2009). Formal clinical 
studies of CR lasting only 6 months in duration have also documented positive impact 
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on many indices of health and risk factors for chronic disease in human (Civitarese et al., 
2007).  
However, it is evident that such a stringent regimen would be problematic in the 
human population due to difficulties with compliance, as well as other quality of life 
issues impacted by CR in humans (McCaffree, 2004; Dirks and Leeuwenburgh, 2006). 
This has increased the attention of the development of CR mimetic substances, which 
are compounds that can mimic CR by targeting metabolic and stress response pathways 
affected by CR, but without restricting caloric intake.  One such compound is 
resveratrol, a SIRT1 activator (Howitz et al., 2003; Hursting et al., 2003; Ingram et al., 
2004; Chen and Guarente, 2007).  
SIRT1 has actions similar to that of CR. SIRT1 is the mammalian homolog of the 
yeast silent information regulator2 (Sir2) gene (Tang and Chua, 2008). This class of 
genes called sirtuins is nicotinamide adenine dinucleotide (NAD)-dependent histone 
deacetylase that regulate a variety of stress responses, including CR (Guarente, 2007; 
Michan and Sinclair, 2007; Lavu et al., 2008). Observations of a link between the Sir 
complex and the length of the yeast replicative lifespan (i.e., the number of generations 
the yeast can bud) was made more than ten years ago (Tang and Chua, 2008). Over-
expression of Sir2 increases the replicative lifespan of yeast, as well as increases 
longevity in invertebrate animal models, including the nematode, C. elegans 
(Tissenbaum and Guarente, 2001), and in the fruit fly, Drosophila melanogaster (Rogina 
and Helfand, 2004). Studies have demonstrated that increased longevity induced by CR 
in yeast requires activation of Sir2, by NAD, and that disabling or knocking out Sir2 
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eliminated the lifespan extension induced by CR (Guarente, 2007; Michan and Sinclair, 
2007; Lavu et al., 2008). Results from a variety of recent rodent studies show that 
resveratrol, the SIRT1 activator, can also produce a remarkable range of beneficial 
effects including protection against adverse effects of high fat diets, neurodegeneration 
and age-related pathologies, such as decreased cardiac function and the incidence of 
cataracts (Baur and Sinclair, 2006; Fukuda et al., 2006; Kim et al., 2007b; Lu et al., 
2008; Pearson et al., 2008). In the mouse embryo, SIRT1 is expressed at high levels in 
the heart, brain, spinal cord, and dorsal root ganglia (Sakamoto et al., 2004). High SIRT1 
levels in the embryonic brain suggest that it might have a role in neuronal and brain 
development. In SIRT1 knock-out mice, postnatal survival is infrequent and 
developmental defects such as exencephaly and retinal anomalies have been observed 
(Cheng et al., 2003; McBurney et al., 2003). If SIRT1 promotes survival and stress 
tolerance in mammalian cells in general, it is likely to do so for CNS neurons as well.  It 
has been noted that SIRT1 activation protects mouse neurons against the cytotoxicity of 
the mutant polyglutamine protein huntingtin (Parker et al., 2005). Over-expression of 
SIRT1 and resveratrol treatment also markedly reduced A deposition and had other 
more general neuroprotective effects (Chen et al., 2005a).  
Mammalian SIRT1 interacts with and regulates not only histone proteins but also 
interacts with various other substrates. Acetylation of lysine residues in the C-terminal 
regulatory domain of p53, the tumor suppressor, enhances the sequence-specific binding 
of p53, and SIRT1 deacetylation of p53 represses its transcriptional activity (Luo et al., 
2001; Vaziri et al., 2001). SIRT1 repressed p53-dependent apoptosis in response to DNA 
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damage and oxidative stress and promotes cell survival under cellular stress induced by 
etoposide treatment or irradiation (Luo et al., 2001; Vaziri et al., 2001).  
Mammalian forkhead (FOXO) transcription factors consist of FOXO1, 3, 4, and 
6. FOXOs have been implicated in regulating metabolism, cell-cycle progression, stress 
tolerance, repair of DNA damage and apoptosis (Accili and Arden, 2004). In mammals, 
SIRT1 deacetylates FOXO3, and shows a dual effect on FOXO3’s function of inducing 
cell death (Brunet et al., 2004). Ku70 another substrate of SIRT1, has also been shown to 
attenuate apoptosis (Sawada et al., 2003; Cohen et al., 2004a). In most cells, Ku, which 
is an heterodimer of two tightly associated subunits called Ku70 and Ku80, is an 
abundant protein located in the nucleus, where it plays a key role in the non-homologous 
end joining process, which is responsible for repairing a major fraction of DNA double 
strand breakages (Jackson, 2002). SIRT1 promotes DNA repair activity and deacetylate 
Ku70, causing it to sequester the proapoptotic factor Bax away from mitochondria, 
thereby inhibiting stress-induced apoptotic cell death (Cohen et al., 2004b; Jeong et al., 
2007). While SIRT1 functions as a key mediator to multiple cellular stresses, 
nicotinamide phosphoribo-syltransferase (Nampt) - mediated NAD biosynthesis 
functions as a pace maker that regulates circadian oscillatory NAD production and fine-
tunes SIRT1 activity at the systemic level (Garten et al., 2009; Imai, 2009; Haigis and 
Sinclair, 2010; Imai, 2010; Imai and Guarente, 2010), because sirtuins require NAD for 
their enzymatic activities. Recent studies have demonstrated the tight functional 
connection between Nampt-mediated NAD biosynthesis and SIRT1 in a number of 
different cell types (Garten et al., 2009; Imai, 2010).  
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OBJECTIVE OF THIS DISSERTATION 
Nicotine and nAChR agonists share many similar effects with CR and SIRT1 
activation. First, they both regulate metabolism by decreasing caloric consumption and 
body weight. Nicotine decreases appetite and increases energy expenditure, which 
results in the fact that cigarette smokers tend to have lower body weights compared to 
non-smokers. Second, they both show well-demonstrated neuroprotective effects in vitro 
and in vivo. Nicotine is proposed to exert its neuroprotective functions by anti-apoptosis, 
calcium regulation, and growth factor mediation. However, there could still be unknown 
pathways through which nicotine could act that are correlated with CR or SIRT1 
activation. Third, both nicotine and CR prevent -amyloid plaque accumulation by 
regulating the amyloid precursor protein (APP) processing. The goal of this study was 
to find a possible correlation between nicotine’s effects and activation of SIRT1 and 
other SIRT1-related genes (SIRT1’s substrates such as p53, Ku70, FoxO, and its 
upstream regulator, Nampt). Because nicotine can be neurotoxic under certain 
circumstances (depending on the dose, duration and time of exposure), it is important to 
elucidate the mechanisms underlying nicotine’s neuroprotective effects for better 
potential therapies against neurodegenerative diseases. On the other hand, although 
SIRT1 mediated neuroprotection and anti-degeneration effects can be achieved by the 
natural activator, resveratrol, and the non-invasive regimen of CR, there are still 
limitations to the use of resveratrol and CR. For example, the bioavailability of 
resveratrol is very low, and resveratrol cannot pass through the blood-brain-barrier to 
exert its actions directly in the brain. CR is a time consuming process and can only work 
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to preventive adverse changes but it does not reverse deficits that have already occurred. 
No research has been done previously to investigate the possible link between nicotine 
and SIRT1 functions. The central hypothesis of this dissertation is that chronic 
activation of high affinity nicotinic receptors protects the brain from adverse effects 
of aging through mechanisms that are similar to those that act in caloric restriction.  
We evaluated this hypothesis by investigating four specific aims: 
1) Examine the effect of loss of high affinity nicotinic receptors using the 2-/- 
mouse, on cortico-hippocampal regions on anatomical changes in aging mouse brain, 
and determine CR-related longevity gene expression. , The 2-/- mouse has been 
proposed to be a neurodegenerative model, because these mice exhibit an accelerated 
aging phenotype. The objective of this aim was to confirm the aging phenotype in our 
2-/- mice in middle age male mice, and to determine whether lack of endogenous 
receptor activation changes expression of genes that are correlated with CR-induced 
longevity.  
2) Evaluate the effect of loss of high affinity nicotinic receptors on cortico- 
hippocampal regions on neuronal plasticity and interneuron population in aged 2-/- and 
control mouse brains. 2-/- mice lack high-affinity nAChRs and exhibit deficits in 
spatial learning and memory, and increased neurodegeneration during ageing including 
decreased cortical thickness, decreased hippocampal volume, and increased neuronal 
densities. These anatomical alterations could result from decreased connectivity due to 
loss of synapses and decreased dendritic arborizations, or result from overt neuronal loss. 
Synaptic loss has been found in the brains of both mouse models of and human patients 
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with several neurodegenerative diseases. 2-/- mice have a tendency to exhibit decreased 
basal dendrite size and decreased process complexity in almost all cortical areas, and 2-
containing nAChRs might be involved in dendritic morphogenesis.  
Loss of GABAergic neuron occurs at a late stage of AD. Chronic dosing with 
nicotine in rats has been shown to increase the number of GABAergic neuron in the 
hippocampal area (unpublished data). Thus, loss of high affinity nicotinic receptor could 
result in decreased numbers of GABAergic interneurons. The objective of this specific 
aim was to determine whether loss of high affinity nicotinic receptor changes neuronal 
plasticity or the GABAergic neuronal population.  
3) Assess the effect of short-term high affinity nicotinic receptor activation 
through nicotine exposure on memory and CR-related longevity gene expression in the 
brain of young adult mice. Nicotine has high affinity for 2-containing nAChRs 
(Zanardi et al., 2002) and nicotine is more accessible than other receptor-specific 
agonists, so we used nicotine as the agonist for 2-containing nAChRs. This specific aim 
not only tested the memory improving effect of nicotine, it also assessed the responses of 
longevity gene expression in the brain to different doses of nicotine in young adult mice 
in a short period of time. 
4) Determine the effect of long-term high affinity nicotinic receptor activation by 
nicotine exposure on memory and CR-related longevity gene expression in the aging 
mouse brain as compared to the effects of caloric restriction. The objective of this fourth 
specific aim was to test whether long-term nicotine exposure or nicotinic receptor 
activation reduced or slowed memory and cognitive decline of aging brains as has been 
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observed with CR, and determine whether any improvement was correlated with 
activation of CR-related longevity genes. The effect of long-term nicotine exposure (4 
months) was determined for rodents for the first time in this study. Although chronic 
(but not long-term) nicotine administration has been proved in rats to be neuroprotective 
and improve memory and cognitive function, it was unknown whether such long term 
exposure sustains or reverses the previously observed effects. It was also crucial to 
compare the effects of long-term nicotine administration with caloric restriction, because 
we hypothesized that they share similar mechanisms. We also tested the neuroprotective 
effect of caloric restriction and nicotine exposure on the normal aging brain to evaluate 
whether any benefits that were observed also could be applied to normal physiological 
aging or were benefits only restricted to pathological conditions. 
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CHAPTER II 
REGULATED EXPRESSION OF NEURONAL SIRT1 AND RELATED GENES 
BY AGING AND NEURONAL 2-CONTAINING NICOTINIC CHOLINERGIC 
RECEPTORS†  
 
SUMMARY 
Longevity genes attenuate the aging process, but their expression in the brain 
during aging remains unknown. Loss of the majority of heteromeric brain nicotinic 
acetylcholine receptors (nAChRs) results in premature brain aging, and altered 
regulation of longevity genes could be involved. Using in situ hybridization, the 
expression of SIRT1, Ku70, Nampt, p53, FoxO3, and UCP5 was determined in 
neocortex and hippocampus of young adult 3-month and middle-aged 18-month-old 
wild-type (WT), and age-matched mice lacking 2-containing (2*) heteromeric 
nAChRs (2-/-). Age-related structural changes were detected in WT mice. In particular, 
cortical thickness was decreased but neuronal density increased, and hippocampal 
volume increased with age. In contrast, young 2-/- mice exhibited increased cortical 
neuronal density, and with age, cortical thickness decreased more dramatically, and 
hippocampal volume did not increase. Thus, young 2-/- mice exhibited cortical signs of 
aging, and aging was accelerated at 18 months. 
____________ 
†Reprinted with permission from “Regulated expression of neuronal SIRT1 and related 
genes by aging and neuronal 2-containing cholinergic receptors” by Huang PS, Son JH, 
Abbott LC, and Winzer-Serhan UH (2011) Neuroscience 196:189-202, Copyright 2011 
by Elsevier Ltd. 
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The longevity genes probed exhibited similar expression patterns in frontal brain 
structures, with strong expression in hippocampus, medial habenula (MHb) and cortex. 
In WT mice, age significantly decreased expression of all genes except SIRT1 in cortical 
structures, and a similar pattern was detected in the MHb. Genotype had no effect on 
expression in young adults in either cortex or MHb, but increased mRNA expression of 
SIRT1, Nampt, and Ku70 was detected in cortex, hippocampus and MHb of aged 2-/- 
mice compared to WT mice. This is the first study to determine age-related expression of 
survival genes in forebrain areas. Although, structural changes indicative of accelerated 
aging are evident in young 2-/- mice, the data suggest that nAChRs do not directly 
regulate expression of survival genes. However, loss of 2* nAChRs could result in 
augmented cellular stress which indirectly increases expression of SIRT1, Nampt, and 
Ku70 as an adaptive response to provide protection against neurodegeneration.  
 
INTRODUCTION 
Nicotine exerts neuroprotective effects and improves cognitive performance via 
activation of neuronal nicotinic acetylcholine receptors (nAChRs) (Socci et al., 1995; 
Zarrindast et al., 1996; Picciotto and Zoli, 2008b). Neuronal nAChRs are ligand-gated 
cation channels (Karlin, 2002), composed of various combinations of  and  subunits 
that form either homomeric or heteromeric receptors (Cooper et al., 1991; Sargent, 
1993a). The heteromeric 42 pentamer is the most abundant neuronal nAChR subtype 
in the central nervous system, widely distributed in mammalian brain, including cortical 
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structures, and pharmacologically characterized by its high affinity for nicotine 
(Picciotto et al., 1998).  
In humans, loss of high affinity nicotinic binding sites is a major histological 
change observed in normal brain ageing and excessive loss is linked to several 
neurodegenerative diseases that also exhibit dementia (Hellstrom-Lindahl and Court, 
2000). Aged (22- to 24-month-old) mice lacking this predominant form of high-affinity 
2* nAChRs (2-/- mice) exhibit increased neurodegeneration with deficits in spatial 
learning and memory compared to age matched wild type (WT) control mice (Zoli et al., 
1999). This suggests that the aging process is accelerated in the brains of 2-/- mice, and 
that age-related changes may already occur in middle-aged (18-month-old) animals. 
In rodents, caloric restriction slows the ageing process and increases longevity, 
with SIRT1 being a key regulator(Agarwal and Baur, 2011). SIRT1 is connected to a 
signaling network that involves a number of longevity factors such as Nampt, Ku70, 
FoxO3 and p53. The silent information regulator 2 (Sir2) protein found in yeast is a 
nicotinamide adenine dinucleotide (NAD)-dependent deacetylase and is positively 
linked to longevity (Kaeberlein et al., 1999; Imai et al., 2000; Lin et al., 2000). SIRT1 is 
the mammalian homolog of Sir2, and a key regulator of cellular defenses and survival in 
response to stress (Brunet et al., 2004; Cohen et al., 2004b). SIRT1 is expressed in the 
brain, where it is upregulated in mouse models of Alzheimer’s disease and amyotrophic 
lateral sclerosis. This is thought to be a neuroprotective adaptational response (Kim et 
al., 2007b), because upregulation of SIRT1 can protect neurons against 
neurodegeneration and neurotoxic insults (Chen et al., 2005a; Kim et al., 2007b).   
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SIRT1 deacetylates numerous factors that govern a wide range of biological 
functions (Michan and Sinclair, 2007). The tumor suppressor gene p53 can be 
deacetylated by SIRT1, thereby inhibiting p53-mediated apoptosis (Luo et al., 2001; 
Vaziri et al., 2001). SIRT1 can attenuate apoptosis by deacetylating the DNA repair 
factor, Ku70 (Cohen et al., 2004b). The FoxO family of transcription factors are typical 
substrates for SIRT1 (Brunet et al., 2004; Nemoto et al., 2004), and their deacetylation 
increases cellular resistance to oxidative stress and inhibits cell death (Giannakou and 
Partridge, 2004). Nampt controls the activity of SIRT1 (Revollo et al., 2004). Nampt is 
induced by stress or nutrient deprivation and increases cellular resistance to damage 
(Yang et al., 2006a). We also included the mitochondria uncoupling protein 5 
(UCP5/BMCP1) in the analysis; UCP5 is highly expressed in the brain (Sanchis et al., 
1998), and thought to exert neuroprotective effects by decreasing production of oxygen 
reactive species (Kim-Han et al., 2001).   
Although it is clear that SIRT1 and SIRT1-related genes are important in cell 
defense and survival, their regulation during aging and whether they are part of 
neuroprotective pathways associated with high-affinity nAChR activation in the central 
nervous system are unknown. In this study we show that cortical signs of aging were 
already present in middle-aged 18-month-old β2-/- mice. Furthermore, we determined 
the expression patterns of SIRT1 and related longevity genes in young and middle-aged 
male WT mouse brains, and investigated whether lack of high-affinity nAChRs affected 
their expression, which might explain the accelerated aging seen in these mice. 
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EXPERIMENTAL PROCEDURES 
 
Animals and tissue preparation 
C57/BL6:2-/- mice, derived from a colony at Baylor College of Medicine 
(Houston, TX, USA, originally from the lab of Dr. Arthur L. Beaudet and now available 
from The Jackson Laboratory, Bar Harbor, MA, USA), were first described by Xu et al. 
(Xu et al., 1999). A breeding colony was established at Texas A&M University’s 
Laboratory Animal Research and Resource (LARR) facility. Young adult (3-month-old) 
(n = 8) and middle-aged (18- to 20-month-old) male β2-/- mice (n = 9), and young adult 
(3-month-old) male WT mice (n = 8) were housed under standard conditions at the 
College of Medicine Animal Care Facility. Middle-aged (18-month-old) WT male 
C57/BL6 mice were purchased from the National Institutes of Health (n = 11). All 
procedures were approved by the Texas A&M University Animal Use Committee and 
carried out in accordance with the National Institutes of Health Guide for the Care and 
Use of Laboratory Animals (National Institutes of Health Publication No. 85-23, revised 
1996).  
Tail biopsies were taken after weaning and genotypes were determined using 
three-way PCR with the following primers: 2P1: GAG ACT AGT GAG ACG TGC 
TAC TTC CAT TTG; 2P2: CTC TGA CTG TAA AGG CAG TGG TTG CTA TAG; 
2P3: TAG CTA TTG ACG ACG TCT TTA AGA TCC. The genotype results were 
verified by in situ hybridization using a rat 2 antisense cRNA probe (Figure II-1).   
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Figure II-1. Expression of 2 nAChR subunit mRNA in WT but not 2-/- mice. 
Representative images of in situ hybridization with 2 nAChR antisense probe in adult 
wild type (WT) (A) and 2-/- (B2) (B) mouse brains. In 2 -/- mice, the hybridization 
signal was undetectable except for hybridization signal in the medial habenula nucleus 
(MHb), which could be the result of cross-reactivity between the rat 2 probe and mouse 
4 mRNA, which is strongly expressed in the MHb. Bregma level -1.82 mm. Hippo, 
hippocampus. DG, dentate gyrus. Tha, thalamus. MHb, medial habenula nucleus. Scale 
bar: 1 mm. 
 
 
All mice were anesthetized using isoflurane (IsoFlo, North Chicago, IL, USA) 
and euthanized by decapitation. The brains were rapidly dissected and frozen in 
isopentane at -20°C, and stored at -80°C until used. Using a cryostat, 15 m thick 
coronal sections, 150 m apart, were cut from Bregma level -1.28 mm to -2.21 mm and 
mounted onto glass microscope slides coated twice with gelatin (Spectrum, Gardena, 
CA, USA) and also with poly-L-Lysine (Sigma, St. Louis, MO, USA). The sections 
were post-fixed with 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4, for 1 
hour at room temperature (RT), washed in 0.1 M phosphate buffer three times, 5 minutes 
each, air-dried, and stored with desiccant at -20°C until used. 
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cRNA probe synthesis 
Extraction of mouse brain RNA was done using Absolutely RNA Miniprep Kit 
(Stratagene, La Jolla, CA, USA). Templates for mouse SIRT1, Ku70, Nampt, FoxO3a, 
p53, and UCP5 were generated by reverse transcription-PCR (SuperScript III First-
Strand Synthesis SuperMix for qRT-PCR, Invitrogen, Carlsbad, CA, USA) and 
subcloned into pPCR-Script Amp SK (+) (Stratagene, La Jolla, CA, USA) (Table II-1).  
 
 
Table II-1. Primers sequence of genes 
Gene Number Forward Reverse 
SIRT1 
(643 bp) 
NM_019812 
ACC TCC TGT TGA CCG 
ATG GA 
ATC CTT TGG ATT CCT 
GCA ACC TGC 
Ku70 
(724 bp) 
AB010282 
TAC AAG ATT TGG ACA 
ACC CAG GCG 
ATC AAA CCT GGC TCA 
TCA AAC CGC 
Nampt 
(910 bp) 
AY679720 
TTC CCG AGG GCT CTG 
TCA T 
TTG GGA TCA GCA ACT 
GGG TCC TTA 
FoxO3a 
(810 bp) 
NM_019740 
ACT CCA TCC GGC ACA 
ACC T 
AGT CTG AAG CAA GCA 
GGT CTT GGA 
p53 
(954 bp) 
NM_011640 
ACC TCA CTG CAT GGA 
CGA TCT GTT 
TCC TCT GTA GCA TGG 
GCA TCC TTT 
UCP5 
(523 bp) 
AF155812 
TCT AAG GGT GAA GTT 
TGC AAC GGC 
AAT GAA GCT GCC AAT 
CAT GCT CCC 
 
 
Plasmids were isolated using the QIAGEN Plasmid Maxi Kit (Qiagen, Valencia, 
CA, USA), linearized by restriction enzymes (Promega, San Luis Obispo, CA, USA) and 
sequenced to verify the orientation. A plasmid containing the full-length sequence for rat 
2 nAChR subunit (2,196 bp) (Dr. J. Boulter, UCLA, CA, USA) was used as a template 
for the 2 cRNA probe. 35S-labeled cRNA probes were synthesized in sense and 
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antisense orientations in the presence of 
35
S-UTP (PerkinElmer Life Science, Boston, 
MA, USA) with T3 or T7 RNA polymerase (Life Technologies/Ambion, TX) by in vitro 
transcription. 
 
In situ hybridization 
Tissue sections were processed for in situ hybridization as previously described 
(Huang and Winzer-Serhan, 2007). Briefly, sections were pre-hybridized with 0.1 g/ml 
proteinase K for 30 minutes at RT followed by 0.1 M triethanolamine and 0.25 % acetic 
anhydride. After overnight (16-20 hours) hybridization at 60°C, sections were treated 
with RNase A at 37°C for 30 minutes, and washed in 4X, 2X, 1X and 0.5X standard 
Saline Sodium Citrate (SSC) at RT followed by a hot wash in 0.1X SSC at 65°C for 30 
minutes. Slides were dehydrated through graded series of alcohols and air-dried. 
Sections were apposed to BioMax MR film (Kodak, Rochester, NY, USA) along with 
[
14
C]-standards of known radioactivity (Amersham, Code RPA 504L, Batch 21, 
Buckinghamshire, UK). After film exposure for one (Nampt, FoxoO3a, p53, UCP5) or 
two days (SIRT1, Ku70), the films were developed in D19 Kodak developer for 4 
minutes, rinsed in water, and fixed in Kodak Rapid Fixer for 5 minutes. 
 
Autoradiogram analysis 
The hybridization signal of each gene was measured in CA1 and CA3 pyramidal 
cell layers and the granule cell layer of the dentate gyrus (DG). The entire cerebral 
cortex and MHb located on individual sections was measured. Quantitative analysis of 
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autoradiograms (density, nCi/g wet weight) was completed using a PC-based image 
analysis system (MCID basic, Imaging Research Inc. St. Catherine, Canada; now 
InterFocus Imaging Ltd, UK). A standard curve (raw optical density vs. nCi/g wet 
weight) was generated using the [
14
C]-standards. Quantitative values determined from 
the autoradiograms were divided by their decay factors to obtain specific values based 
on the calibration day. Specific hybridization was determined by subtracting values for 
non-specific hybridization from total values. 
 
Neocortex thickness 
Using autoradiographic films from UCP5 cRNA hybridization, Bregma level -
1.28 mm to -2.21 mm, images were captured at the level of the barrel fields of the 
primary somatosensory cortex according to the Mouse Brain Library atlas (Rosen et al., 
2000). The thickness of the primary somatosensory cortex was measured at the area 
directly external to the CA2 of hippocampus from each picture (indicated in Figure II-
2A and B) from the external border of layer I to the internal border of layer VI using 
NIH ImageJ 1.40 (Rasband, 1997-2011). The measurements were calibrated using a 
ruler imaged by MCID basic (60 pixels per mm). 
 
Relative dorsal hippocampal volume 
Tissue sections were stained with thionin (Sigma, St. Louis, MO, USA) and 
coverslipped. Four sections from each mouse, selected using systematically random 
sampling, each 150 m apart, from Bregma level -1.28 mm to -2.21 mm, were 
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photographed using a microscope with a 4X objective (Nikon Eclipse E400) equipped 
with a camera (Nikon digital camera DXM 1200). Either the left or right side of the 
hippocampus was used for area measurements of the entire hippocampus. The 
measurements were calibrated using scale bars provided by the microscopy software 
NIS-Elements D 3.10 (165 pixels per mm). The granular cell layer of the DG in the 
upper and lower blade, and the pyramidal cell layer of CA1 and CA3 (hippocampus 
proper) were measured using NIH ImageJ 1.40. Volumes were calculated using the 
following formula based on the Cavalieri Method: volume = area × section thickness (15 
m) × number of skipped sections (10) between measured sections. 
 
Neuron cell density 
Frozen sections were warmed to RT and dried thoroughly for 30 minutes. The 
sections were then stained with ProLong® Gold antifade reagent containing 4'-6-
diamidino-2-phenylindole (DAPI) (Invitrogen, Carlsbad, CA, USA), and allowed to dry 
overnight. DAPI-stained sections were examined using epifluorescence, and images 
were acquired using a Zeiss Axioplot2 research microscope (Carl Zeiss, Inc., 
Thornwood, NY, USA) equipped with a three-chip Hamamatsu video camera. Images 
were taken from seven different brain regions: CA1 and CA3 pyramidal cell layers, the 
granular cell layer and hilar region of the DG, and layer II/III, IV, and V/VI of the barrel 
field region of primary somatosensory cortex. Only cells with a large, round, 
euchromatic nucleus were counted as neurons. 
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Statistics 
The expression of each gene was collected and analyzed independently from 
each other, because each gene was assessed from a different set of tissue sections. For 
age comparisons in WT mice gene expression, cortico-hippocampal area data were 
analyzed using two-way ANOVA (region and age). Data from gene expression in the 
MHb in WT mice were analyzed using Student’s t-test (age was the only variable). For 
genotype comparison of gene expression at a specific age, percent control based on age-
matched WT was used, which allowed us to combine data from two repeated 
experiments. The data were calculated leaving genotype as the only variable and 
therefore, analyzed using Student’s t-test. For neuronal cell density, data were analyzed 
using two-way ANOVA (age and genotype). For cerebral cortex thickness, two-way 
ANOVA was used (age and genotype). A three-way ANOVA was used for the 
hippocampal volume study (region, age, and genotype). When a significant interaction 
was noted in a three-way ANOVA at the level of three variables, each individual 
category was further analyzed by a two-way ANOVA; when significant interactions 
were noted in a three-way ANOVA at the level of two variables or in a two-way 
ANOVA, each individual category was further analyzed by a one-way ANOVA; when 
no interaction was noted, the ANOVA was followed by a Tukey’s post hoc test if the 
collected model p-value was significant. When a main effect was noted in a two-way 
ANOVA when the collected model p-value was significant, the p-value of the main 
effect was further analyzed by a Tukey’s post hoc test. All statistics were carried out 
using PC-based SPSS 15.0. Significance was defined as p < 0.05. 
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RESULTS 
 
Morphological and histological changes in middle-aged 2-/- male mice 
 
Cortical thinning is accelerated in middle-aged 2-/- mice compared to age-matched 
wild type mice. 
Cortical hypotrophy has been reported in the somatosensory cortex of 22 to 24-
month-old 2-/- mice compared to age matched WT controls (Zoli et al., 1999). Here we 
examined changes in 18-month-old (middle-aged) WT and 2-/- mice to determine 
whether signs of aging were already detectable in this age group. Eighteen-month-old 
WT mice showed a significant 10.16 % decrease in thickness in primary somatosensory 
cortex compared to 3-month-old WT mice (two-way ANOVA: main effect of age, F(1, 
21) = 14.49, p = 0.001; main effect of genotype, F(1, 21) = 0.055, p = 0.817; genotype 
by age interaction, F(1, 21) = 0.891, p = 0.356. WT 3-month-old: 1.1 mm, WT 18-
month-old: 0.98 mm, Tukey’s post hoc test: p = 0.053) (Figure II-2A, C and E). There 
was no difference in cortical thickness between 3-month-old WT and 2-/- mice, but 
eighteen-month-old 2-/- mice had a more robust 16.45 %, decrease in the same region 
compared to 3-month-old 2-/- mice (2-/- 3-month-old: 1.12 mm, 2-/- 18-month-old: 
0.94 mm, Tukey’s post hoc test: p = 0.01) (Figure II-2B, D and E). Cortical thinning, 
while characteristic for the normal aging cortex, was accelerated in middle-aged 2-/- 
mice.   
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Figure II-2. Primary somatosensory cortex thickness was significantly decreased in 
middle-aged 2-/- mice. A-D, Representative images of in situ hybridization with UCP5 
antisense probe in 3-month-old (3mo) WT. Schematic diagrams in A shows the cortical 
area in which of thickness measurement (indicated in B) was taken. (A), 3-month-old 
2-/- (B), 18-month-old (18mo) WT (C), and 18-month-old 2-/-(D) mouse brains, 
showing the primary somatosensory cortex (S1). Bregma level -1.82 mm. Scale bar: 1 
mm. E, Quantification of the primary somatosensory cortex thickness. Error bars: 
standard error of the mean (SEM). Two-way ANOVA, age vs. genotype, Tukey’s post 
hoc test, * p < 0.05. 
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A reduction in cortical thickness is often accompanied by a change in neuronal 
cell density. To determine neuronal density in WT and 2-/- mice, DAPI stained nuclei 
were counted in defined areas (WT 3-month-old, n = 4; WT 18-month-old, n = 11; 2-/- 
3-month-old, n = 4; 2-/- 18-month-old, n = 8). In cortical layers II/III, 18-month-old 
WTs had significantly higher neuronal density compared to 3-month-old WT mice (two-
way ANOVA: main effect of genotype, F(1, 23) = 0.914, p = 0.349; main effect of age, 
F(1, 23) = 11.145, p = 0.003; genotype by age interaction, F(1, 23) = 4.525, p = 0.044; 
Tukey’s post hoc test: p = 0.005). However, 3-month-old 2-/- mice exhibited a 
significantly higher density of neurons compared to age-matched WT mice (Tukey’s 
post hoc test: p = 0.012) (Figure II-3A and B), but there was no further increase in 
density with age in 2-/- mice. In layers V/VI, neuronal density was increased in 18-
month-old WT mice compared to 3-month-old WT mice (two-way ANOVA: main effect 
of genotype, F(1, 23) = 0.578, p = 0.455; main effect of age, F(1, 23) = 5.483, p = 0.028; 
genotype by age interaction, F(1, 23) = 3.185, p = 0.087; Tukey’s post hoc test: p = 
0.025) (Figure II-3C and D). In young 2-/- mice a trend towards increased neuronal 
density was detected in layers V/VI compared to young WT mice with no further 
increase with age. Together these results show that cortical alterations were already 
present in young adult 2-/- mice prior to any age-related changes seen in WT mice. 
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Difference in relative dorsal hippocampal volume is due to a smaller granular cell layer 
in the dentate gyrus of middle-aged 2-/- mice. 
The hippocampus is an important area with respect to aging and cognitive 
function. Although aged rodents exhibit functional hippocampal decline (Deupree et al., 
1993) and significant deficits in spatial memory (Barnes, 1987), several studies have 
indicated that age-related decreases in hippocampal area, volume or cell density do not  
 
 
 
Figure II-3. Neuronal cell density increased in middle-aged WT and young adult 2-/- 
mice compared to young adult WT mice. Neuronal cell densities were counted in 
primary somatosensory cortex layer II/III (Ctx3) (A, B), and primary somatosensory 
cortex layer V/VI (Ctx5) (C, D). A and C, Representative images of the DAPI stained 
sections. Bregma level -1.82 mm. Scale bars: 100 µm. B and D, Quantification of 
neuronal cell density. Error bars: SEM. Two-way ANOVA, age vs. genotype, Tukey’s 
post hoc test, * p < 0.05, ** p < 0.01. 
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occur until very old age (Rasmussen et al., 1996; Calhoun et al., 1998; von Bohlen und 
Halbach and Unsicker, 2002). Since 2-/- mice exhibited premature age-related changes 
in the cortex, it is possible that signs of aging might already appear in the hippocampus 
of 18-month-old 2-/- mice. The relative volume of the dorsal hippocampal was 
determined in young and middle-aged WT (n = 4, n =11, respectively), and 2-/- mice (n 
= 4; n = 8, respectively). Hippocampal volume increased significantly by 16.6% in 18-
month-old WT compared to 3-month-old WT mice, whereas in 2-/- mice, a non-
significant trend towards a 11.8 % increase was detected (two-way ANOVA: main effect 
of genotype, F(1, 23) = 0.303, p = 0.587; main effect of age, F(1, 23) = 8.50, p = 0.008; 
genotype by age interaction, F(1, 23) = 0.244, p = 0.626. WT 3-month-old: 1.23 mm
3
, 
WT 18-month-old: 1.44 mm
3
, Tukey’s post hoc test: p = 0.018; 2-/- 3-month-old: 1.23 
mm
3
, 2-/- 18-month-old: 1.38 mm3, Tukey’s post hoc test: p = 0.161) (Figure II-4A). 
To further elucidate whether the age-related change in hippocampal volume also affected 
the principal cell layers, we measured the volume of the granular cell layer of the DG 
and pyramidal cell layer of the hippocampus proper (CA1/CA2 and CA3). The DG 
granule cell layer volume significantly increased by 19.0 % in 18-month-old compared 
to 3-month-old WT mice. However, in 2-/- mice there was no change in granule cell 
layer volume in the DG with age (-4 %) (three-way ANOVA (two regions, dentate gyrus 
granular cell layer and CA pyramidal cell layer, were considered as another variable 
here): main effect of region, F(1, 46) = 145.0, p < 0.0001; main effect of genotype, F(1, 
46) = 1.731, p = 0.195; main effect of age, F(1, 46) = 11.12, p = 0.002; genotype by 
region interaction, F(1, 46) = 0.017, p = 0.896; genotype by age interaction, F(1, 46) = 
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3.186, p = 0.081; region by age interaction, F(1, 46) = 2.252, p = 0.14; genotype by 
region by age interaction, F(1, 46) = 1.288, p = 0.262. WT 3-month-old: 0.087 mm
3
, WT 
18-month-old: 0.103 mm
3
, Tukey’s post hoc test: p = 0.022; 2-/- 3-month-old: 0.092 
mm
3
, 2-/- 18-month-old: 0.088 mm3, Tukey’s post hoc test: p = 0.527) (Figure II-4B).  
Thus, a significantly larger granule cell layer was detected in 18-month-old WT mice but 
not 2-/- mice (Tukey’s post hoc test: p = 0.007) (Figure II-4B). In contrast, the 
pyramidal cell layer of the hippocampus proper exhibited significantly increased volume 
with age in both WT and 2-/- mice (WT 3-month-old: 0.127 mm3, WT 18-month-old: 
0.146 mm
3
, Tukey’s post hoc test: p = 0.04; 2-/- 3-month-old: 0.125 mm3, 2-/- 18-
month-old: 0.139 mm
3
, Tukey’s post hoc test: p = 0.049) (Figure II-4C).  
Neuronal density was determined in different hippocampal regions and the 
density was significantly higher in the hilar region of the DG in 18-month-old 2-/- mice 
compared to age-matched WT mice (two-way ANOVA: main effect of genotype, F(1, 
23) = 7.44, p = 0.012; main effect of age, F(1, 23) = 0.081, p = 0.779; genotype by age 
interaction, F(1, 23) = 0.797, p = 0.381; Tukey’s post hoc test: p = 0.003) (Figure II-5C 
and D). In the pyramidal cell layer of the CA3 region of the hippocampus, 3-month-old 
2-/- mice had significantly higher neuronal density compared to 18-month-old 2-/- 
mice, and there was a trend towards higher density in 3-month-old 2-/- mice compared 
to age-matched WT mice (two-way ANOVA: main effect of genotype, F(1, 23) = 2.027, 
p = 0.168; main effect of age, F(1, 23) = 0.714, p = 0.407; genotype by age interaction, 
F(1, 23) = 6.47, p = 0.018, Tukey’s post hoc test: p = 0.012 and 0.066, respectively) 
(Figure II-5E and F). In contrast, no differences were detected in neuronal cell densities 
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in the granular layer of the DG and pyramidal layer of CA1 region between young and 
aged mice or between genotypes (data not shown).  
Thus, in WT mice, cortical thickness decreased and neuronal density increased 
with age, whereas hippocampal volume increased but neuronal density remained the 
same, suggesting that aging affects the cortex at a younger age than the hippocampus. In 
contrast, in 2-/- mice cortical thickness decreased more drastically and neuronal density 
was already significantly higher in 3-month-old 2-/- mice compared to age-matched 
WT mice. This suggests that loss of 2* heteromeric nAChRs affects the cortex at a 
young age, perhaps setting it up for higher sensitivity to aging-related insults. In the 
hippocampus, which seemed unaffected by aging in WT mice, a significant difference in 
DG granular cell layer volume and increased neuronal density in the hilar region in 
middle-aged 2-/- mice compared to age-matched WT mice suggested that loss of 2* 
heteromeric nAChRs accelerated age-related changes in the hippocampus, a trend 
similar to that found in cortex. 
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Figure II-4. Relative dorsal hippocampal volume increased with age in wild-type but 
not 2-/- mice. A, Dorsal hippocampal volume measured from Bregma level -1.46 to -
2.06. B, Dentate gyrus granular cell layer volume. C, Volume of hippocampal proper 
(CA1 and CA3) pyramidal cell layer. Error bars: SEM. Two-way ANOVA, age vs. 
genotype, One-way ANOVA each for age and genotype, * p < 0.05, ** p < 0.01. 
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Figure II-5. Neuronal cell density was changed in the hippocampus. Neuronal cell 
density was measured in the granular cell layer of the dentate gyrus (A, B), hilar region 
of the dentate gyrus (C, D), and CA3 pyramidal cell layer of the hippocampus (E, F). A, 
C, and E show representative images of DAPI stained sections. Bregma level -1.82 mm. 
Scale bars: 100 μm. B, D, and F show quantification of neuronal cell density. Error bars: 
SEM. Two-way ANOVA, age vs. genotype, Tukey’s post hoc test, * p < 0.05, ** p < 
0.01. 
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Most longevity regulatory genes probed in this study are highly expressed in 
cortical structures and exhibit decreased expression levels with aging 
 
Expression of longevity regulatory genes in adult mouse brain 
Several longevity genes are linked to the aging process (Salminen and 
Kaarniranta, 2009). To determine the mRNA expression pattern of SIRT1 and other 
related longevity regulatory genes, we performed in situ hybridization in sections from 
3-month-old WT mice using SIRT1, Nampt, Ku70, p53, FoxO3 and UCP5 antisense and 
sense cRNA probes to detect specific and non-specific hybridization, respectively (n = 
4). Expression levels of mRNAs were quantified in several cortical and hippocampal 
regions including the granular cell layer of the DG, the pyramidal cell layer of CA1 and 
CA3 of hippocampus, the MHb and the neocortex. All sense probes exhibited low 
background hybridization signal indicating low levels of non-specific hybridization 
(Figure II-6A-C and 6G-I insets). The most intense in situ hybridization signal for 
SIRT1 mRNA was found in the hippocampus and MHb (Figure II-6A). SIRT1 was also 
broadly expressed in the cerebral cortex with increased expression intensity in layers 
II/III and V/VI (Figure II-6A). In thalamus and hypothalamus, moderate to low signal 
was detected with increased SIRT1 mRNA expression in the arcuate, ventromedial, and 
dorsomedial nuclei (Figure II-6A). Quantitative data demonstrated that the DG exhibited 
the highest mRNA expression, which was almost twice that of any other region 
measured, whereas SIRT1 mRNA levels in CA1 and CA3 were comparable to those 
found in the neocortex (Figure II-6D).   
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This is the first description of the mRNA expression pattern of Nampt and Ku70 
in a rodent brain. The hybridization signal for Nampt was very strong in all fields of the 
hippocampus, and uniformly distributed moderate signal was observed in the neocortex 
(Figure II-6B). Higher levels of expression were also found in the claustrum and 
endopiriform nucleus, and in the MHb. Moderate to low levels were detected in the 
amygdala, thalamus and hypothalamus (Figure II-6B). Quantitative analysis of cortical 
structures showed that expression intensities for Nampt were highest in the granule layer 
of the DG and CA3 pyramidal layer; whereas, expression intensity was significantly 
lower in the neocortex (Figure II-6E).   
Messenger RNA expression levels of Ku70 were high in the hippocampus, 
moderate in the neocortex and the MHb, and low to moderate in the thalamus and 
hypothalamus regions (Figure II-6C). Quantitative data showed that Ku70 mRNA was 
expressed highest in the DG followed by CA3, and CA1, with neocortex expressing the 
lowest level of mRNA among regions measured (Figure II-6F).   
FoxO3 mRNA was strongly expressed in all fields of the hippocampus, 
neocortex, and piriform cortex in a pattern similar to that obtained with non-isotopic in 
situ hybridization (Hoekman et al., 2006) (Figure II-6G). In the neocortex, expression 
was strongest in cortical layers II/III and V/VI. In addition, expression of FoxO3 mRNA 
also was detected in the MHb and evenly distributed in the amygdala, thalamus and 
hypothalamus (Figure II-6G). Quantitative comparison of cortical structures showed that 
the highest expression level was found in the granule cell layer of the DG, followed by 
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similar expression levels in the pyramidal cell layer of CA1 and CA3 and the neocortex 
(Figure II-6J).   
All fields of the hippocampus exhibited high levels of p53 mRNA expression. In 
the neocortex, p53 mRNA was evenly distributed through all layers, and p53 mRNA was 
also moderately expressed in the MHb (Figure II-6H). In the amygdala, thalamus and 
hypothalamus moderate, evenly distributed hybridization signals for p53 were found 
(Figure II-6H). This expression pattern in adult mouse brain is similar to that reported 
previously for rat brain (van Lookeren Campagne and Gill, 1998). Quantitative 
comparison revealed that among regions measured, p53 mRNA expression was highest 
in the DG, followed by the CA1 and CA3 and lowest in the neocortex (Figure II-6K). 
UCP5 mRNA was expressed highly in the principal layers of CA1, CA3 and DG 
of the hippocampus. In the neocortex, moderate to high levels were detected with 
slightly increased expression in layers I and VI. Other areas such as the caudate putamen 
and amygdala also exhibited moderate levels, whereas expression levels were low in 
thalamus and hypothalamus with the exception of the MHb and a few hypothalamic 
nuclei, which is similar to the mRNA distribution pattern previously described (Sanchis 
et al., 1998) (Figure II-6I). Quantitative comparison of UCP5 measured in hippocampus 
and cortex showed that mRNA expression was highest in the DG, followed by CA1 and 
CA3 and lowest in neocortex (Figure II-6L). 
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Decreased expression of longevity regulatory genes in cortical regions of 18-month-old 
WT compared to 3-month-old WT mice 
Although most longevity genes have been implicated to function in aging, it is 
not known how age affects their expression. Therefore, mRNA expression levels of 
longevity genes were determined in 18-month-old WT mice and compared to 3-month-
old WT mice on a region-matched basis (3-month-old WT, n = 4; 18-month-old WT, n = 
5). Except for SIRT1 (two-way ANOVA: main effect of age, F(1, 28) = 2.05, p = 0.163; 
main effect of region, F(3, 28) = 106.4, p < 0.0001; age by region interaction, F(3, 28) = 
0.209, p = 0.889) and Nampt (two-way ANOVA: main effect of age, F(1, 28) = 3.42, p = 
0.075; main effect of region, F(3, 28) = 97.06, p < 0.0001; age by region interaction, F(3, 
28) = 1.353, p = 0.277) (Figure II-6D, E), the other four genes showed a significant 
general age effect with 18-month-old WT mice exhibiting lower mRNA expression 
levels than 3-month-old animals (two-way ANOVA, main effect of age: Ku70, F(1, 28) 
= 103.9, p < 0.0001; FoxO3, F(1, 28) = 4.32, p = 0.047; p53, F(1, 28) = 16.44, p < 
0.0001; UCP5, F(1, 28) = 5.55, p = 0.026; main effect of region: Ku70, F(3, 28) = 287.5, 
p < 0.0001; FoxO3, F(3, 28) = 63.28, p < 0.0001; p53, F(3, 28) = 269.2, p < 0.0001; 
UCP5, F(3, 28) = 107.9, p < 0.0001; age by region interaction: Ku70, F(3, 28) = 6.012, p 
= 0.003; FoxO3, F(3, 28) = 0.305, p = 0.821; p53, F(3, 28) = 5.691, p = 0.004; UCP5, 
F(3, 28) = 0.496, p = 0.688) (Figure II-6F and J-L). Ku70 had the strongest age-related 
effect, and the cortical regions examined showed significantly reduced Ku70 
hybridization levels in 18-month old mice (Tukey’s post hoc test: DG: 22.5%, p = 0.001; 
CA1: 19.1%, p = 0.002; CA3: 22.9%, p = 0.001; neocortex: 18.7%, p = 0.001) (Figure 
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II-6F). FoxO3 mRNA expression was significantly reduced in the neocortex by 20.3% 
(Tukey’s post hoc test: p = 0.018) (Figure II-6J), and this reduction was significant in 
layers V/VI (15.7%) and a strong trend in layers II/III (14%) (two-way ANOVA: main 
effect of age, F(1, 14) = 11.04, p = 0.005; main effect of layer, F(1, 14) = 28.19, p < 
0.0001; age by layer interaction: F(1, 14) = 0.052, p = 0.824; Tukey’s post hoc test: p = 
0.043 and 0.057, respectively). The strongest reduction in p53 mRNA expression was 
detected in the DG (18.3%) and CA3 (9.6%) (Tukey’s post hoc test: p = 0.012 and 0.056 
respectively) (Figure II-6K). There was a trend towards decreased UCP5 mRNA 
expression in CA3 (11.2%) between 3-month and 18-month-old mice (Tukey’s post hoc 
test: p = 0.079) (Figure II-6L). Taken together, mRNA levels decreased with age for the 
longevity regulatory genes Ku70, FoxO3, p53 and UCP5 in the cortico-hippocampal 
area, with an especially significant decline for Ku70, whereas Nampt only showed a 
trend towards decreased expression in older animals (Figure II-6E). 
 
Increased mRNA levels of SIRT1, Nampt and Ku70 in middle-aged 2-/- mice 
compared to age-matched WT mice in cortical regions 
Because most genes we examined showed decreased mRNA levels in 18-month 
old WT mice, and 18-month old 2-/- mice exhibited a premature ageing in cortex and 
hippocampus, we hypothesized that mRNA expression levels would be further decreased 
in cortical regions of middle-aged 2-/- mice compared to age-matched WT mice. To 
test this hypothesis, we performed in situ hybridization with the same set of genes on 3- 
and 18-month-old 2-/- mice (WT 3-month-old, n = 7; WT 18-month-old, n = 11; 2-/-  
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Figure II-6. Ku70, FoxO3, p53 and UCP5 mRNA expression levels were decreased in 
cortico-hippocampal regions in middle-aged wild-type mice. A-C and G-I: 
Representative autoradiographic images of in situ hybridization for SIRT1 (A, D), 
Nampt (B, E), Ku70 (C, F), FoxO3 (G, J), p53 (H, K), and UCP5 (I, L) derived with 
antisense probes in 3-month-old WT mice. Insets: sense probes. Bregma level -1.82 mm. 
Scale bar: 1 mm. Scale bar of inset: 2 mm. D-F and J-L, Quantification of mRNA 
expression intensities of each gene in the granular cell layer of the dentate gyrus (DG), 
pyramidal cell layer of CA1 and CA3 of the hippocampus, and the neocortex (Ctx). 
Error bars: SEM. Two-way ANOVA, age vs. region, # general age effect p < 0.05, ## 
general age effect p < 0.01, Tukey’s post hoc test, * p < 0.05, ** p < 0.01. 
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3-month-old, n = 7; 2-/- 18-month-old, n = 8). In situ hybridization patterns were 
identical between WT and β2-/- young and adult mice suggesting that there were no 
qualitative changes in mRNA distributions in response to loss of 2* heteromeric 
nAChRs. For quantitative analysis, mRNA expression levels were analyzed in the 
granular cell layer of the DG, pyramidal cell layer of CA1 and CA3 of the hippocampus 
and neocortex. In young adult 2-/- mice, mRNA expression levels were not 
significantly different from WT mice for any of the genes tested, although there were 
trends towards higher Nampt mRNA expression in CA1 and lower Ku70 mRNA 
expression in the DG of 3-month-old 2-/- mice compared to WT mice (Student’s t-test, 
p = 0.061 and 0.066, respectively) (Figure II-7A, C and E).  
In middle-aged 2-/- mice, mRNA expression levels were comparable to age-
matched WT mice for p53, FoxO3, and UCP5 (p > 0.05). However in 18-month-old 
mice, SIRT1 mRNA expression intensity was significantly affected by genotype 
demonstrating increased mRNA expression in the DG and CA3 (Student’s t-test, p = 
0.024 and 0.039 respectively) (Figure II-7B). Nampt mRNA expression was 
significantly increased in middle-aged 2-/- compared to age-matched WT mice in CA3 
(Student’s t-test, p < 0.001) (Figure II-7D). Eighteen-month-old 2-/- mice also 
exhibited increased mRNA levels of Ku70 compared to age-matched WT mice. The up-
regulation of Ku70 mRNA levels was significant in all cortical regions tested including 
the DG, CA1 and CA3 of the hippocampus and neocortex (Student’s t-test, DG: p = 
0.012, CA1: p = 0.04, CA3: p = 0.017, neocortex: p = 0.007) (Figure II-7F). 
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Figure II-7. SIRT1, Nampt, and Ku70 mRNA expression levels were increased in 
cortico-hippocampal regions in middle-aged 2-/- compared to age-matched wild-type 
mice. Quantification of mRNA expression of SIRT1 (A, B), Nampt (C, D), and Ku70 (E, 
F) in 3-month-old (A, C, and E) and 18-month-old (B, D, and F) WT and 2-/- mice. 
Regions measured included granular cell layer of the dentate gyrus (DG), CA1 and CA3 
pyramidal cell layer of the hippocampus, and neocortex (Ctx). Data were presented as % 
control of WT at both ages. Error bars: SEM. Student’s t-test, * p < 0.05, ** p < 0.01. 
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Similar changes of longevity regulatory gene expression levels in MHb 
The MHb, a brain area with strong expression of nAChRs (Quick et al., 1999; 
Grady et al., 2009), also exhibited medium to high signals of hybridization for all 
longevity regulatory genes probed (Figure II-6). Therefore, we determined if similar age- 
and phenotype-related changes in gene expression levels took place, compared to those 
seen in cortical structures. The mRNA levels between 3-month-old and 18-month-old 
WT mice (3-month-old WT, n = 4; 18-month-old WT, n = 5) and between 2-/- mice 
and age-matched WT (WT 3-month-old, n = 7; WT 18-month-old, n = 11; 2-/- 3-
month-old, n = 7; 2-/- 18-month-old, n = 8) were measured and compared in the MHb.   
In agreement with our cortico-hippocampal data, significant age-related decreases in 
expression intensities were found for Nampt, Ku70, p53 and UCP in middle-aged 
compared to young WT mice (Student’s t-test, Nampt: 16.2%, p = 0.027; Ku70: 22.3%, 
p = 0.042; p53: 28.1%, p = 0.01; UCP5: 17.9%, p = 0.01) (Figure II-8A). Only SIRT1 
and FoxO3 mRNA expression exhibited no change. In 3-month old mice, phenotype did 
not affect the expression intensity in the MHB of any gene tested (data not shown). At 
18 months of age, most longevity regulatory genes showed increased mRNA levels in 
2-/- mice compared to age-matched WT except for FoxO3 and UCP5 (Student’s t-test, 
SIRT1: p = 0.042; Nampt: p = 0.042; Ku70: p = 0.023; p53: p = 0.047) (Figure II-8B). 
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Figure II-8. Changes of survival gene expression observed in medial habenula (MHb) 
are similar to those in cortico-hippocampal areas. A, Quantification of mRNA expression 
levels in the MHb of 3-month- and 18-month-old wild-type mice. B, Comparison of 
mRNA levels of SIRT1, Nampt, Ku70 and p53 in 18-month-old WT and 18-month-old 
2-/- mice. Error bars: SEM. Student’s t-test, * p < 0.05. 
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DISCUSSION 
 
Anatomical changes in middle-aged WT and 2-/- mice 
The nicotinic cholinergic system is critically involved in the aging process, and 
its impairment is often correlated with human dementia (Picciotto and Zoli, 2008b). A 
previous study had shown that mice lacking high affinity heteromeric 2* nAChRs 
exhibit enhanced age-related cortical atrophy in 22- to 24-month old mice (Zoli et al., 
1999). In this study we show that an age-related decline in cortical thickness is already 
enhanced in middle-aged, 18-month-old 2-/- mice, and that anatomical alterations in 
the cortex in the form of increased neuronal density can be detected in young, 3-month-
old, 2-/- mice. Thus, lack of 2* heteromeric nAChRs affects anatomical features in 
young adults, prior to a functional cognitive decline (Zoli et al., 1999). The increase in 
neuronal density at an early age in 2-/- mice suggests a decrease in synaptic 
connectivity, and the age-related decrease in cortical thickness without further increase 
in cell density likely reflects increased neuronal loss in the neocortex of 2-/- mice. This 
finding is supported by similar results in 2-/- mice exhibiting enhanced neuronal loss of 
spiral ganglion neurons underscoring the importance of 2* nAChR to prevent early 
neuronal aging not only in the brain but also in peripheral neurons (Bao et al., 2005). 
However, it is possible that the observed differences, in particular those that indicate a 
small although significant difference between young and middle-aged WT mice were the 
result of different housing conditions and/or colonies, since the middle-aged WT mice 
were obtained from an outside source. 
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In the hippocampus, there was an age-related increase in hippocampal volume in 
WT mice in all hippocampal fields. Additional experiments indicated that the 
hippocampal volume increases up to 12 months of age in WT mice and remained 
constant thereafter (data not shown). This significant increase in dorsal hippocampal 
volume was not detected in 2-/- mice. Specifically, the volume increased in CA1 and 
CA3 regions of the dorsal hippocampus but not in the DG. The DG is a known site for 
cell proliferation throughout adulthood, where new cells primarily differentiate into 
granular neurons and form axonal connections with the major hippocampal subfields 
(Stanfield and Trice, 1988; Cameron et al., 1993; Hastings and Gould, 1999). These 
results suggest that initially the DG develops normally in 2-/- mice, but adult 
neurogenesis is either decreased, survival of newly generated neurons is impaired, or 
both. These results are supported by the observations that in young 2-/- mice the rate of 
proliferation in the DG and the survival of newly born cells are not affected (Mechawar 
et al., 2004). However, in older animals hippocampal neurogenesis is significantly lower 
in 2-/- mice compared to age-matched WT mice (Harrist et al., 2004). Taken together, 
functional 2* heteromeric nAChRs seem to be important for synaptic integrity, 
neuronal survival, and adult neurogenesis, although, the underlying mechanisms remain 
unknown. 
 
Expression of survival genes in young and middle-aged WT mice 
In this study we described expression patterns for six different survival genes: 
SIRT1, Nampt, Ku70, p53, FoxO3, and UCP5, which is the first time mRNA 
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distributions for Nampt, Ku70 and p53 have been described in adult mouse brain.  
SIRT1 mRNA, which was expressed throughout the forebrain, was not changed in 
middle-aged animals compared to young mice in either cortex hippocampus or MhB, 
and thus was the only gene that was completely unaffected by aging in cortical 
structures. This finding is in line with other reports that SIRT1 mRNA levels remain 
unchanged despite significantly increased protein levels in response to fasting (Kanfi et 
al., 2008; Ramadori et al., 2008) suggesting that SIRT1 protein levels are not necessarily 
correlated with gene expression.   
Nampt is the rate-limiting component in the biosynthesis pathway of NAD. 
Studies indicate that an age-related decline in Nampt-regulated NAD synthesis could 
contribute to reduced SIRT1 activity and subsequently affect neuronal viability (van der 
Veer et al., 2007; Borradaile and Pickering, 2009). Nampt, which was strongly expressed 
in the hippocampus, especially in the DG and CA3, exhibited a trend (p = 0.075) 
towards decreased expression in middle-aged WT mice. Thus, decreased Nampt 
expression and activity in middle-aged and especially senescent animals could affect 
SIRT1 function thereby reducing SIRT1-mediated protection, which could result in 
decreased vitality of the aging brain. 
Ku70, which can be co-immunoprecipitated with the deacetylase SIRT1 (Cohen 
et al., 2004a), mediates DNA repair and maintenance of mitochondrial integrity. 
Decreased acetylation of Ku70 results in increased binding to and repair of double-
stranded DNA (Smith and Jackson, 1999). Ku70-/- mice have increased developmental 
cortical apoptosis due to decreased repair of double-strand DNA breaks created by 
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oxidative damage (Narasimhaiah et al., 2005). This crucial function of Ku70 might also 
play a critical role in the mature brain, and in particular in metabolically active areas 
such as hippocampus, cortex and MHb where strong Ku70 mRNA expression was 
detected. Ku70 mRNA expression was negatively correlated with aging in all cortical 
and hippocampal areas and in the MHb, and exhibited the most dramatic and widespread 
decline of all genes investigated. A similar negative correlation of Ku70 expression with 
age has been detected in aged but cycling, non-neuronal cells (Ju et al., 2006; Prall et al., 
2007). Decreased expression of Ku70 would leave neurons vulnerable to oxidative DNA 
damage, which increases with age (Lovell and Markesbery, 2007). This effect might be 
even more dramatic considering that NAD-dependent SIRT1 function might be reduced 
in the aging brain due to decreased levels of NAD. An increase in Ku70 acetylation 
would reduce its activity, which could further increase vulnerability of aged neurons to 
toxic insults.  
FoxO3 forms a complex with SIRT1 in response to stress, leading to enhanced 
stress resistance in mammalian dividing cells (Brunet et al., 2004). There was striking 
overlap between the mRNA expression pattern of SIRT1 and FoxO3 suggesting that 
those genes are associated, and could form SIRT1/FoxO3 complexes in neurons, similar 
to those seen in non-neuronal cells. The age-related decrease of FoxO3 mRNA 
expression in hippocampus and cortex detected here suggest a reduced ability to form 
FoxO3/SIRT1 complexes, which could have implications for neuronal survival. 
However, future studies need to determine if, indeed, FoxO3 and SIRT1 form complexes 
in cortex or hippocampus and if complex formation is altered during aging.  
 64 
Our study detected substantial expression of p53 mRNA in hippocampus, cortex 
and MHb at a time of very little cell cycling or cell death in young adults, and an age-
related decline of expression levels (Buss et al., 2006; Sibille et al., 2007). Whether p53 
mRNA is translated into protein in the CNS, and is involved in cell division or cell death 
remains unknown. High expression of p53 has also been detected in the developing rat 
brain (van Lookeren Campagne and Gill, 1998), and disruption of p53 causes abnormal 
brain development in mice (Armstrong et al., 1995). Thus, in addition to its widely 
known role in apoptosis, p53 might have an alternative function as a regulator of gene 
targets that stabilize non-dividing cells like neurons.  Furthermore, its apoptotic function 
might be diminished in the brain because of deacetylation of p53 by SIRT1.  
Deacetylation decreases binding of p53 to its target sequences and represses 
transcriptional activity, thereby suppressing p53-mediated apoptosis (Bitterman et al., 
2002). Since SIRT1 is expressed in the same brain areas and most likely in the same 
neurons, SIRT1 could shift the function of p53 to cell protection rather than cell death. If 
this is the case, then p53 expression might be beneficial in the mature brain, and age-
related decreased expression together with reduced expression of Ku70 and FoxO3, 
could further contribute to decreased neuronal vitality of neurons.   
UCP5 also is expressed in the adult brain (Andrews et al., 2005). Uncoupling 
activity results in reduced oxidative stress and decreased mitochondrial membrane 
potential with subsequently reduced cell death (Liu et al., 2006). This process could 
contribute to the proposed neuroprotective function of UCPs, which might be 
particularly important in high energy consuming areas such as hippocampus, cortex and 
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MHb (Kim-Han et al., 2001), where UCP5 is robustly expressed. The expression of 
UCP5 mRNA in the hippocampus, cortex and MHb decreased with age. This could 
increase oxidative stress, but also decrease calcium regulation which might influence 
synaptic plasticity and neurotransmission, and subsequently reduce neuronal survival 
(Andrews et al., 2005).   
Taken together, the expression of the longevity gene SIRT1 and several of its 
target genes are robust in cortex, hippocampus and MHb of young adult mice. However, 
decreased expression of several genes is evident in middle-aged, 18-month-old mice. 
The similar regulatory pattern between cortical structures and the MHb suggest a similar 
regulation of gene expression in different brain regions, and might also apply to other 
areas not included in this analysis. The combination of decreased Nampt, FoxO3, Ku70 
and UCP5 expression could render the brain more vulnerable to insults and neural 
damage prior to overt functional cognitive decline, and could contribute to the aging 
process. 
 
Expression of survival genes in 2-/- mice 
2-/- mice showed increased age-related atrophy in cortex and hippocampus, and 
alterations in cortical and hippocampal structures were already detected in young adults 
underscoring the importance of normal heteromeric nAChRs function in deterring early 
aging in the adult brain. Heteromeric nAChRs are also involved in the regulation of body 
weight (Huang and Winzer-Serhan, 2007), and can be tied to the insulin/IGF-1 signaling 
pathway (Sugano et al., 2006), which has been implicated in the regulation of survival 
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genes by caloric restriction (Cohen et al., 2004b). Although, insulin/IGF-1 signaling 
might be deregulated in 2-/- mice, and could contribute to the accelerated brain aging, 
there was no difference between genotypes in any of the genes analyzed in young adult 
2-/- and WT mice. This suggests that these genes are not directly affected by loss of 
2* nAChRs in young animals. In contrast, middle-aged 2-/- mice exhibited increased 
Ku70 mRNA expression and although spatially restricted, increased expression levels of 
Nampt and SIRT1 compared to WT mice. Together these data suggest that the early 
onset of brain aging in 2-/- mice is not the result of decreased expression of survival 
genes, and indicates an alternative mechanism by which heteromeric nAChR activation 
provides neuroprotection. However, in older animals, loss of nAChRs in 2-/- mice 
could potentially increase neurotoxic stress, which then could result in increased 
expression of certain survival genes such as Ku70, Nampt and SIRT1, in an attempt to 
provide neuroprotection similar to that seen with caloric restriction (Kim et al., 2007b).  
In support of this explanation, lack of serotonin 1B receptors which also results in early 
onset brain aging, is accompanied by increased expression of SIRT5 mRNA expression 
in cortex (Rosen et al., 2000). 
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CHAPTER III 
LACK OF HIGH AFFINITY NICOTINIC ACETYLCHOLINE RECEPTORS 
DECREASES NUMBER OF GABAERGIC INTERNEURONS BUT NOT 
SYNAPTIC DENSITY IN THE HIPPOCAMPAL REGION OF MIDDLE-AGED 
MICE 
 
SUMMARY 
Loss of high affinity nicotinic acetylcholine receptors (nAChRs) in 2 knockout 
(2-/-) mice has been correlated with accelerated neurodegeneration during aging, 
including, decreased cortical thickness, decreased hippocampal volume, and increased 
neuronal densities. These anatomical alterations could result from decreased 
connectivity due to loss of synapses or decreased dendritic arborization, or result from 
loss of neurons. In this study, we performed Golgi-Cox staining to investigate spine 
density and dendritic arborization, and we used immunohistochemistry (IHC) to localize 
synaptic markers: synapsin I and PSD95 for presynaptic vesicles and postsynaptic 
densities, respectively, and a marker for GABAergic neurons, glutamic acid 
decarboxylase (GAD) 67, to study synaptic and inhibitory interneuron densities. For 
Golgi-Cox staining, brains from 18-month-old male 2-/- and wild type (WT) mice were 
fixed and stained in Golgi-Cox solution at room temperature in the dark for 4 months 
and 80 m coronal brain sections were cut. The number of primary dendrites, somatic 
area, apical spine density, and basal spine density were determined. For IHC, 12 µm 
coronal sections were cut using perfused brains from 18-month-old male WT and 2-/- 
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mice and stained with antibodies specific for GAD67, synapsin I, and PSD95. Golgi 
staining revealed that the number of primary dendrites, somatic area, apical spine 
density, and basal spine density for pyramidal cells in neocortical layers II/III were 
identical between WT and 2-/- mice. Mean gray values for synapsin I and PSD95 IHC 
staining were measured. No differences were found in any region of the hippocampus 
indicating that loss of high affinity nAChRs did not affect synaptic density in this area. 
Numbers of GAD67 positive neurons per area were determined in the hippocampus. The 
cell density of inhibitory interneurons in the hippocampus showed a general genotype 
effect in all three regions, CA1, CA3, and the dentate gyrus (DG), with 2-/- mice 
displayed significantly lower GAD67 cell density compared to aged-matched WT mice 
(two-way ANOVA, CA1: p = 0.04; CA3: p = 0.006; DG: p = 0.014). Significant 
differences were specifically observed in the CA1 molecular layer (p = 0.024), CA3 
oriens (p = 0.043), and DG molecular layer (p = 0.013). Experiments were done to 
evaluate the synaptic and GABAergic interneuron density in different layers of the 
neocortex and characterize the GABAergic subpopulation most affected by loss of high 
affinity nAChRs. Thus far, the data suggest that loss of endogenous activation of 
heteromeric nAChRs has little effect on synaptic connections, but strongly impairs 
survival of hippocampal GABAergic neurons.     
 
INTRODUCTION 
Loss of nicotinic binding sites, especially in cortico-hippocampal regions, is one 
of the major histological changes observed in normal brain ageing as well as 
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neurodegenerative diseases related with dementia such as AD. Pentameric nAChRs are 
ligand-gated cation channels formed by various combinations of  and  subunits. The 
7- and 42-containing receptors are the most abundant and widely distributed in 
mammalian brains.          
Activation of neuronal nAChRs by nicotine and nicotinic agonists exerts 
neuroprotective effects. 2 subunit knock-out mice (2-/- mice) lack high-affinity 
nAChRs and exhibit deficits in spatial learning and memory, and increased 
neurodegeneration during ageing including decreased cortical thickness, decreased 
hippocampal volume, and increased neuronal densities. These anatomical alterations 
could result from decreased connectivity due to loss of synapses or decreased dendritic 
arborization, or result from loss of neurons. 
Synaptic loss has been found in both mouse models and human patients with 
several neurodegenerative diseases (Hof and Morrison, 2004; Shankar, 2010; Jindahra et 
al., 2012; Marcello et al., 2012; Pienaar et al., 2012). 2-/- mice have a tendency towards 
decreased basal dendritic size and complexity in almost all cortical areas, and 2 
containing nAChRs might be involved in dendritic morphogenesis (Ballesteros-Yanez et 
al., 2010).    
Loss of GABAergic neurons occurs during the later stages of AD. GABAergic 
interneurons play important roles in controlling the timing of pyramidal cell firing, 
synchronizing network activity, and the generation of cortical rhythms. They also seem 
to play an important role in responding to dynamic changes in excitation, increasing the 
dynamic range of cortical circuits, controlling sensory receptive fields and plasticity, and 
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maintaining the excitatory and inhibitory balance necessary for the transfer of 
information while preventing runaway excitation (McBain and Fisahn, 2001; Pouille and 
Scanziani, 2001; Wehr and Zador, 2003; Markram et al., 2004; Trevelyan et al., 2006; 
Klausberger and Somogyi, 2008; Haider and McCormick, 2009). GAD mediated GABA 
synthesis occurs in the cytosol, and GABA is transported into synaptic vesicles by the 
vesicular GABA transporter. Triggered by an action potential, vesicular GABA is 
released in a Ca
2+
-dependent manner (Gonzalez-Burgos et al., 2011). In parvalbumin 
(PV) neuron terminals, PV may act as a Ca
2+
 buffer that binds residual Ca
2+
 after 
activation of the Ca
2+
 sensor that triggers GABA release (Gonzalez-Burgos et al., 2011). 
Malfunction of these neurons has been implicated in a number of diseases ranging from 
epilepsy to schizophrenia, anxiety disorder and autism (Cossart et al., 2001; Noebels, 
2003; Levitt et al., 2004; Cobos et al., 2005; Gonzalez-Burgos and Lewis, 2008). 
Chronic dosing with nicotine in rat neonates increases the number of GABAergic 
neurons in the hippocampal area (unpublished data from Dr. Ursula H. Winzer-Serhan, 
Department of Neuroscience and Experimental Therapeutics, Texas A&M Health 
Science Center, Bryan, TX). Thus, loss of high affinity nicotinic receptors could result in 
decreased numbers of GABAergic interneurons. 
In this study, we performed Golgi-Cox staining to investigate dendritic spine 
density.  We also used IHC for synaptic markers: synapsin I and PSD95 for presynaptic 
vesicles and postsynaptic densities, respectively, and as a marker for GABAergic 
neurons, GAD67, to study synaptic and inhibitory interneuron densities. 
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EXPERIMENTAL PROCEDURES 
 
Animals and tissue preparation  
Male C57BL/6: +/+ (wild type) and 2-/- mice were group housed in a room that 
was on a 12-hour light/dark cycle. All mice were given food and water ad libitum until 
they reached an average age of 17 months. For Golgi-Cox staining (n = 6), mice were 
anesthetized using isoflurane and decapitated. Brains were dissected into right and left 
hemispheres and put directly into Golgi-Cox solution. For immunohistochemistry 
staining (n = 6), mice were anesthetized with an intraperitoneal injection of 
ketamine/xylazine and transcardially perfused with Tyrode’s saline followed by 4% 
paraformaldehyde. Brains were removed, cryoprotected in 20% sucrose overnight and 
rapidly frozen. Coronal sections through the rostral hippocampi were cut (12m) and 
mounted on gelatin coated glass microscope slides. Adjacent sections on the same slide 
were separated by 15 sections. Tissue sections were stored at -70°C until used. All 
procedures were approved by the Texas A&M University Animal Use Committee and 
carried out in accordance with the National Institutes of Health Guide for the Care and 
Use of Laboratory Animals (National Institutes of Health Publication No. 85-23, revised 
1996). 
 
Golgi-Cox staining  
Each pair of half brains sat in 50 to 100 ml of filtered 0.8% potassium chromate, 
1% potassium dichromate, 1% mercuric chloride Golgi-Cox solution in the dark at room 
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temperature for 5 months. Each half brain was rinsed in deionized water, briefly 
immersed in 70% ethanol and then encased in paraffin. Thick 75-100 µm coronal 
sections through the region of the rostral hippocampus were cut using a sliding 
microtome. Sections were then reacted with 5% ammonium hydroxide for 20 minutes, 
dehydrated, and mounted onto plain glass microscope slides using permount. 
 
Immunohistochemistry staining  
Antigen retrieval was carried out for 15-30 minutes, in 10 mM trisodium citrate 
buffer at 80°C. Subsequently the sections were processed for standard 
immunohistochemistry using diaminobenzidine as the chromagen (Abbott and 
Jacobowitz, 1999). GAD67: mouse monoclonal, 1:20,000 (Chemicon); parvalbumin: 
mouse monoclonal, 1:20,000 (Chemicon); synapsin I: rabbit polyclonal, 1:10,000 
(AbCam). PSD95: rabbit polyclonal, 1:5000 (AbCam). 
 
Data analysis  
For Golgi-Cox, sections were examined by light microscopy using a microscope 
(Nikon Eclipse E400) equipped with a camera (Nikon digital camera DXM 1200) and an 
oil-100X objective. With the investigator blind to the genotype, 6 to 8 cortical layer II/III 
pyramidal cells from each animal were selected for analysis. Dendritic lengths and 
somatic areas were measured using ImageJ 1.43S (Rasband, 1997-2011). Again, with the 
investigator blind to the genotype, for GAD67 and parvalbumin, cell counts that were 
carried out in specific regional areas were converted into cell densities. Cells were 
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counted using the 10X objective. Photomicrographs of each section analyzed were taken 
using the 4X objective. Areas were measured using ImageJ 1.43S. For synapsin I and 
PSD95, four sections per animal (both sides) were photographed using the 4X objective 
for the hippocampus, and the 10X objective for the somatosensory cortex. Exposure 
conditions were kept constant during photographing. Using NIH-imageJ 1.43S, pictures 
were converted to 8 bit and inverted, and the mean gray value and modal gray value 
were measured (0 = pure black; 255 = pure white). For the hippocampus, measurements 
were done at the CA1 stratum oriens, CA1 pyramidal cell layer, CA1 stratum radiatum, 
CA1 molecular layer, CA3 stratum oriens, CA3 pyramidal cell layer, CA3 molecular 
layer (combined with striata lucidum and radiatum), dentate gyrus (DG) molecular layer, 
DG granular cell layer, and DG hilus region (Fig. IV-1). For the somatosensory cortex, 
measurements were done within a 300 m wide column and separated into layer II & III, 
IV, V, and VI. Mean gray values were measured using ImageJ 1.43S. 
 
Statistics  
SPSS 14.0 was used for data analysis. Two-way ANOVAs (genotype vs. region) 
followed by the Tukey’s HSD post hoc test was used for GAD67, PV, synapsin, and 
PSD95 immunohistochemistry analysis. The Student’s t-test was used for somatic area, 
dendritic number, and dendritic spine density analysis. = 0.05. 
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Figure III-1. Anatomy of mouse hippocampal cross section. 
 
 
RESULTS 
GAD67 labeled GABAergic interneurons were examined in middle-aged 2-/- 
and wild type mice. In the hippocampus, all three areas (CA1, CA3 and DG) displayed 
significant decreases in GAD67 positive cell density in 2-/- mice as compared to age-
matched wild type (Fig. III-2). In the hippocampal CA1 area, analysis using two-way 
ANOVA (subregion vs. genotype) indicated a general genotype effect (p = 0.04), with 
the molecular layer showing a significant difference between the two genotypes after 
running Tukey’s HSD post hoc test (p = 0.024) (Fig. III-2B). In the hippocampal CA3 
region, analysis using a two-way ANOVA indicated a general genotype effect (p = 
0.006), with the stratum oriens layer showing a significant difference between the two 
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genotypes after running the Tukey’s HSD post hoc test (p = 0.043) (Fig. III-2C). In the 
DG, the two-way ANOVA also indicated a general genotype effect (p = 0.014), with the 
molecular layer showing significant difference between genotypes, after running the 
Tukey’s HSD post hoc test (p = 0.013) (Fig. III-2D). However, in the somatosensory 
cortex no difference was found between the genotypes (Fig. III-2E).  
The decrease in GABAergic cell density could be accounted for by the  possible 
decreased presence of parvalbumin expressing interneurons, so parvalbumin labeled 
GABAergic interneurons were investigated in middle-aged 2-/- and wild type mice 
(Fig. III-3). Unlike GAD67, except for hippocampal CA1 region, none of other regions 
showed any difference in parvalbumin cell densities between the two genotypes. In the 
hippocampal CA1, the two-way ANOVA indicated a strong interaction between 
genotype and subregion (p < 0.001), so the subregions were further analyzed separately 
using Student’s t-test. Only the pyramidal cell layer showed a decrease in parvalbumin 
immunopositive cell density in 2-/- mice as compared to age-matched wild type mice 
(Fig. III-3B). Levels of pre‐ and post‐synaptic markers measured by synapsin I (Fig. III-
4) and PSD95 (Fig. III-5) respectively using immunohistochemistry did not change in 
the cortico‐hippocampal region in middle-aged 2-/- mice as compared to wild type 
mice.  There also was no difference between middle-aged 2 knock‐out mice and wild 
type mice with respect to the number of primary dendrites, the soma area, and the 
dendritic spine density of cerebral cortex layer III pyramidal cells (Fig. III-6). 
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Figure III-2. GAD67 labeled GABAergic interneurons were investigated in middle-
aged 2-/- and wild type mice. Hippocampus: two-way ANOVA, region vs. genotype; 
neocortex: Student’s t-test. WT, n = 6; KO, n = 5. # general genotype effect p < 0.05, ## 
general genotype effect p < 0.01, * Post-hoc Tukey’s HSD test p < 0.05. Scale bars: 
insets-10 m; whole regions- 500 m; subregions- 100 m. 
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Figure III-3. Parvalbumin labeled GABAergic interneurons were investigated in 
middle-aged 2-/- and wild type mice. Hippocampus: two-way ANOVA, region vs. 
genotype; neocortex: Student’s t-test. WT, n = 6; KO, n = 5. # general genotype effect p 
< 0.05, ## general genotype effect p < 0.01, * Post-hoc test p < 0.05. Arrowheads in 
inset indicate parvalbumin positive neurons. Identify abbreviations used in the figure. 
Scale bars: insets-10 m; whole regions- 500 m; subregions- 100 m. 
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Figure III-4. Levels of pre‐synaptic markers that were measured by synapsin I using 
immunohistochemistry. Hippocampus: two-way ANOVA, region vs. genotype; 
neocortex: Student’s t-test. WT, n = 6; KO, n = 5. DG, dentate gyrus; Ori, oriens layer; 
Py, pyramidal cell layer; Rad, stratum radiatum; Mol, molecular layer; SLu, stratum 
lucidem; Gra, granular cell layer; Ctx, neocortex; Alv, alveus. Scale bars: 100 m. 
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Figure III-5. Levels of post‐synaptic markers measured by PSD95 using 
immunohistochemistry. Hippocampus: two-way ANOVA, region vs. genotype; 
neocortex: Student’s t-test. Wild type mice = WT, n = 6; B2-/- mice = KO, n = 5. Scale 
bars: 100 m. 
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Figure III-6. No differences were observed between middle-aged 2 knock‐out mice 
and wild type mice with respect to the number of primary dendrites, the soma area, and 
dendritic spine density for neocortex layer III pyramidal cells. Student’s t-test, n = 6. 
Red arrowheads: primary dendrites; blue arrow head: axon; dashed line: measured soma 
area. Scale bars: 10 m. 
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DISCUSSION 
GABAergic interneurons represent 10-20% of all neocortical neurons in rodents 
(Rudy et al., 2011). GABAergic neurons have the capacity to synthesize GABA from 
glutamate via the enzymatic activity of GAD, for which there are two gene products with 
different molecular size: GAD65 and GAD67 (Soghomonian and Martin, 1998). These 
two GAD isoforms differ with respect to a number of properties, but their specific 
functions are still not fully understood (Soghomonian and Martin, 1998). However, 
GAD65 and GAD67 are differentially expressed in GABAergic terminals in a cell type-
specific manner. The ratio of GAD67/GAD65 expression  has been shown to vary 
significantly with respect to different types of terminals (Fish et al., 2011). Though the 
differential functional roles of GAD67 and GAD65 are still poorly understood, in mice, 
GAD67 deficiency has been associated with major developmental defects. GAD67-/- 
animals are born with several deficits including cleft palate, and this knockout has 
proven lethal and with ~ 90% reduction of total GABA concentration in brain tissue 
(Asada et al., 1997; Ji and Obata, 1999). In contrast, GAD65-/- mice are able to survive 
into adulthood, displaying only a ~20% reduction in total brain GABA concentration 
(Asada et al., 1996). GAD65-/- mice also display increased susceptibility to epileptiform 
seizures (Asada et al., 1996; Kash et al., 1997), increased anxiety (Kash et al., 1999), and 
altered fear conditioning (Sangha et al., 2009).  Importantly, when GAD67 is reduced 
but not totally absent, there is marked impairment in the maturation of cortical 
GABAergic synaptic connections (Chattopadhyaya et al., 2007). GAD65 and GAD67 
both comprise ~50% of total GAD protein in the mouse neocortex while the proportions 
 82 
of GAD protein in human cortex are unknown (Sheikh et al., 1999). Our results 
indicated that loss of endogenous activation of heteromeric nAChRs strongly impairs 
survival of GAD67 positive hippocampal interneurons in middle-aged mice. This is in 
line with the unpublished previous results that chronic dosing with nicotine in rat 
neonates increases the number of GABAergic neurons in the hippocampal area.  
Numerous studies of rodent brain tissue have suggested that among GABAergic 
interneurons, the Ca
2+
-bonding protein PV and the neuropeptide somatostatin (SST) are 
particularly useful, because they define non overlapping groups of interneurons in the 
cortex and account for 40% and 30% of GABAergic interneurons in the somatosensory 
cortex, respectively (Gonchar and Burkhalter, 1997; Kawaguchi and Kubota, 1997; 
Ascoli et al., 2008; Lee et al., 2010; Miyoshi et al., 2010; Xu et al., 2010). The other ~ 
30% of the total population are ionotropic serotonin receptor 5HT3a (5HT3aR) neurons, 
which are exclusively on GABAergic neurons and this GABAergic neuronal population 
does not overlap with PV and SST expressing interneurons (Morales and Bloom, 1997; 
Ferezou et al., 2002; Puig et al., 2004; Rudy et al., 2011).  
Subtypes of hippocampal interneurons were differentially affected by the loss of 
2‐nAChRs. While GAD67 positive cells were decreased in all areas of the 
hippocampus in our experiments, the PV positive neurons only decreased in the CA1 
pyramidal layer in middle-aged 2‐/‐mice, suggesting that PV positive neurons in the 
CA1 pyramidal layers were more susceptible to chronic nicotine treatment than PV 
positive cells in other areas. The decreased in GAD67 positive cells in other areas than 
CA1 pyramidal layers in the hippocampus was due to the SST or 5HT3aR expressing 
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GABAergic neurons. The reasons for CNE differential regulations in GABAergic 
subtypes in difference areas need further study.   
Our data indicated that both pre‐and post‐synaptic marker levels did not change 
in response to loss of high affinity nAChRs. Using Golgi stain, there was no change in 
somatic area, number of primary dendrite and dendritic spine density in response to loss 
of high affinity nAChRs. It has been shown that acute nicotine treatment significantly 
increases synapsin I activity, which is mediated by 2‐nAChRs, but not total protein 
level (Jackson et al., 2009). Prenatal nicotine exposure significantly increased PSD95 
levels at postnatal day1, but it is not known whether this effect is mediated by 
2‐nAChRs (Wang et al., 2011). Nicotine exposure also has been shown to increase 
spine density in both the nucleus accumbens and prefrontal cortex (Brown and Kolb, 
2001; Gonzalez et al., 2005). Our results indicated that the spine density was not 
changed in pyramidal cells in cortical layer III of somatosensory cortex. Some studies 
have found that nicotine exposure will increase branching in the motor cortex, but other 
more recent studies have found  no effect on the adjacent somatosensory cortex (Brown 
and Kolb, 2001; Gonzalez et al., 2005). These suggest that neurons in the somatosensory 
cortex may have more resistance toward loss of endogenous nAChRs activation than 
other brain areas such as the nucleus assumbens and prefrontal cortex.  
Together, the data suggest that loss of endogenous activation of heteromeric 
nAChRs has little effect on synaptic connections, but strongly impairs survival of 
hippocampal GABAergic neurons. 
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CHAPTER IV 
EFFECTS OF CHRONIC ORAL NICOTINE ON FOOD CONSUMPTION, 
ANXIETY AND EXPRESSION OF SIRT1 AND RELATED GENES IN YOUNG 
ADULT MOUSE BRAIN  
 
SUMMARY 
Nicotine exerts numerous effects on energy metabolism, anxiety and cognitive 
performance by activating neuronal nicotinic acetylcholine receptors (nAChRs). 
Nicotine’s anorectic action results in lower body weight and body mass index. Caloric 
restriction (CR) has beneficial effects and activates expression of a series of longevity 
genes like SIRT1. Therefore, we hypothesized that nicotine exposure would decrease 
food intake and also increase expression of longevity genes. Young adult (3-month-old) 
C57BL/6 male mice were dosed for three weeks with 300 g/ml nicotine in drinking 
water containing saccharin. 
125
I-epibatidine binding sites were measured using receptor 
autoradiography in brain slices from nicotine- and control-treated mice. Increased 
nAChR binding, a hallmark of chronic nicotine exposure (CNE), was detected in the 
neocortex (p = 0.055) and hippocampus (p = 0.019) indicating that relevant levels of 
nicotine reached the brain. CNE significantly decreased average daily food intake (p = 
0.005), and reduced daily weight gain (p = 0.063), resulting in lower body weight (p = 
0.043). Nicotine’s effect on cognitive function was evaluated using a modified elevated 
plus maze (EPM) and an object recognition test, and no significant differences due to 
treatment were observed. Nicotine’s anxiolytic effect was determined in an open field 
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test. The results revealed a significantly lower thigmotaxis index (p = 0.021) and less 
margin time (p = 0.025) in the nicotine-treated mice compared to control mice indicating 
decreased anxiety. Finally, using isotopic in situ hybridization with cRNA probes for 
several genes associated with CR, we found that mRNA levels for SIRT1 (p = 0.014), 
Nampt (p = 0.023), and Ku70 (p = 0.002) were significantly increased in cortico-
hippocampal areas in the brains of nicotine-treated mice compared to controls, with 
Ku70 exhibiting the most robust change. However, mRNA expression levels for FoxO3, 
p53, and the neurotrophic factors NT-3 and BDNF remained unchanged. These data 
indicate that three weeks of oral nicotine self-administration is anxiolytic, decreases 
caloric consumption, increases nAChR binding sites, and expression of SIRT1 and 
several of its target genes. 
 
INTRODUCTION 
Nicotine is the major psychoactive ingredient in tobacco smoke (Hajek et al., 
1988) and interacts with neuronal nicotinic acetylcholine receptors (nAChRs). NAChRs 
are pentameric ligand gated cation channels that are either homomerically or 
heteromerically formed by different subunit combinations. Among these combinations, 
heteromeric 42 nAChRs have high affinity for nicotine, and are the most widely 
expressed nicotinic receptors in the mammalian brain together with homomeric 7 
nAChRs, which have lower affinity for nicotine. The combined effects of nicotine 
influence behaviors such as food intake, anxiety and cognitive performance (Cooper et 
al., 1991; Sargent, 1993b; Picciotto et al., 1998). The neuroprotective effects of nicotine 
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and its agonists have been widely reported both in vivo, and in vitro (Picciotto and Zoli, 
2008a). Preclinical studies indicate that nicotine and its agonists can protect neurons 
from excitotoxicity, and other insults including amyloid beta induced neuronal toxicity. 
Thus, nicotinic agonists including nicotine might prevent neuronal death due to 
neurodegeneration, which is particularly important in neurodegenerative diseases such as 
Alzheimer’s disease (AD) and Parkinson’s disease (PD) (Owman et al., 1989; Socci and 
Arendash, 1996; O'Neill et al., 1998). Furthermore, epidemiological studies have shown 
that smoking is negatively correlated with PD and AD (Fratiglioni and Wang, 2000), 
suggesting that nicotine, the major psychoactive ingredient in tobacco smoke, may 
prevent or delay the development of AD and PD.  
Cholinergic deficits are characteristic for AD, and decreased numbers of nAChRs 
have been detected in postmortem brain slices from AD patients (Whitehouse et al., 
1986; Whitehouse et al., 1988). Several studies have demonstrated that smoking 
increases nAChRs in the brains of smokers, most likely due to chronic nicotine 
exposure, which results in receptor upregulation (Perry et al., 1999; Mukhin et al., 2008). 
In addition, experiments have shown that nicotine and nicotinic agonists, when given 
acutely, can improve memory and cognitive function (Wilson et al., 1995; Rezvani and 
Levin, 2001; Levin and Rezvani, 2002). Thus, medicinal use of nicotine or related 
nAChR agonists could have beneficial therapeutic effects, by increasing nAChRs in the 
brain, protect against neuronal degeneration caused by a number of different insults, and 
improve cognitive function, and hence, protect the brain against age-related cognitive 
decline and neurodegeneration. Therefore, despite its abuse potential, nicotine and 
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nicotinic receptor agonists have been evaluated for their therapeutic potential, especially 
during aging or to repair brain injury (Nordberg et al., 2002; White and Levin, 2004; 
Aleisa et al., 2006; Weiss et al., 2007; Srivareerat et al., 2009).  
However, it should be noted that nicotine not only acts in the CNS it also 
interacts with nAChRs in the peripheral nervous system (PNS) and enteric nervous 
system (ENS). In the PNS, nAChRs are major regulators of the sympathetic and 
parasympathetic functions, and enteric nAChRs regulate gastrointestinal motility 
(Torocsik et al., 1991; Wessler et al., 1992). In addition, nicotine is an addictive drug 
that stimulates dopamine release and activates the reward pathway in the CNS (Kleijn et 
al., 2011; Zhang et al., 2012). Thus, if nicotine were to be used therapeutically, a low 
dose of nicotine would need to be administered to avoid PNS- and ENS-related side 
effects, and to reduce the potential for abuse.  
Nicotine also has an anorectic action and subsequent decreases in body weight 
and body mass index following nicotine use have been documented both in human and 
experimental animals (Wager-Srdar et al., 1984; Hajek et al., 1988; Bellinger et al., 
2003). Caloric restriction (CR) is a regimen that extends lifespan in all mammalian 
species studied so far including rodents and primates (Picard and Guarente, 2005; Wolf, 
2006). It is believed that the longevity effect of CR is mediated by SIRT1, a 
nicotinamide adenine dinucleotide-dependent deacetylase (Cohen et al., 2004b; Tang 
and Chua, 2008). It is becoming apparent that SIRT1 is a key regulator of cell defenses 
and survival in response to stress in mammals, and upregulation of SIRT1 can protect 
neurons against neurodegeneration and neurotoxic insults (Chen et al., 2005b; Kim et al., 
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2007a). In aged mice lacking high affinity nAChRs, the expression levels of SIRT1 and 
its regulator and substrate, Nampt and Ku70 respectively, are increased, and this is 
thought to be a stress response due to lack of endogenous neuroprotection via 
heteromeric nAChR activation (Huang et al., 2011). However, little is known about 
SIRT1 expression or other CR-related genes in response to nicotine. Although no direct 
relationship has been reported between brain-derived neurotrophic factor (BDNF), 
neurotrophin-3 (NT-3) and SIRT1, studies have shown that BDNF and NT-3 levels are 
upregulated by CR in rats (Duan et al., 2001; Kumar et al., 2009), and chronic exposure 
to nicotine in adults and neonatal rats also has been shown to increase both BDNF and 
NT-3 expression levels too (Son and Winzer-Serhan, 2009).  
Considering the similarities between the actions of nicotine and CR, nicotine’s 
anorexic effects could play a significant part in its neuroprotective function by activation 
of growth factor expression and CR-related genes. In this study we determined a low but 
effective, centrally acting dose of nicotine administered orally via drinking water to 
mice, and evaluated the consequences on behavior and gene expression on SIRT1 and 
related genes, and on NT3 and BDNF. 
 
EXPERIMENTAL PROCEDURES 
 
Animals and drug administration 
Young adult male C57BL/6 mice, originally obtained from the Jackson 
Laboratory, were used in this study. A breeding colony was established at Texas A&M 
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University’s Laboratory Animal Research and Resource facility. At three months of age, 
mice were individually caged and randomly assigned to different dosing groups (n = 5).  
 
 
Table IV-1. Nicotine free base provided in 2% saccharine drinking water of each 
treatment group.  
Treatment day 
Day 
1 
Day 
2 
Day 
3 
Day 
4 
Day 
5 
Day 
6 
Day 
7 
Day 8-
23
a
 
Dosage 
(g/ml) 
Control 0 0 0 0 0 0 0 0 
Low 20 20 20 20 20 20 20 20 
Medium 20 40 60 80 100 100 120 120 
High 20 40 80 120 160 200 250 300 
a
 Mice were euthanized on day 23 of treatment. 
 
 
Mice received 2% saccharine (saccharin sodium salt hydrate, > 98%) (Sigma, St. 
Louis, MO, USA) in their drinking water two weeks prior to actual dosing with nicotine 
to establish their individual daily drinking volume. (-)-Nicotine (hydrogen tartrate) 
(Sigma) was administered in water containing 2% saccharine as previously described 
(Ribeiro-Carvalho et al., 2009). Four final nicotine concentrations were tested: control - 
0 g/ml (0 mg/kg/day), low - 20 g/ml (approximately 5 mg/kg/day, free base), medium 
- 120 g/ml (approximately 30 mg/kg/day, free base), and high - 300 g/ml 
(approximately 55 mg/kg/day, free base). Animals in the medium and high dose groups 
initially received 20 g/ml of nicotine on day 1 and the concentrations were gradually 
increased until the final concentrations were reached on day 7 and day 8, respectively 
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(Table IV-1). Animals were treated until day 23. On day 20 to 22, all mice were 
subjected to behavior tests and then euthanized on day 23. Access to food was ad 
libitum. Food intake and body weight were monitored every three days from day 1 to 
day 19 and normalized to the first measurement of each individual animal. All 
procedures were approved by the Texas A&M University Animal Use Committee and 
carried out in accordance with the National Institutes of Health Guide for the Care and 
Use of Laboratory Animals (National Institutes of Health Publication No. 85-23, revised 
1996). 
 
Open field 
To test locomotor, exploratory and anxiety behaviors, on day 20 of nicotine 
treatment, mice were placed individually in an open field (length × width × height: 20 × 
20 × 30 cm) (Versamax animal activity monitor and analyzer, AccuScan Instruments, 
Columbus, OH, USA) equipped with vertical and horizontal beam sensors. The 
apparatus was constructed using transparent Plexiglas, located in a quiet room, and 
environmental cues including lighting and experimenter were kept constant during 
testing. Mice were accustomed to the experimental room for 5 minutes, and then placed 
in the open field for 30 minutes. Activity was recorded every minute. The open field 
chamber was cleaned with 50% ethanol between mice. Horizontal activity, total 
distance, movement time, rest time, stereotype counts, stereotype time, margin distance, 
margin time, center distance, center time, rearing activity, and rearing time were 
automatically recorded. 
 91 
Elevated plus maze 
Cognitive functions were tested in an modified elevated plus maze (EPM) test as 
described previously (Biala and Kruk, 2009). The EPM apparatus was made of 
Plexiglas, which was painted matte black from the outside. The maze consisted of two 
open arms (without walls) facing opposite, and another two enclosed arms (15.25 cm 
high walls on three sides with one end left open) facing opposite so that they formed a 
plus shape as previously described (Walf and Frye, 2007). Each arm was 30 cm long and 
5 cm wide. The whole maze was elevated 40 cm off the ground, located in a quiet room 
illuminated by a central dim red light, and environmental cues were kept constant during 
testing. All mice were accustomed to the experimental room for 5 minutes before 
acquisition and retention trials. The maze was cleaned with 50% ethanol between mice. 
On day 20 of nicotine treatment, mice were individually subjected to an acquisition trial. 
Each mouse was placed at one end of one open arm facing away from the central 
platform and allowed to move from the open arm to either of the enclosed arms. A 
successful entry was considered when all four limbs were in the enclosed arm. If a 
mouse did not enter an enclosed arm within 90 seconds, it was placed in one of the 
enclosed arms and allowed to explore for another 60 seconds. On the next day (24 hours 
later, day 21), all mice were subjected to a retention trial in the same manner, and the 
time to successful entry was recorded as T2.  
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Object recognition 
One-trial object recognition was performed on day 22 of nicotine treatment to 
study recognition memory as previously described (Bevins and Besheer, 2006) with 
minor changes. A transparent Plexiglas chamber (length × width × height: 20 × 40 × 30 
cm) (AccuScan Instruments) coated outside with white bench protector (VWR, West 
Chester, PA, USA) was setup in a quiet room where the environmental cues including 
lighting were kept constant during testing. Mice were allowed to familiarize with the 
chamber individually for 5 minutes. Two identical sample objects (medium heavy duty 
black binder clips, 3.2 × 5.5 cm, OfficeMax) were placed in the back left and right 
corners of the chamber. The test animal was placed at the center of the chamber facing 
the front opposite to the sample objects with its nose pointing to either side and allowed 
to explore for 5 minutes. After a two-hour interval, one of the sample objects was 
replaced by a novel object (standard wooden clothes pin, 8.5 × 1 cm). The mouse was 
placed back into the chamber as described, and allowed to explore for 2 minutes. The 
chamber was cleaned with 50% ethanol between mice, and 3 minutes passed before the 
next test. A video camera (DIGITAL IXUS 50, Canon, Japan) was setup right above the 
apparatus so that the entire area including objects was recorded. Direct contact scoring 
was done by a blind investigator using XNote Stopwatch (free evaluation version, 
http://www.stopwatch-timer.com, dnSoft Research Group, accessed in 2011). The total 
time test animals spent on exploring objects (both sample and novel), and the time ratio 
(novel/total time) were analyzed and calculated. 
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Tissue preparation 
All mice were anesthetized using isoflurane (IsoFlo, North Chicago, IL, USA) 
and decapitated on day 23. Approximately 1 ml of trunk blood was collected from each 
mouse, kept on ice, and centrifuged at 4°C 3000 rpm for 20 minutes. One hundred to 300 
l of serum was collected from each mouse and sent to Bioanalytical Core Laboratory 
Service Center (Department of Pharmaceutics, School of Pharmacy, Virginia 
Commonwealth University, Richmond, VA, USA) for analysis of nicotine and cotinine 
levels. The brains were rapidly dissected, frozen on powdered dry ice, and stored at -
80°C until used. For in situ hybridization, 14 m thick coronal sections, 196 m apart, 
were cut using a cryostat from Bregma level -1.70 mm to -2.30 mm and thaw-mounted 
onto glass microscope slides coated with gelatin (Spectrum, Gardena, CA, USA) and 
poly-L-Lysine (Sigma). The sections were post-fixed with 4 % paraformaldehyde in 0.1 
M phosphate buffer, pH 7.4, for 1 hour at room temperature (RT), washed in 0.1 M 
phosphate buffer three times, 5 minutes each, air-dried, and stored with desiccants at -
20°C until used. For epibatidine binding, sections were collected the same way but 
mounted on glass microscope slides coated twice with gelatin only. Sections were then 
boxed with desiccant, left at 4 °C overnight, and stored at -80°C until used.  
 
Epibatidine binding 
Epibatidine binding was performed as previously described with minor changes 
(Huang and Winzer-Serhan, 2006b). Tissue sections were warmed to RT and pre-
incubated 5 minutes in Tris-HCl buffer (50 mM Tris-HCl, 120 mM NaCl, 5 mM KCl, 
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2.5 mM CaCl2, 1 mM MgCl2, pH 7.4). Sections were then incubated with 0.4 nM [
125
I]-
Epibatidine (PerkinElmer Life Science NEX358, Boston, MA, USA, specific activity: 
2200 Ci/mmol) for 1 hour at RT. For non-specific binding, sections were incubated with 
the presence of 400 M (-)-nicotine hydrogen tartrate. Sections were washed in ice-cold 
Tris-HCl buffer twice for 1 minute, followed by 10 seconds in cold double-distilled 
(dd)H2O, and dried under air stream for 1 hour. Sections were dried at RT overnight 
before exposure to BioMax MR Film (Kodak, Rochester, NY, USA). After 1-day of 
exposure, films were developed in D19 Kodak developer for 4 minutes, rinsed in water, 
fixed in Kodak Rapid Fixer for 5 minutes, and air-dried. 
 
cRNA probes synthesis and in situ hybridization 
Templates for the synthesis of cRNA probes were generated from mouse SIRT1, 
Ku70, Nampt, FoxO3a, p53, and rat NT-3 as previously described (Son and Winzer-
Serhan, 2009; Huang et al., 2011). A pBSks plasmid containing a 750-base region 
complementary to rat BDNF mRNA  (kindly provided by Dr. Carl Cotman, UC Irvine, 
CA) was used (Berchtold et al., 1999). The template for rat GAPDH is commercially 
available (Applied Biosystems/Ambion, TX). 
35
S-labeled cRNA probes were 
synthesized in antisense orientation in the presence of 
35
S-UTP (PerkinElmer Life 
Science) with T3 or T7 RNA polymerase (Applied Biosystems/Ambion) by in vitro 
transcription.  
The method for in situ hybridization was described earlier (Winzer-Serhan et al., 
1999). Briefly, tissue sections were pre-hybridized with 0.1 g/ml proteinase K for 10 
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minutes at RT followed by 0.1 M triethanolamine and 0.25 % acetic anhydride. After 
overnight (16-20 hours) hybridization at 60°C, sections were treated with RNase A at 
37°C for 30 minutes and washed in standard Saline Sodium Citrate (SSC) followed by a 
hot wash in 0.1X SSC at 65°C for 30 minutes. Slides were dehydrated through graded 
series of alcohols and air-dried. Sections were exposed to BioMax MR film along with 
[
14
C]-standards (Amersham, Code RPA 504L, Batch21, Buckinghamshire, UK), and the 
films were developed as described in receptor binding section. 
 
Autoradiogram analysis 
Quantitative analysis of autoradiograms was done using a PC-base image 
analysis system, MCID basic (InterFocus Imaging Ltd, Haverhill, Suffolk, UK). For 
receptor binding, raw optical density (ROD) was measured in the hippocampus 
(combined measures in the molecular layers of the DG and the stratum lacunosum 
molecular of the CA1 in hippocampus proper), thalamus (the post thalamic nucleus and 
the ventral posteriomedial thalamic nucleus), and cerebral cortex (the deeper layer IV-V 
of the visual and somatosensory cortex). For the analysis of the hybridization signal, a 
standard curve (ROD vs. nCi/g wet weight) was generated using [
14
C]-standards and 
ROD values were converted to nCi/g wet weight. Measurements were taken in the 
pyramidal cell layer of the CA1 and CA3, and in the granular cell layer of the DG of the 
hippocampus, and in the entire cerebral cortex located on individual sections. All 
hybridization signals were normalized to the level of GAPDH of the same region. All 
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anatomical structures were located according to the Mouse Brain Library atlas (Rosen et 
al., 2000). 
 
Statistical analysis 
SPSS 14.0 was used for statistical analysis. Significance was defined as p ≤ 0.05. 
For food intake and body weight changes, repeated measurements were used for 
between-subject effects after nicotine reached the highest dose in all groups (day 8), and 
Student’s t-tests were used to determine significant differences at each time point 
between nicotine and control groups. For open field, object recognition and EPM, 
Student’s t-tests were performed to compare between nicotine and control groups. For 
receptor binding and gene expression, Student’s t-tests and two-way analysis of variance 
(ANOVA) (region vs. treatment) were used, respectively. After performing the two-way 
ANOVA, the Tukey HSD was used as a post hoc test when needed. All data were 
presented as average ± SEM. 
 
RESULTS 
 
Dose of nicotine in drinking water and blood nicotine and cotinine levels 
Nicotine and cotinine were not detected in the serum of control mice (< 2 ng/ml 
and < 1 ng/ml, respectively). In the low and medium nicotine group (20 g/ml and 120 
g/ml, respectively), mice had undetectable levels of nicotine (< 2 ng/ml). Cotinine 
levels ranged from of 3.2 to 25.0 ng/ml with an average of 11.7 ng/ml in the low nicotine 
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group, and from 2.0 to 586.9 ng/ml with average of 151.8 ng/ml in the medium nicotine 
group. In mice exposed to high levels of nicotine (300 g/ml) nicotine levels ranged 
from 0 to 21.1 ng/ml with an average of 6.2 ng/ml, and cotinine ranged from 41.4 to 
578.1 ng/ml with an average of 192 ng/ml.  
There was no difference in food intake and body weight between controls and 
low- and medium-nicotine-treatment groups (food intake: repeated measurements, 
between-subject effect, p = 0.52; body weight: repeated measurements, between-subject 
effect, p = 0.88). In addition, numbers of nAChR receptor binding sites measured in 
cortex, hippocampus and thalamus, showed no significant difference between controls 
and low and medium doses of nicotine (cortex: one-way ANOVA, p = 0.63; 
hippocampus: one-way ANOVA, p = 0.56; thalamus: one-way ANOVA, p = 0.45). 
Thus, together the results indicated that the low and medium doses may not be high 
enough to exert a central effect in mice. Only the high dose of nicotine resulted in 
significant differences in these measures, therefore, going forward, the high dose group 
is referred to as the “nicotine group”, and is the only nicotine treatment group that was 
compared to control mice in detail.  
 
Food intake and body weight changes 
Food intake and body weight were monitored every three days. Food intake at 
the first measurement was the same between control- and nicotine-treatment groups 
(control: 3.61 ± 0.14 g/day; nicotine: 3.75 ± 0.07 g/day), so subsequent measurements 
were normalized to the first measurement for each individual mouse, and comparisons 
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were made between groups starting from day 8, when the total dose of nicotine was 
reached (300 g/ml), and carried out to day 19. To avoid fluctuations in food intake and 
body weight caused by behavioral testing on day 20 to 23, data from days 20 to 23 were 
not included, but nicotine treatment continued. The average food intake was significantly 
lower in nicotine-treated compared to control mice (control: 4.30 ± 0.26 g/day; nicotine: 
3.79 ± 0.13 g/day; repeated measurements, between-subject effect, p = 0.005) (Fig. IV-
1). Due to variability in daily food intake, differences were only significant on day 11-13 
(control: 4.62 ± 0.15 g/day; nicotine: 4.06 ± 0.20 g/day; Student’s t-test, p = 0.011) and 
day 17-19 (control: 4.98 ± 0.19 g/day; nicotine: 4.51 ± 0.14 g/day; Student’s t-test, p = 
0.001) (Fig. IV-1). Overall, nicotine-treated mice decreased their food intake by about 
12% compared to controls, which was equal to an 88% calorically reduced diet for 12 
days (day 8 to day 19).  
Similar to food intake, body weights on the first day of treatment were identical 
between groups (control: 26.59 ± 1.00 g; nicotine: 26.39 ± 0.70 g), so subsequent 
measurements were normalized to the weight of each individual animal on the first day 
of body weight measurement. Body weights in control mice continuously increased over 
the treatment period, whereas body weights for nicotine-treated mice did not change. 
With the beginning of the full-dose nicotine treatment, after day 8, control mice gained 
on average 0.16 ± 0.04 g/day, resulting in a higher body weight at the end of the 
treatment. In contrast, nicotine-treated mice exhibited a slight loss of 0.02 ± 0.07 g/day, 
which result in a lower body weight at the end of the treatment as compared to control 
mice (weight gain, repeated measurements, between-subject effect, p = 0.063) (Fig. IV-
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2B). This resulted in a significant, 4% difference in body weight between treatment 
groups at the end of the treatment period (control: 27.59 ± 0.83 g; nicotine: 26.39 ± 0.51 
g; body weight, repeated measurements, between-subject effect, p = 0.043) (Fig. IV-2A). 
 
 
 
Figure IV-1. Nicotine-treated mice decreased their food intake compared to controls. 
Measurements from each mouse were normalized to their first measurements (day 2-4) 
and analyzed. Measurements were taken every three days until day 19. The dash line 
indicates the day nicotine administration reached the full dose (day 8). Con, control 
group. Nic, nicotine-treated group. Error bars: SEM. Repeated measurements, between-
subject effect, ## p < 0.01. Student’s t-test, compare between control and nicotine group, 
* p < 0.05, ** p < 0.01. 
 
 
 
 100 
 
Figure IV-2. Nicotine-treated mice did not gain as much weight as controls (B), which 
results in a lower body weight in the nicotine-treated mice (A). Body weight 
measurements from each mouse were normalized to their first measurements (day 1) and 
analyzed. Measurements were taken every three days until day 19. The dash line 
indicates the day nicotine administration reached the full dose (day 8). Con, control 
group. Nic, nicotine-treated group. Error bars: SEM. A, Repeated measurements, 
between-subject effect, # p < 0.05. Student’s t-test, compare between control and 
nicotine group, * p < 0.05. B, Repeated measurements, between-subject effect, p = 
0.063. 
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Locomotor activity, anxiety and memory behavioral tests 
On treatment day 20, mice were subjected to a 30 minute-open field test to assess 
locomotor activity, exploratory and anxiety behaviors. Twelve parameters were analyzed 
(see material and methods: open field). Of those, only margin and center time showed 
significant differences between treatment groups. All other parameters were not affected, 
indicating that locomotor activity and exploratory behavior were not impaired nor 
increased by chronic nicotine treatment. Mice were in the open field for 30 minutes, 
during which control mice spent 78% of the time at the margins, which was significantly 
longer than nicotine-treated mice which spent only 64% of the time at the margins (30 
minutes overall, Student’s t-test, p = 0.025) (Fig. IV-3A). When analyzed by 10 minute 
intervals, control mice spent significantly more time at the margins of the field than 
nicotine-treated mice during the first and second intervals (first Interval: control: 425 ± 
17 sec, nicotine: 352 ± 24 sec, Student’s t-test, p = 0.037; second Interval: control: 496 ± 
19 sec, nicotine: 392 ± 35 sec, Student’s t-test, p = 0.031), but differences diminished 
during the last interval when nicotine-treated mice spent more time at the margins 
(control: 475 ± 36 sec; nicotine: 411 ± 20 sec) (Fig. IV-3A). There was no difference in 
the margin distance or total distance traveled between groups; however, thigmotaxis 
(margin distance / total distance), thought to be an index of anxiety in mice (Simon et al., 
1994), was significantly higher in control than nicotine-treated mice in the second 10 
minutes interval (control: 0.71 ± 0.04; nicotine: 0.59 ± 0.03; Student’s t-test, p = 0.021) 
(Fig. IV-3B).  
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Figure IV-3. Anxiety levels were reduced in nicotine-treated mice as compared to 
controls indicated by margin time (A) and thigmotaxis index (B) in the open field test. A, 
Margin time is presented as second (sec). B, Thigmotaxis index is margin distance 
divided by total distance. Time in the open field was divided into three 10 minutes (min) 
intervals. Con, control group. Nic, nicotine-treated group. Error bars: SEM. Student’s t-
test, compare between control and nicotine group, * p-value of individual 10-minute 
interval < 0.05, # p-value of the whole 30 minutes < 0.05. 
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For memory and cognitive function, mice were tested in a modified EPM and an 
object recognition test, but neither test showed significant differences between treatment 
groups (modified EPM, T2: control: 21.2 ± 3.83 sec, nicotine: 22.2 ± 4.13 sec. Student’s 
t-test, p = 0.86; object recognition, time ratio: control: 0.49 ± 0.09, nicotine: 0.66 ± 0.11. 
Student’s t-test, p = 0.265). 
 
Epibatidine binding 
Receptor autoradiography using 
125
I-Epibatidine binding was performed to 
evaluate nicotinic receptor binding sites after chronic treatment to validate nicotine 
exposure in the brain (Corringer et al., 2006). Non-specific binding was negligible and 
the binding pattern was the same as previously reported with strong binding in the 
thalamic dorsal lateral geniculate nucleus, medial habenula, and fasciculus retroflexus, 
moderate binding in neocortical structures and low levels of binding in the hippocampus 
(Perry and Kellar, 1995; Huang and Winzer-Serhan, 2006a) (Fig. IV-4). In the 
hippocampus, low numbers of binding sites were with increased binding in the dorsal 
hippocampal commissure, alveus, lacunosum molecular layer, and the molecular layer of 
the dentate gyrus (Fig. IV-4A). In the hippocampus, relative 
125
I-Epibatidine binding 
levels measured as ROD values were determined in stratum lacunosum molecular of the 
CA1, and the molecular layer of the dentate gyrus in control- and nicotine-treated 
animals. 
125
I-Epibatidine binding was significantly higher in nicotine-treated mice than 
in controls (control: 0.39 ± 0.010; nicotine: 0.42 ± 0.003; Student’s t-test, p = 0.019) 
(Fig. IV-4B). Moderate 
125
I-Epibatidine binding was detected in the neocortex with more 
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intense binding in layers IV to VI compared to layers II/III (Fig. IV-4A). Relative 
125
I-
Epibatidine binding levels were measured in visual and somatosensory cortex in layers 
IV to VI from control- and nicotine-treated animals. The numbers of 
125
I-Epibatidine 
binding sites in nicotine-treated mice were higher than in controls (control: 0.48 ± 0.011; 
nicotine: 0.50 ± 0.007; Student’s t-test, p = 0.055) (Fig. IV-4B). In contrast, relative 
binding levels were not affected by nicotine treatment in thalamic areas (control: 0.70 ± 
0.024; nicotine: 0.68 ± 0.011) (Fig. IV-4B). 
 
Expression of longevity genes and neurotrophins 
The expressions of five CR-related longevity genes were assessed in this study. 
The expression patterns were the same as previously reported (Huang et al., 2011). The 
mRNA expression levels were measured in principal layers of hippocampal CA1, CA3 
and DG, and in layers II to VI of somatosensory cortex and normalized to GAPDH 
expression. There was a significant nicotine treatment effect, with nicotine increasing the 
overall expression levels of SIRT1, Ku70 and Nampt (two-way ANOVA, general 
treatment effect, p = 0.014, p = 0.002 and p = 0.023, respectively) (Fig. IV-5A, B and 
C). Post hoc analysis revealed that Ku70 mRNA expression was significantly increased 
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by nicotine treatment in CA1 (control: 96.1 ± 5.5; nicotine: 120.0 ± 7.0; Student’s t-test, 
p = 0.028) (Fig. IV-5B). In contrast, no significant treatment effects were detected for 
FoxO3 and p53 mRNA expression (Fig. IV-5E, F), although, there was an overall trend 
detected for FoxO3 with nicotine-treated mice exhibiting higher levels than controls 
(two-way ANOVA, general treatment effect, p = 0.089) (Fig. IV-5D). 
The effects of chronic nicotine exposure on growth factor mRNA expression 
were determined for BDNF and NT-3. The expression patterns were the same as 
previously described (Son and Winzer-Serhan, 2009; Di Liberto et al., 2010). 
Measurements for BDNF were taken in the same areas as for the CR-related longevity 
genes described above, but NT-3 expression was measured only in CA2 and dentate 
gyrus since only these areas expressed NT-3 in the mouse brain. There were no 
significant differences nor trends in expression intensity or expression pattern in 
response to treatment for either neurotrophins, which correspond to another study 
showing that chronic oral nicotine has no effect on BNDF levels (Kivinummi et al., 
2011) (Fig. IV-5F). 
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Figure IV-4. Nicotine treatment increased the level of 
125
I-epibatidine bindings to 
heteromeric nAChRs in the cortico-hippocampal regions. A, Representative images of 
receptor autoradiograph. Scale bars: 2 mm. B, Quantitative analysis in the thalamus 
(Tha), neocortex (Ctx), and hippocampus (Hippo). Binding levels were presented as raw 
optical density (ROD). Con, control group. Nic, nicotine-treated group. Error bars: SEM. 
Student’s t-test, * p < 0.05. 
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Figure IV-5. SIRT1, Ku70 and Nampt mRNA levels were increased in cortico-
hippocampal regions in nicotine-treated mice as compared to controls. Quantification of 
mRNA levels of SIRT1 (A), Ku70 (B), Nampt (C), FoxO3 (D), p53 (E), and BDNF (F). 
Regions measured included granular cell layer of the dentate gyrus (DG), CA1 and CA3 
pyramidal cell layer of the hippocampus, and neocortex (Ctx). Data were normalized to 
GAPDH levels of the same areas. Con, control group. Nic, nicotine-treated group. Error 
bars: SEM. Two-way ANOVA, general treatment effect, # p < 0.05, ## p < 0.01. 
Student’s t-test, * p < 0.05. 
 
 
 108 
DISCUSSION 
The main purpose of this study was to identify a low dose of nicotine self-
administered via drinking water to mice that is safe and effective, and therefore, suitable 
for long-term treatment. Blood levels of nicotine and cotinine were determined, and, as 
indications of a centrally acting dose, food intake, body weight gain and number of 
nicotinic receptor binding sites were measured. Based on these parameters, the highest 
dose of nicotine in the drinking water (300 g/ml) was the only dose in this study that 
resulted in detectable nicotine blood levels, reduced food intake and body weight, and 
increased numbers of high affinity nAChR binding sites. In addition, we determined the 
effects of chronic treatment (300 g/ml) on behavioral measures of anxiety and learning 
and memory, and expression of SIRT and CR-related genes, and the neurotrophic factors 
BDNF and NT3. 
 
Dose of nicotine in drinking water and blood nicotine levels 
In this study, we treated young adult C57BL/6 male mice for a period of three 
weeks with three doses of nicotine via drinking water, which is non-invasive, stress-free 
and requires no additional handling, and therefore, can be used over long-periods of 
time. It is an established method of chronic self-administration, and is a viable 
alternative to repeated injections or surgical implantation of minipumps. In addition, 
administration via drinking water provides the nicotine fluctuations seen in smokers or 
people using oral nicotine replacement medications such as nicotine gums, sprays or 
lozenges. However, oral nicotine administration results in reduced bioavailability due to 
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ion trapping of nicotine in the acidic milieu in the stomach (Hukkanen et al., 2005), slow 
absorption through the gastrointestinal tract and rapid metabolism in the liver (Le 
Houezec et al., 1989). Additionally, mice metabolize nicotine more rapidly than rats or 
humans. Thus, it is difficult to estimate the bioavailability of orally administered 
nicotine based on the dose (Miller et al., 1977; Pekonen, 1993). Therefore, we initially 
evaluated different doses of nicotine and measured blood nicotine and cotinine levels. 
All three doses were well tolerated by the animals with no apparent negative effects on 
general appearance. In this study, the low and medium doses (20 g/ml and 120 g/ml, 
respectively) resulted in blood nicotine levels that were below the detection limit, and in 
highly variable blood cotinine levels suggesting, that the doses were too low to provide 
consistent nicotine exposure. Only the highest dose of nicotine (300 g/ml) had low but 
detectable blood nicotine levels with an average of 6.2 ng/ml. This blood nicotine 
concentration is comparable to levels seen in people using nicotine gum but below that 
after smoking a cigarette or using oral tobacco products like chewing tobacco or snuff 
(Hukkanen et al., 2005). Thus, 300 g/ml provided a low but effective dose in mice that 
is similar to a low dose in humans treated with nicotine replacement medications. The 
300 g/ml dose resulted in highly variable blood cotinine levels with an average of 192 
ng/ml, which is in line with findings from other groups. Research conducted in mice 
treated with nicotine via drinking water at concentrations of 200 to 500 g/ml resulted in 
plasma cotinine levels ranging from 652 to 1450 ng/ml (Pietila and Ahtee, 2000; 
Brunzell et al., 2003). The large variability of plasma cotinine levels between and within 
studies is likely due to the relatively short half-life of plasma cotinine in mice (20-40 
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minutes) compared to other species (rats 5-6 hours and human 19 hours) (Miller et al., 
1977; Benowitz et al., 1983; Petersen et al., 1984; Pekonen, 1993), and therefore, does 
not provide a reliable surrogate measure of blood nicotine levels in mice. Thus, the oral 
administration route in mice requires large doses of nicotine in drinking water to reach 
measurable blood levels of nicotine and cotinine that are comparable to low doses 
detected in humans.  
 
Dosing effects on food intake and body weight 
Chronic nicotine reduces body weight and suppress food intake in humans and 
laboratory animals through activation of nAChR located in brain stem and 
hypothalamus, thereby activating the central hypothalamic melanocortin system (Mineur 
et al., 2011). In neonates, even very low doses of nicotine reduce body weight gain, and 
in humans, people using nicotine replacement therapy during smoking cessation exhibit 
reduced weight gain (Allen et al., 2005; Huang et al., 2006; Ferguson et al., 2011).  
Thus, low doses of nicotine activating nAChRs in the CNS affected food intake and 
body weight. This anorexic effect of nicotine was seen only in our highest nicotine-
treatment group whereas low and medium doses had no effect on either food intake or 
body weight. This result supports the findings from the blood nicotine tests that only the 
highest dose of 300 g/ml of chronic nicotine treatment through drinking water results in 
low but effective nicotine levels. However, decreases in body weight and food intake 
have not consistently been reported with chronic oral nicotine administration (Sparks 
and Pauly, 1999), or were only seen after prolonged treatment (Pietila and Ahtee, 2000). 
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In our experiments, nicotine started to exhibit an effect on food intake and weight gain 
around the time the highest dose of nicotine was reached. However, as can be seen in 
Figure 1 and 2, food intake and body weight gain were highly variable on days 14 to 16 
of treatment. This corresponded to a period of construction in adjacent rooms in the 
vivarium. Although we cannot be certain, we believe that the construction noise caused 
stress for all animals in this study, which might have contributed to the altered feeding 
behavior during those days, which also affected body weight gain. Thus, different 
housing conditions or strain sensitivity to stress might explain inconsistencies in the 
results between our study and those reported by others. 
 
Upregulation of high affinity binding sites 
Another hallmark of CNE indicating that relevant amounts of nicotine reach the 
brain where nicotine can interact with nAChRs, is an increase in CNS heteromeric 
nicotinic binding sites (Corringer et al., 2006). Chronic nicotine treatment in rodents 
increases high affinity nicotinic binding sites in cortico-hippocampal regions (Pietila et 
al., 1998; Sparks and Pauly, 1999; Nuutinen et al., 2005). Human smokers also have 
greater densities of high affinity nAChRs compared to nonsmokers, most likely due to 
the action of nicotine on neuronal nAChR numbers (Perry et al., 1999; Mukhin et al., 
2008). Using receptor autoradiography, we determined that only the highest treatment 
dose of nicotine increased 
125
I-epibatidine binding to heteromeric nAChRs in cortico-
hippocampal regions, whereas, low and medium doses had no effect. This finding 
correlates well with other studies using an oral administration route via drinking water 
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that reported increased numbers of high affinity nAChR binding sites (Sparks and Pauly, 
1999; Nuutinen et al., 2005; Andreasen et al., 2009).  
Together, nicotine and cotinine blood levels, food intake, body weight, and 
receptor binding results indicate that this oral self-administration route is effective in 
reaching meaningful levels of nicotine in the brain, but that due to the rapid metabolism 
that occurs in mice, high levels of nicotine need to be administered in the drinking water. 
 
Effects of chronic nicotine exposure on behavioral measures 
Nicotine has been shown to have effects on anxiety and depression in both 
human and animal studies. In humans, smokers experience a lower anxiety level than 
non-smokers when challenged with stress, and increased anxiety levels during smoking 
cessation, which suggests that nicotine exposure reduces anxiety (Gilbert et al., 1989; 
Perkins and Grobe, 1992; Tate et al., 1993). However, in rodents, nicotine’s effects on 
anxiety are complex, and chronic or acute nicotine administration can result in either an 
anxiolytic or anxiogenic response which depends on several factors such as the dose, 
regimen and time after drug administration, and behavioral state of the animals 
(Picciotto et al., 2002).  An open field behavior test was used to access locomotion, 
exploratory activity and anxiety-like behavior in animals receiving the high dose of 
nicotine and compared to controls. Our results indicated that locomotor and exploratory 
activities were not changed in response to CNE. However, two parameters suggested 
that anxiety levels were reduced in nicotine-treated mice. Several animal studies also 
support an anxiolytic effect of chronic nicotine and nicotinic agonists (Brioni et al., 
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1994; Levin et al., 2007), but one study reported no change in anxiety-like behavior in 
male mice after chronic oral administration (Caldarone et al., 2008). Thus, in agreement 
with other studies, voluntary oral CNE does not result in increased anxiety, and in fact, 
might have anxiolytic effect in nicotine-treated male mice. 
Several studies provide evidence of improved cognitive function after CNE in 
mouse models of AD, schizophrenia, attention deficit hyperactivity disorder, and stress-
induced memory impairment (Aleisa et al., 2006; Weiss et al., 2007; Srivareerat et al., 
2009; Rushforth et al., 2011) as well as in animals without pathological conditions 
(Levin and Torry, 1996). Therefore, we evaluated learning and memory in a modified 
version of the EPM which tests the escape latency from the open arm into the enclosed 
center after one training trail as a measure for spatial memory (Biala and Kruk, 2009), 
and in the object recognition test, a measure of short-term memory (Bevins and Besheer, 
2006). We did not detect a difference in escape time in the modified EPM or in the 
object recognition test between animals treated with the high dose of nicotine and 
compared to controls. Thus, in this study, oral CNE did neither improve nor impair 
cognitive functions, which could be due to the small sample size (n = 5) although, there 
was not even a trend towards increased or decreased cognitive performance.  However, 
in our study we used young adult male mice without any impairments which are at their 
optimal level of memory performance, and in line with findings by other, nicotine 
treatment might not improve cognitive functions in young adults (Aleisa et al., 2006). 
This also supports Newhouse’s theory that results of nicotine stimulation are a reflection 
of baseline cognitive performance level (Newhouse et al., 2004).   
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Effects of chronic nicotine exposure on gene expression   
This study is the first to examine the possible relationship between the effect of 
nicotine and the expression of CR-related longevity genes namely SIRT1, Ku70, Nampt, 
p53, FoxO3, and the neurotrophic factors BDNF, and NT-3. Our previous study showed 
that 2 knockout mice which lack the predominant heteromeric nAChR subtype in the 
brain, increased their longevity gene expression in middle-aged 18-month old mice 
compared to age-matched wild type mice (Huang et al., 2011). This could be an 
adaptational response due to the accelerated aging, which is observed in these mice, and 
as seen in other mouse models of neurodegeneration (Zoli et al., 1999; Kim et al., 
2007a), or 2-nAChRs could directly influence expression of longevity genes. In this 
study, we evaluated the effects of CNE on the expression of several of these CR-
regulated survival genes to test if chronic activation of nAChRs affects their expression, 
and expression of the neurotrophic factors BDNF and NT-3 which are regulated by 
nicotine in adults and during development (French et al., 1999; Son and Winzer-Serhan, 
2009; Srivareerat et al., 2009). Increased expression of CR-related genes and 
neurotrophic factors could be beneficial to maintain healthy brain functions, and prevent 
insult- or age-related cognitive impairments, and thus could provide a mechanism 
through which nicotine asserts its positive effects on learning and memory, and reduces 
premature aging. In particular, increased expression of SIRT1 has been shown to not 
only protect against neurodegeneration but also play a vital role in normal brain function 
(Gao et al., 2010).   
 115 
SIRT1, Ku70, and Nampt exhibited changes in mRNA expression levels in 
response to CNE in cortico-hippocampal regions whereas mRNA expression of p53 and 
FoxO3 and of BDNF and NT-3 were not different from controls. Thus, it is possible that 
there is a molecular link between activation of nAChRs and SIRT1-related longevity 
genes. Nicotine, by interacting with nAChRs, activates multiple intracellular signaling 
pathways including PI3 kinase-AKT, JAK2/STAT3 and MEK/ERK (Kawamata and 
Shimohama, 2011) which could regulate transcription of CR-related genes. CNE results 
in altered gene expression of numerous genes in several brain tissues, including genes 
involved in mitochondrial pathways, thus, linking nicotine to cellular metabolism (Wang 
et al., 2009), which could contribute to the increased expression of SIRT1, Nampt and 
Ku70 found in this study. However, CNE caused a mild reduction in caloric 
consumption (88%), and thus, an indirect regulation of CR-related genes though caloric 
restriction cannot be ruled out. Other studies have shown that CR of 70 – 60% increases 
expression of SIRT1 in the brain (Qin et al., 2006b). However, it is possible that even a 
mild reduction in caloric intake could increase expression of SIRT1 and related genes. 
Further studies need to be done to better understand this action of nicotine and nicotinic 
agonists on the SIRT1 signaling pathway.    
It is not clear why CNE in this study did not affect the expression of the 
neurotrophic factors, BDNF and NT-3, as seen by others (French et al., 1999; Kenny et 
al., 2000; Son and Winzer-Serhan, 2009; Srivareerat et al., 2009). Perhaps the dose of 
nicotine administered via drinking water did not achieve brain levels high enough to 
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stimulate expression of these genes, or there are species differences between rat and 
mouse and the previous studies had been done in rats.  
Oral self-administration of nicotine via drinking water provides a stress-free 
route of chronic drug treatment but requires high doses in order to reach biological 
active levels of nicotine in mice brain.  Three weeks of systemic nicotine treatment 
decreased food intake and body weight gain and increased expression of high affinity 
nicotine binding sites, all hallmarks of chronic exposure to nicotine. CNE did not impair 
cognitive functions and had an anxiolytic effect in 3-month-old male mice. CNE 
increased expression levels of SIRT1, Nampt, and Ku70 in cortico-hippocampal regions. 
The up-regulation of these genes may contribute to the beneficial neuroprotective effect 
of nicotine.  
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CHAPTER V 
LONG-TERM NICOTINE AND CALORIC RESTRICTION TREATMENT 
IMPROVE MEMORY IN MIDDLE-AGED MICE AND DIFFERENTIALLY 
REGULATE SIRT1, NAMPT AND KU70 GENE EXPRESSION IN CORTICO-
HIPPOCAMPAL AREAS  
 
SUMMARY 
Nicotine, the major psychoactive ingredient in tobacco smoke, which functions 
through activating neuronal nicotinic acetylcholine receptors (nAChRs), exerts 
neuroprotective effects through unknown pathways. In this study we sought to determine 
if the neuroprotection provided by chronic nicotine exposure shares the same 
mechanisms as caloric restriction (CR), since both have been shown to be 
neuroprotective. CR provides neuroprotection through activation of the deacetylase 
SIRT1, and nicotine could act through a similar mechanism. Fourteen-month-old 
C57BL/6 male mice were assigned to one of three treatment groups for 4 months: CR 
mice received 70% caloric restriction and no nicotine; nicotine (NC) mice, received ad 
libitum food and 300 μg/ml of nicotine in water; control (AL) mice, received ad libitum 
food and water. At 18 months of age, CR mice showed a higher level of anxiety than NC 
and control mice, as detected by increased margin time in the open field test. There was 
no difference between groups with respect to short-term memory object recognition. In 
the modified elevated plus maze, which tests long-term spatial memory, both CR and 
NC mice showed significantly better performance as compared to control mice (p = 
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0.023). In the Morris water maze, both spatial acquisition and probe trials did not reveal 
any significant difference between groups, but performers above the median in the NC 
group displayed a trend to perform better above median performers in the AL group in 
the probe trial, while the poor performers, below the median, in these groups did not 
have any difference in their performance. After behavior testing, mouse brains were 
collected and sectioned for nAChR binding using epibatidine and in situ hybridization 
using cRNA probes for Nampt, SIRT1 and Ku70. Epibatidine binding was increased in 
NC mice compared to CR mice and AL mice in both neocortex and hippocampus (p = 
0.053, p < 0.001, respectively), demonstrating that nicotine treatment caused 
upregulation of heteromeric nAChRs in these brain areas but CR did not. CR mice had 
significantly increased expression levels of SIRT1, Nampt, and Ku70 in the neocortex; 
whereas in the hippocampus (CA1, CA3, and dentate gyrus). Only Ku70 mRNA 
expression levels were significantly increased. In contrast, NC mice did not show any 
difference in gene expression for SIRT1, Nampt or Ku70 in any of the cortico-
hippocampal areas examined. These results indicate that long-term CR and nicotine 
treatment improve memory in aging mice, but they probably accomplish these effects 
through different mechanisms. 
 
INTRODUCTION 
Smoking is negatively correlated with PD and AD. Nicotine is the major 
psychoactive ingredient in tobacco smoke and is neuroprotective.  Loss of nAChRs, 
especially in cortical regions, is one of the major histological changes in normal brain 
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ageing and neurodegenerative diseases like AD. In contrast, mice lacking high-affinity 
nAChRs exhibit accelerated neuronal ageing and early onset of age-related deficits in 
spatial learning and memory.  Thus, chronic nicotine administration, which increases the 
number of nicotinic binding sites might be beneficial during aging and delay age-related 
cognitive decline. 
Nicotine also decreases appetite and increases energy expenditure, which 
contributes to the observations that body weight or body mass index are lower in 
cigarette smokers than in non-smokers.  Thus, nicotine administration could result in 
CR. 
CR is a regimen that extends the lifespan in all mammalian species tested and 
increases the expression of survival genes such as SIRT1, a nicotinamide adenine 
dinucleotide (NAD)-dependent deacetylase. SIRT1 is expressed in the brain and 
upregulation of SIRT1 protects neurons against neurodegeneration and attenuates 
apoptosis by deacetylating the DNA repair factor Ku70. Nicotinamide 
phosphoribosyltransferase (Nampt), a NAD biosynthetic enzyme, controls the activity of 
SIRT1.  Nampt is induced by stress or nutrient deprivation and increases cellular 
resistance to damage.   
The hypothesis of this study was that long-term nicotine exposure or nicotinic 
receptor activation improves age-related memory and cognition decline as has been 
observed with CR, and the improvement is thought to result from activation of CR-
related longevity genes.   In this study, the effects of long-term nicotine exposure (4 
months) were determined for mice. Although chronic (but not long-term) nicotine 
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administration has been proved on rats to be neuroprotective and improve memory and 
cognitive function, this study is the first with such a long term exposure to test whether 
the effects sustain or not.  It was also important to compare the effects of long-term 
nicotine administration with caloric restriction; since we hypothesized that they share 
similar mechanisms. We also tested the neuroprotective effect of both caloric restriction 
and nicotine exposure on normal aging process because we believed that the benefits are 
general and not restricted to any specific disease pathology. In this study we determined 
if chronic nicotine treatment or CR starting in middle-aged mice, can delay age-related 
cognitive decline, and if chronic nicotine and CR-treatments share similar mechanisms 
resulting in beneficial effects in aging animals.    
 
EXPERIMENTAL PROCEDURES 
 
Animals and treatments 
A breeding colony of C57BL/6 mice, originally obtained from the Jackson 
Laboratory, was established at Texas A&M University’s Laboratory Animal Research 
and Resource facility. At 14 months of age, male mice were individually caged, 
randomly assigned to different treatment groups for 4 months, and tested at 18 months of 
age (n = 9): control (AL) mice – received 2% saccharin in water (saccharin sodium salt 
hydrate, Sigma, St. Louis, MO, USA) and a control diet (NIH31) ad libitum; nicotine 
treated (NC) mice – received 300 g/ml nicotine free base ((-)-nicotine hydrogen 
tartrate, Sigma) in 2% saccharin in water and a control diet (NIH31) ad libitum; caloric 
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restriction (CR) mice – received 2% saccharin water and a 30 to 40% restricted diet (70 
to 60% of AL, by weight, NIH31-fortified). Both the NIH31 and NIH31-fortified diets 
were purchased from the National Institute on Aging. All groups started to receive 2% 
saccharin in water two weeks prior to day 1 of the actual treatment regime, to establish 
their individual daily drinking and food consumption volume. Animals in the NC group 
initially received 30 g/ml of nicotine on day 1, and the concentration was gradually 
increased until the final concentration was reached on day 7. Meanwhile, animals in the 
CR group started to receive 40% restricted diet (60% of AL). A 40% caloric restriction 
lasted until day 28, and the amount of food given was then increased to 70% of AL due 
to the dramatic loss of body weights in the CR mice. All treatments lasted until day 126 
(4 months) (Table IV-1). On days 115 to 125, mice were subjected to behavior testing 
and then euthanized on day 126. Food consumption, water intake and body weight were 
monitored throughout the dosing period, and the amount of food given to CR mice were 
subject to change according to the amount of food consumption observe in AL mice. All 
procedures were approved by the Texas A&M University Animal Use Committee and 
carried out in accordance with the National Institutes of Health Guide for the Care and 
Use of Laboratory Animals (National Institutes of Health Publication No. 85-23, revised 
1996). 
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Table V-1. The schedule of CR and NC treatments 
Group Day 1 2 3 4 5 6 7-27 28-126 
a 
CR 
% food of AL  
(by weight) 
60 60 60 60 60 60 60 70 
NC 
Nicotine 
concentration in 2% 
saccharin water  
(g/ml, free base) 
30 50 100 150 200 250 300 300 
a 
All mice were sacrificed on day 126. 
 
 
Behavior tests  
 
Modified elevated plus maze (mEPM) 
Long-term spatial memory was tested in a two-trial mEPM on days 115 and 116 
as described previously (Biala and Kruk, 2009). The EPM apparatus was made of 
Plexiglas painted matte black from the outside. The maze consisted of four 30 cm long 
and 5 cm wide arms: two open arms (without walls) facing opposite, and another two 
enclosed arms (15.25 cm high walls on three sides with one end left open) facing 
opposite so that they formed a plus shape (Walf and Frye, 2007). The whole maze was 
elevated 40 cm off the ground, located in a quiet room illuminated by a central dim red 
light, and environmental cues were kept constant during testing. All mice were 
accustomed to the experimental room for 10 minutes before both acquisition (day 115) 
and retention (day 116) trials. The maze was cleaned with 70% ethanol between mice. In 
the acquisition trial, mice were individually placed at one end of one open arm facing 
away from the central platform and allowed to move from the open arm to either of the 
enclosed arms. A successful entry was considered when all four limbs were in the 
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enclosed arm. If a mouse did not enter an enclosed arm within 90 seconds it was placed 
in one of the enclosed arms and allowed to explore for another 60 seconds,. On the next 
day (24 hours later), all mice were subjected to a retention trial in the same manner, and 
the time to successful entry was recorded as T2. T2 values on the retention trial were 
used as an index of memory. The improvement of memory and learning is characterized 
by decreases in the T2 values. 
 
Open field 
All mice were tested in an open field equipped with vertical and horizontal beam 
sensors for locomotion, exploratory and anxiety behaviors on day 117. The mice were 
placed individually in an open field (length × width × height: 20 × 20 × 30 cm) 
(Versamax animal activity monitor and analyzer, AccuScan Instruments, Columbus, OH, 
USA) equipped with vertical and horizontal beam sensors. The apparatus was 
constructed from transparent Plexiglas and located in a quiet room. All environmental 
cues including lighting were kept constant during testing. Mice were accustomed to the 
experimental room for 30 minutes, and then placed in the open field for another 30 
minutes. Activities were recorded every minute and analyzed in 5 minutes segments (6 
segments total). The open field chamber was cleaned with 70% ethanol between mice. 
Total distance, movement time, margin distance, margin time, and center distance were 
automatically recorded. 
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Object recognition 
Short-term recognition memory was tested in a one-trial object recognition test 
on day 118 in the manner of “two sample objects with one environment” as described 
previously (Bevins and Besheer, 2006) with minor changes. A transparent Plexiglas 
chamber (length × width × height: 20 × 40 × 30 cm) (AccuScan Instruments) covered on 
the outside with white bench protector (VWR, West Chester, PA, USA) was setup in a 
quiet room where environmental cues were kept constant during testing. Mice were 
allowed individually to become familiarized with the chamber for 10 minutes. Two 
identical sample objects (medium heavy duty black binder clips 3.2 × 5.5 cm, 
OfficeMax) were placed in the back left and right corners of the chamber. The test 
animal was placed at the center of the chamber facing the front opposite to the sample 
objects with its nose pointing to either side and then allowed to explore for 10 minutes. 
After a one-hour interval, one of the sample objects was replaced by a novel object 
(standard wooden clothes pin, 8.5 × 1 cm). The mouse was placed back into the chamber 
as described, and allowed to explore for 3 minutes. The chamber was cleaned with 70% 
ethanol between mice. Each exploration period was recorded by a video camera 
(DIGITAL IXUS 50, Canon, Japan) setup directly above the apparatus. Using XNote 
Stopwatch (free evaluation version, http://www.stopwatch-timer.com, dnSoft Research 
Group, accessed in 2011), direct contact scoring was done by a blind investigator. The 
total time test subjects spent exploring the objects (both sample and novel), and the time 
ratio (novel/total time) were calculated and used as an index of short-term memory. 
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Morris water maze (MWM) 
To assess long-term spatial learning and memory, mice were subjected to the 
MWM on days 119 to 125 as previously described (Vorhees and Williams, 2006) with 
minor changes. The maze was made of a stainless-steel circular tank painted white inside 
(diameter × height: 120 × 50 cm) and divided into four quadrants labeled N (north), E 
(east), S (south) and W (west), clockwise. An 8 × 8 cm transparent platform was 
constructed from clear Plexiglas. The tank was filled with a depth of 30 cm room 
temperature (RT) water. The whole experiment was divided into three parts: the cued 
trial (day 119), spatial acquisition (days 120-124) and probe trial (day 125). In the cued 
trial, white curtains were placed around the maze to block any distant visual cues, and 
the platform was elevated 1cm above the water surface and marked by yellow and red 
tape. This established a control condition to test the animals’ ability to distinguish visual 
cues and to learn to swim to a cued goal (visible platform marked with yellow and red 
tape). In this one-day cued trial, each mouse was subjected to 6 training trials with all 
different start-goal combinations: N-SE, E-NE, S-SW, W-SE, S-NE and N-NW. Each 
subject was gently placed in the starting position facing the outside perimeter of the 
maze and allowed swim to the goal platform within 60 seconds. If a mouse failed to 
swim to the platform within 60 seconds, that mouse was lead to the platform. Once the 
mouse reached the platform, it was allowed to stay there for another 15 seconds. 
Animals that could not perform the cued trail were eliminated from the subsequent 
spatial acquisition and probe trial. The spatial acquisition consisted of 5 consecutive 
days (days 120-124). On the wall of the tank, colored and shaped cues were given, and 
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the curtains used in the cued trial were removed. The outer environment including the 
experimenter was considered as distal visual cues and stayed constant. In the spatial 
acquisition, the colored tape on the platform was removed, and the platform was 
submerged 1.5 cm under the water surface and fixed in the center of the SW quadrant, 
which was designated as the target quadrant. In each spatial acquisition day, each mouse 
was subjected to 4 training trials that each had different start locations (Table IV-2). 
Each subject was gently placed at the starting location facing the outside perimeter of the 
maze and allowed to find the platform within 60 seconds. If a mouse failed to find the 
platform within 60 seconds, that mouse was lead to the platform. Once the mouse 
reached the platform, it was allowed to stay on the platform for another 15 seconds to 
orientate itself. In the last trial, which was the probe trial (day 125), the platform in the 
target quadrant was removed. All mice were allowed to swim in the maze individually 
for 30 seconds and then they were removed from the maze. The whole procedure was 
videotaped using a camera (DIGITAL IXUS 50, Canon, Japan) and manually analyzed 
using Tracker 3.10 (http://www.cabrillo.edu/~dbrown/tracker, Open Source Physics, 
accessed in 2011). For the spatial acquisition, three parameters: latency (time to find the 
platform), path length, and cumulative distance from the platform were acquired for each 
mouse. Each acquisition was averaged in blocks of four trials and analyzed. In the probe 
trial, two parameters were acquired for each mouse: time in target quadrant and distance 
in target quadrant. 
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Table V-2. Start locations in MWM spatial acquisitions 
Acquisition Day Trial 1 Trial 2 Trial 3 Trial 4 
1 N E SE NW 
2 SE N NW E 
3 NW SE E N 
4 E NW N SE 
5 N SE E NW 
6 (Probe) NE    
The goal (platform) was located in the SW quadrant during acquisition.   
 
 
Tissue preparation  
Mice were anesthetized using isoflurane (IsoFlo, North Chicago, IL, USA) and 
decapitated on day 126. The brains were rapidly removed, cut mid-saggitally into two 
halves, frozen in powdered dry ice, and stored at -80°C until used. One neocortex 
(cerebral hemisphere) was sectioned into fourteen m thick coronal sections, 196 m 
apart, using a cryostat, starting at Bregma level -1.70 mm and ending at -2.30 mm. For in 
situ hybridization, sections were thaw-mounted onto glass microscope slides coated with 
gelatin (Spectrum, Gardena, CA, USA) and poly-L-Lysine (Sigma). Sections were then 
post-fixed with 4 % paraformaldehyde in 0.1 M phosphate buffer, pH 7.4, for 1 hour at 
RT and stored with desiccant at -20°C until used. For epibatidine binding, sections were 
mounted on glass microscope slides coated twice with gelatin, left at 4°C overnight with 
desiccant and stored at -80°C until used. For the other half of the brain, the neocortex 
and hippocampus were dissected separately on ice for immunoblot analysis. Tissues 
were mixed with ice-cold RIPA buffer containing protease inhibitor, homogenized using 
a sonic dismembrator (Thermo Fisher Scientific, MA, USA), incubated on ice for 30 
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minutes, and then centrifuged at 14000 rpm for 20 minutes at 4°C. The supernatant was 
collected, mixed with Lamelli buffer and stored at -80°C until used. 
 
Epibatidine binding  
Epibatidine binding was performed as previously described (Huang and Winzer-
Serhan, 2006b) with minor changes. Tissue sections were pre-incubated 5 minutes in 
Tris-HCl buffer (50 mM Tris-HCl, 120 mM NaCl, 5 mM KCl, 2.5 mM CaCl2, 1 mM 
MgCl2, pH 7.4) and then incubated with 0.4 nM [
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I]-Epibatidine (PerkinElmer Life 
Science NEX358, Boston, MA, USA, specific activity: 2200 Ci/mmol) for 1 hour at RT. 
For non-specific binding, sections were incubated with the presence of 400 M (-)-
nicotine hydrogen tartrate. Sections were washed in ice-cold Tris-HCl buffer twice for 1 
minute, followed by 10 seconds in cold ddH2O, and dried at RT overnight before 
exposure to BioMax MR film (Kodak, Rochester, NY, USA). After 1-day exposure, 
films were developed in D19 Kodak developer for 4 minutes and fixed in Kodak Rapid 
Fixer for 5 minutes. 
 
cRNA probe synthesis and in situ hybridization  
Templates for the synthesis of cRNA probes were generated for mouse SIRT1, 
Ku70 and Nampt as previously described (Son and Winzer-Serhan, 2009). 
35
S-labeled 
cRNA probes were synthesized in the antisense orientation in the presence of 
35
S-UTP 
(PerkinElmer Life Science) and either T3 or T7 RNA polymerase (Applied 
Biosystems/Ambion) using in vitro transcription. The method for in situ hybridization 
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has been described in detail previously (Winzer-Serhan et al., 1999; Huang et al., 2011). 
In brief, tissue sections were pre-hybridized with 0.1 g/ml proteinase K for 10 minutes. 
After overnight (16-20 hours) hybridization at 60°C with 
35
S-labeled cRNA probes, 
sections were treated with RNase A at 37°C for 30 minutes and washed. Slides with 
adhered sections were exposed to BioMax MR film along with [
14
C]-standards 
(Amersham, Code RPA 504L, Batch21, Buckinghamshire, UK), and the films were 
developed as described in the previous epibatidine binding section. 
 
Autoradiogram analysis       
Quantitative analysis of autoradiograms was carried out using MCID basic 
(InterFocus Imaging Ltd, Haverhill, Suffolk, UK). For receptor binding, raw optical 
density (ROD) was measured in the hippocampus (the molecular layers of both dentate 
gyrus (DG) and the hippocampal proper), thalamus (the post thalamic nucleus and the 
ventral posteriomedial thalamic nucleus), and cerebral cortex (layers IV-V, of the visual 
and somatosensory cortex). For analysis of the hybridization signal, a standard curve 
(ROD vs. nCi/g wet weight) was generated using [
14
C]-standards and ROD values were 
converted to nCi/g wet weight. Measurements were taken in the pyramidal cell layer of 
the CA1 and CA3, in the granular cell layer of the DG of the hippocampus, and in the 
entire cerebral cortex located on individual sections. All anatomical structures were 
located according to the Mouse Brain Library atlas (Rosen et al., 2000).   
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Immunoblot analysis   
Both cerebral cortex and hippocampus samples were separated under reducing 
and denaturing conditions on 7.5% sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) gels and transferred onto polyvinylidene fluoride (PVDF) 
membranes. Membranes were incubated overnight with primary antibodies for Ku70 
(1:3000, Millipore, Billerica, MA, USA) and -actin (1:20000). Blots were visualized 
using appropriate secondary antibodies conjugated to horseradish peroxidase and an 
enhanced chemiluminescence (ECL) detection system (Pierce, Rockford, IL, USA). 
Relative protein expression was reported as a ratio to -actin. Quantification was 
determined by densitometry using ImageJ 1.43u (Rasband, 1997-2011). All 
measurements were repeated three times.   
  
Statistics 
PASW Statistics 18 was used for statistical analysis. Significance was defined as 
p ≤ 0.05. Food consumption, water intake, body weight changes, open field, and spatial 
acquisition using the MWM were analyzed using repeated measurements for between-
subject effects and one-way analysis of variance (ANOVA) for differences between 
groups at each time point. For object recognition, mEPM, probe trials using the MWM, 
receptor binding, gene expression, and immunoblot, one-way ANOVA was performed to 
compare between treatments. When needed the Tukey HSD was used as a post hoc test 
after one-way ANOVA. All data were presented as average ± SEM.  
 
 131 
RESULTS 
 
Body weights of NC mice were significantly lower than controls despite equal 
amounts of food consumption 
A summary of changes in body weights is presented in Figure IV-1A. Body 
weights of control mice gradually increased throughout the 4 months of the experiment. 
The average weight gain in control mice was 0.039 ± 0.013 g per day, causing a 
significantly higher body weight when mice were 18-months-old as compared to when 
they were 14-months-old (18-month-old AL mice: 41.42 ± 1.60 g, 14-month-old AL 
mice: 36.16 ± 1.63 g, Student’s t-test p = 0.05). On the other hand, nicotine treatment 
caused a very subtle loss of body weight of 0.002 ± 0.011 g per day. There was a 
difference in average weight gain between AL and NC mice (Repeated measurements, 
test of between-treatments effects p = 0.001, Tukey HSD, NC vs. AL p = 0.08.) (Fig. IV-
1B). The body weights of NC mice when they were 18-months-old were not different 
from 14-month-old mice (18-month-old NC mice: 37.41 ± 1.73 g, 14-month-old NC 
mice: 37.91 ± 1.60 g. Student’s t-test p = 0.835). CR caused a dramatic decrease in body 
weight (0.05 ± 0.012 g per day), and the average weight gain in CR mice was 
significantly lower than both AL and NC mice (Repeated measurements, test of 
between-treatments effects p = 0.001, Tukey HAS, CR vs. NC p = 0.023, CR vs. AL p < 
0.0001). Body weights of 18-month-old CR mice were significantly lower than 14-
month-old CR mice (18-month-old CR mice: 29.12 ± 0.49 g; 14-month-old CR mice: 
36.07 ± 0.59 g. Student’s t-test p < 0.0001). Overall, the average body weight of AL 
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mice during the 4 months treatment was significantly higher than those of both NC and 
CR mice, and the average body weight of NC mice was significantly higher than that of 
CR mice (AL: 39.96 ± 1.37 g, NC: 38.67 ± 1.16 g, CR: 29.43 ± 1.25 g. Repeated 
measurements, test of between-treatments effects p < 0.0001, Tukey HSD, CR vs. NC p 
< 0.0001, CR vs. AL p < 0.0001, NC vs. AL p = 0.02). Treatment for 4 months with 
either nicotine or CR caused significant lower body weights in these middle-age mice 
(although in a different degree) when compared to control (AL) mice.  
The amount of water intake was also monitored. CR mice significantly drank 
more than both AL and NC mice during the entire treatment (AL: 5.65 ± 0.43 ml, NC: 
4.45 ± 0.27 ml, CR: 12.8 ± 0.62 ml. Repeated measurements, test of between-treatments 
effects p < 0.0001, Tukey HSD, AL vs. CR p < 0.0001, NC vs. CR p < 0.0001). The NC 
mice decreased the amount of water that they drank only at the beginning of the 
treatment period and gradually increased their amount of water intake until the amounts 
were the same as control mice. Overall there was only a trend of water intake difference 
between NC and AL mice (AL vs. NC p = 0.065) (Fig. IV-1C).   
Food consumption by CR mice was controlled to 60% of AL at the beginning of 
the treatment and then adjusted to 70% of AL starting at day 28. The restricted food 
consumption caused the body weight of CR mice to decrease. However, the lower body 
weights in NC compared to AL mice was not caused by a decrease in food consumption 
since there was no difference in food consumption between AL and NC mice (AL: 5.24 
± 0.46 g/day, NC: 5.49 ± 0.33 g/day, repeated measurements, test of between-treatments 
effects p = 0.7) (Fig. IV-1D). 
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Figure V-1. Body weights of NC mice were significantly lower than control (AL) mice 
despite of equal amounts of food consumption. A, Body weights were normalized to the 
first measurement for each individual mouse. Repeated measurements, test of between-
treatments effects p < 0.0001, Tukey HSD, CR to NC p < 0.0001, CR to AL p < 0.0001, 
NC to AL p = 0.02. Comparisons between the last time point to the first time point: 
Student’s t-test, AL p = 0.05, CR p < 0.0001, NC p = 0.835. B, Body weight gains are 
presented as g/day. Repeated measurements, test of between-treatments effects p = 
0.001, Tukey HSD, CR to NC p = 0.023, CR to AL p < 0.0001, NC to AL p = 0.08. C, 
Water intake is presented as ml/day. Repeated measurements, test of between-treatments 
effects p < 0.0001, Tukey HSD, AL to CR, p < 0.0001, NC to CR p < 0.0001, AL to NC 
p = 0.065. D, Food consumption is presented as g/day. Comparisons were only made 
between NC and AL mice, since the food consumption by CR mice was controlled to 
60% of AL up to day 28 and 70% of AL after day 28. Repeated measurements, tests of 
between-treatments effects p = 0.696. The left dash line indicates the time when both 
nicotine and caloric restriction treatments started. The right dash line indicates the time 
when treatments ended and all mice were euthanized. Each dot represents the 
measurement of the week. AL, control; NC, nicotine group; CR, caloric restricted group. 
Error bars: SEM. 
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Locomotion was not impaired by treatment, but the anxiety level increased in CR 
mice compared to both AL and NC mice 
After 4 months of treatment, each mouse was subjected to a 30-minute open field 
test for locomotor and anxiety levels. Among the 6 parameters used (total distance, 
movement time, margin distance, margin time, center distance, and thigmotaxis index), 
total distance, movement time, margin distance and center distance did not show any 
difference between treatments indicating that locomotor activity was not impaired by 
either chronic nicotine treatment or CR. However, CR mice spent significantly more 
time at the margin of the open field compared to both AL and NC mice in the first and 
second 5-minute intervals (First 5 minutes: AL: 99.0 ± 18.85 sec, NC: 131.5 ± 18.34 sec, 
CR: 170.21 ± 12.14 sec. One-way ANOVA p = 0.041, Tukey HSD, AL vs. CR p = 
0.033.  Second 5 minutes: AL: 107.4 ± 13.75 sec, NC: 120.4 ± 14.15 sec, CR: 175.3 ± 
18.41 sec. One-way ANOVA p = 0.012, Tukey HSD, AL vs. CR p = 0.015, NC vs. CR p 
= 0.045) (Fig. IV-2). This difference disappeared after 10 minutes in the open field. The 
longer margin time exhibited by CR mice compared to AL and NC mice in the first 10 
minutes indicated a higher anxiety level in CR mice when they entered a new 
environment. The thigmotaxis, an index of anxiety (margin distance / total distance), 
also showed that CR mice are more anxious than both AL and NC mice in the first and 
second 5-minute intervals in the open field (first 5 minutes: AL: 0.45 ± 0.05, NC: 0.48 ± 
0.03, CR: 0.59 ± 0.03. One-way ANOVA p = 0.046, Tukey HSD, NC vs. CR p = 0.044. 
second 5 minutes: AL: 0.42 ± 0.02, NC: 0.44 ± 0.03, CR: 0.56 ± 0.03. One-way 
ANOVA p = 0.007, Tukey HSD, AL vs. CR p = 0.011, NC vs. CR p = 0.021). There 
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were no differences in both margin time and thigmotxis index between AL and NC mice 
indicating that long-term CNE did not change the anxiety level in mice.   
 
 
 
Figure V-2. Anxiety level increased in CR mice compared to both AL and NC mice. 
Margin time is presented as a percentage of the time spent by control mice. Time in the 
open field was separated into six segments, five minutes each, and analyzed individually. 
AL, control; NC, nicotine group; CR, caloric restricted group. Error bars: SEM. One-
way ANOVA, Tukey HSD, * p < 0.05. 
 
 
While short-term memory was not impaired by treatment, long-term memory 
improved in both CR and NC mice  
One-hour interval object recognition is a test for short-term learning and 
memory. After 4 months of treatment, we examined the total time each mouse spent on 
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exploring objects (novel time + sample time) and the ratio of time that mice spent on 
exploring the novel object (novel time / total time) after they had explored the sample 
objects one hour previously. The total exploration time was not different between groups 
as anticipated, demonstrating that neither of our treatments impaired the interest and 
ability of these mice to explore objects (AL: 18.63 ± 2.98 sec, NC: 19.71 ± 2.88 sec, CR: 
21.12 ± 1.75 sec. One-way ANOVA p = 0.808). However, the ratio of time that mice 
spent on exploring the novel object was not different between groups either indicating 
that our treatments did not change the short-term memory in these mice (AL: 0.58 ± 
0.07, NC: 0.41 ± 0.09, CR: 0.50 ± 0.04. One-way ANOVA p = 0.259).  
Long-term memory was assessed by mEPM and MWM in these mice at the end 
of the 4 month treatment period. In mEPM, we examined the time (T2) that each mouse 
took on the second day to escape from the open arm to one of the enclosed arms of the 
maze, after they had explored the maze on the first day. Our results showed that both CR 
and NC mice took significantly less time to find the enclosed arm, indicating an 
improvement in long-term spatial memory as compared to control (AL) mice (T2, CR: 
48.9 ± 11.8 sec, NC: 48.0 ± 10.6 sec, AL: 85.3 ± 4.8 sec. One-way ANOVA p = 0.023, 
Tukey HSD, AL vs. CR p = 0.043, AL vs. CR p = 0.038) (Fig. IV-3). There was no 
difference in the times exhibited by NC and CR mice to find the enclosed arm.  
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In the MWM, mice demonstrated successful learning curves in the five-day 
spatial acquisition detected using latency, path length, and cumulative distance. No 
difference between treatment groups was observed for any of the three measurements 
(Fig. IV-4). In the probe trial, no difference was detected between groups for time spent 
in the target quadrant or in the percent of the path length located in the target quadrant 
for all mice tested. We then analyzed performance between mice defined as good versus 
poor performers. For each treatment group the mice were ranked from the best to worst 
scores. Good performing mice were defined as the mice that were in the top half of the 
ranking and the poor performers were the bottom half of the ranking.   Good performers 
in the NC group displayed a trend to perform better than the good performers in the AL 
group with respect to both parameters (Time in target quadrant: two-way ANOVA p = 
0.075, Tukey HSD, AL vs. NC p = 0.076; percent path length in the target quadrant: 
two-way ANOVA p = 0.058, Tukey HSD, AL vs. NC p = 0.051. No differences were 
observed between CR and NC or between AL and CR groups and the poor performers 
had no difference at all between groups (Fig. IV-5). This suggested that nicotine might 
be effective to a subgroup of aging mice. 
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Figure V-3. Modified EPM indicated that long-term memory was improved in both CR 
and NC mice as compared to AL mice. The time for successful entry into an enclosed 
arm in the second-day retention trial was recorded as T2, and used as in index of spatial 
memory and learning ability. mEPM, modified elevated plus maze; AL, control; NC, 
nicotine group; CR, caloric restricted group. Error bars: SEM. One-way ANOVA, Tukey 
HSD, * p < 0.05. 
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Figure V-4. No difference between groups was detected in the 5-day spatial acquisition 
in the MWM. Three parameters were examined: A, latency; B, path length, C, 
cumulative distance. SA, spatial acquisition; AL, control; NC, nicotine group; CR, 
caloric restricted group. Error bars: SEM. 
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Figure V-5. No difference was detected between groups in the probe trial for the MWM. 
(A) Time in the target quadrant and (B) percent path length in the target quadrant were 
plotted with each individual animal. AL, control; NC, nicotine group; CR, caloric 
restricted group. Bars indicated the medians for each group. 
 
 
Heteromeric nAChR binding sites were increased in NC mice in neocortical areas 
compared to AL and CR mice 
Increased heteromeric nicotinic binding sites are hallmark of CNE. In this study, 
we used 
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I-Epibatidine binding levels measured as ROD values to determine the 
number of heteromeric nicotinic binding sites in the cortico-hippocampal area, thalamus, 
and the medial habenular nucleus. In the neocortex, binding levels were determined in 
layers IV to VI of the visual and somatosensory cortex. There was a trend towards 
higher binding in NC mice as compared to AL mice, and no difference was detected 
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between CR and AL mice (AL: 0.15 ± 0.012, NC: 0.19 ± 0.011, CR: 0.16 ± 0.011. One-
way ANOVA p = 0.053, Tukey HSD, AL vs. NC p = 0.057) (Fig. IV-6A). In the 
hippocampus, binding levels were determined in the stratum lacunosum molecular layer 
of the CA1 and the DG molecular layer. Binding levels in NC mice were significantly 
higher than both AL and CR mice, and no difference was detected between CR and AL 
mice (AL: 0.09 ± 0.006, NC: 0.12 ± 0.007, CR: 0.09 ± 0.005. One-way ANOVA p < 
0.0001, Tukey HSD, AL vs. NC p < 0.0001, CR vs. NC p = 0.001) (Fig. IV-6B). In the 
thalamus and medial habenular nucleus, no difference was detected between treatment 
groups showing that the up regulation of heteromeric nAChRs was specific to cortico-
hippocampal areas in response to CNE but not CR (thalamus: AL: 0.23 ± 0.01, NC: 0.24 
± 0.01, CR: 0.23 ± 0.01; medial habenular nucleus: AL: 0.16 ± 0.01, NC: 0.17 ± 0.01, 
CR: 0.17 ± 0.01) (see Fig. IV-6C and D for thalamus and medial habenular nucleus 
respectively). 
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Figure V-6. Heteromeric nAChR binding sites were increased in NC as compared to AL 
and CR mice in the neocortex (A) and hippocampus (B) but not thalamus (C) and medial 
habenular nucleus (D). Epibatidine binding levels are presented using ROD values. 
ROD, raw optical density; Ctx, neocortex; HP, hippocampus; Tha, thalamus; MHb, 
medial habenular nucleus; AL, control; NC, nicotine group; CR, caloric restricted group. 
Error bars: SEM. One-way ANOVA, Tukey HSD, ** p < 0.01. 
 
 
Messenger RNA levels of SIRT, Nampt, and Ku70 were increased in the cortico-
hippocampal areas in response to CR but not NC 
Using in situ hybridization, mRNA levels of SIRT, Nampt, and Ku70 were 
determined in the principal layers of hippocampal CA1, CA3 and DG, and in layers II to 
VI of the somatosensory cortex. A summary of the comparisons is presented in Figure 
IV-7. After 4 months of treatment, CR significantly increased SIRT1 expression levels 
generally in the cortico-hippocampal areas when compared to NC mice (Two-way 
ANOVA (treatment vs. region), test of between-treatments effects p = 0.006, Tukey 
HSD, CR vs. NC p = 0.005). There was no difference between CR and AL mice or 
between NC and AL mice. The difference was specifically detected in the neocortex 
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using Tukey’s HSD post hoc test (One-way ANOVA p = 0.036, Tukey HSD, CR vs. NC 
p = 0.033) but not in other hippocampal regions (Fig. IV-7A).  
Nampt showed similar changes as SIRT1 in that CR mice significantly increased 
Nampt expression levels as compared to both AL and NC mice (Two-way ANOVA 
(treatment vs. region), test of between-treatments effects p < 0.0001, Tukey HSD, CR vs. 
AL p = 0.022, CR vs. NC p < 0.0001). There was no difference observed in Nampt 
expression levels between AL and NC mice. The difference was again specifically 
detected in the neocortex and a trend towards a difference was observed for the DG 
between CR and NC mice (One-way ANOVA, cortex: p = 0.034, DG: p = 0.085, Tukey 
HSD, cortex: CR vs. NC p = 0.035, DG: CR vs. NC p = 0.073). The CA1 and CA3 
regions of hippocampus did not show any differences in Nampt expression between 
treatment groups (Fig. IV-7B).  
Ku70 gene expression showed the most dramatic changes in response to CR. 
Ku70 mRNA levels were increased in CR mice as compared to both NC and AL mice 
(Two-way ANOVA (treatment vs. region), test of between-treatments effects p < 0.0001, 
Tukey HSD, CR vs. AL p < 0.0001, CR vs. NC p < 0.0001), and the differences were 
significant in all cortico-hippocampal areas measured (One-way ANOVA, cortex: p = 
0.004, CA1: p = 0.002, CA3: p = 0.008, DG: p = 0.003, Tukey HSD, cortex: CR vs. NC 
p = 0.021, CR vs. AL p = 0.005, CA1: CR vs. NC p = 0.005, CR vs. AL p = 0.004, CA3: 
CR vs. NC p = 0.029, CR vs. AL p = 0.011, DG: CR vs. NC p = 0.007, CR vs. AL p = 
0.01). There was no difference between NC and AL mice with respect to Ku70 mRNA 
expression levels (Fig. IV-7C). 
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Figure V-7. Messenger RNA levels of SIRT (A), Nampt (B), and Ku70 (C) were 
increased in cortico-hippocampal areas in response to CR but not NC. In situ 
hybridization levels are presented as a percentage of expression levels exhibited by 
control mice. Ctx, neocortex; CA1, pyramidal cell layer of hippocampal CA1; CA3, 
pyramidal cell layer of the hippocampal CA3; DG, granular cell layer of the 
hippocampal dentate gyrus; AL, control; NC, nicotine group; CR, caloric restricted 
group. Error bars: SEM. Two-way ANOVA (treatment vs. region), test of between-
subjects effects: treatment effect, Tukey HSD, (A), CR vs. NC, ## p < 0.01; (B), CR vs. 
NC, ## p < 0.01, CR vs. AL, † p < 0.05; (C), CR vs. NC, ## p < 0.01, CR vs. AL, †† p < 
0.01. One-way ANOVA, Tukey HSD, ** p < 0.01, * p < 0.05. 
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Despite observed changes in mRNA levels, Ku70 protein levels in cortico-
hippocampal areas were not affected by treatment  
Because Ku70 mRNA showed the most change in response to the treatments 
used in this study, we examined protein levels of Ku70 to determine whether the protein 
levels changed in accordance with the observed changes in mRNA levels. Tissues were 
dissected into neocortex and hippocampus, and none of these areas showed changes in 
Ku70 protein levels (Ratio to AL, cortex: CR: 1.27 ± 0.32, NC: 0.93 ± 0.10; 
hippocampus: CR: 1.2 ± 0.12, NC: 1.1 ± 0.25. One-way ANOVA, cortex: p = 0.44, 
hippocampus p = 0.68) (Fig. IV-8). 
 
 
 
Figure V-8. Despite changes in mRNA levels, Ku70 protein levels in the cortico-
hippocampal areas were not affected by either treatment. Protein levels are presented as 
ratio of protein expression observed in control mice. Representative images of 
immunoblots from Ku70 and -actin are shown below. AL, control; NC, nicotine group; 
CR, caloric restricted group. Error bars: SEM. 
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DISCUSSION 
This study was the first to examine the correlation and compare the effect of 
nicotine and CR on food consumption, body weight, anxiety level, memory and the 
expression of CR-related genes: SIRT1, Ku70, and Nampt. Our previous study showed 
that 2-/- mice, which lack the predominant heteromeric nAChR subtype, increase their 
longevity gene expression in middle-aged 18-month old compared to age-matched wild 
type mice (Huang et al., 2011). We believe that this is an adaptational response as seen 
in other mouse models of neurodegenerative diseases, due to the accelerated aging 
observed in these mice (Zoli et al., 1999; Kim et al., 2007a), and although the 2-
nAChRs do not directly interact with these longevity genes, lack of endogenous nAChR-
mediated neuroprotection could create a stressful situation for neurons that could induce 
up regulation of expression of these genes. We also found that CNE using 300 g/ml in 
drinking water has effects on food intake, body weight, anxiety levels and CR related 
gene expression. In this study, we treated middle-aged C57BL/6 male mice with the high 
dose of nicotine via drinking water, which was found to be effective in Chapter III, for 4 
months, a relatively long period of time in a mouse’s life span and compared that 
exposure with the same time length of time of CR. We observed significant effects on 
food intake, receptor binding, and anxiety levels. The expression of SIRT1 and related 
genes was up regulated in the cortico-hippocampal area in the brain in CR mice, but not 
NC mice. This indicates that long-term chronic nicotine administration does not alter the 
SIRT1 related signaling pathway like CR does, but has a potential to improved memory 
and cognitive functions.  
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One of the goals of this study was to determine the effects of long-term nicotine 
given orally to mice. This has not been studied previously. We found that long-term 
CNE resulted in reduced body weight but not food consumption and increased numbers 
of nAChR binding sites, which are hallmarks of CNE and would indicate an effective 
dose of nicotine reached the brain. The animals tolerated this dose and route of nicotine 
well, with no apparent negative effects on general appearance. Nicotine given in 
drinking water minimizes stress that is caused by daily nicotine injections, especially for 
long-term studies, and also provides the nicotine fluctuations seen in smokers or people 
using oral nicotine replacement medications such as nicotine gums, sprays or lozenges. 
Chronic nicotine reduces body weight and suppresses food intake through the central 
hypothalamic melanocortin system (Mineur et al., 2011). These anorexic effects were 
seen only in our short-term nicotine study. However, long-term nicotine treatment did 
not reduce food consumption but reduced weight gain. This indicated that the reduction 
of body weight by means of nicotine is not only an effect of less food intake, but also of 
higher metabolic function. It’s also interesting to look into why long-term nicotine does 
not activate the hypothalamic melanocortin system to suppress food intake as short-term 
CNE found by others. It is also possible that the inactivation or less responsiveness of 
the hypothalamic melanicortin system in our long-term study was due to an older age of 
these mice.  
The hallmark of CNE that indicates sufficient amounts of nicotine reached the 
brain where nicotine interacts with nAChRs, is the increase in heteromeric nicotinic 
binding sites (Corringer et al., 2006). Four to 7 weeks of chronic nicotine treatment in 
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rodents increases high affinity nicotinic binding sites in cortico-hippocampal regions 
(Pietila et al., 1998; Sparks and Pauly, 1999; Nuutinen et al., 2005). Human smokers 
also have greater densities of high affinity nAChR compare to nonsmokers (Perry et al., 
1999; Mukhin et al., 2008). Using receptor autoradiography, we showed that long-term 
nicotine treatment still increased the level of 
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I-epibatidine binding to heteromeric 
nAChRs in the cortico-hippocampal regions. The binding site upregulation effect by 
CNE was not adapted by long-term activation. Whether the upregulated nAChRs remain 
functional or are desensitized needs further investigation. The CR did not increase high 
affinity nicotinic binding sites.  
Behavior tests were used to access locomotion, exploratory activity, anxiety-like 
behavior, and spatial learning. Our results indicated that locomotor and exploratory 
activities were not changed by CR or long-term CNE. However, results from the open 
field test indicated that anxiety levels were increased in CR mice. Long-term nicotine 
treated mice did not change their anxiety levels when compared to control mice. This 
showed that the anxiolytic effect of CNE is only seen in short-term treatment. Long-term 
nicotine administration did not release anxiety. Nicotine’s effects on anxiety are 
complex and depend on the dose, time, and regimen of administration (Picciotto et al., 
2002). The positive impact of stress on smoking frequency, smokers yielded a lower 
anxiety level than non-smokers when challenged with stress, and the increased anxiety 
level during smoking cessation in human study all suggest that nicotine exposure 
reduces anxiety levels (Gilbert et al., 1989; Perkins and Grobe, 1992; Tate et al., 1993). 
Animal studies also support the anxiolytic effect of chronic nicotine and nicotinic 
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agonists (Brioni et al., 1994; Levin et al., 2007). Our result indicated that this effect did 
not sustain when the nicotine exposure was long-term or when the mice were at an older 
age, and CR had an anxiogenic effect to mice. Aging might change the effects of 
nicotine on the stress system, or the stress system might be less responsive in older mice. 
Spatial learning and memory was evaluated in mEPM, object recognition and 
MWM. The object recognition test was to test short-term memory and no difference was 
found between treatments. Some studies provide evidence of improved short-term 
memory after CNE in mouse models of AD, schizophrenia, attention deficit 
hyperactivity disorder, and stress-induced memory impairment (Aleisa et al., 2006; 
Weiss et al., 2007; Srivareerat et al., 2009; Rushforth et al., 2011) as well as animals 
without pathological condition (Levin and Torry, 1996). The mEPM indicated an 
improvement in long-term memory in both CR and NC groups, but this result was not 
firmly detected again using MWM.  
Long-term nicotine did not change SIRT1, Ku70 and Nampt mRNA levels as 
was observed with short-term nicotine exposure and with CR. The anorectic effect of 
short-term chronic nicotine could cause the mice to undergo short term CR and result in 
up regulated gene expression and potentially provides a neuroprotective effect. Increased 
SIRT1, Ku70, and Nampt gene expressions were seen in the cortico-hippocampal 
regions in CR mice in this study. SIRT1 attenuates apoptosis by deacetylating the DNA 
repair factor Ku70, which sequesters proapoptotic factor Bax away from mitochondria 
(Cohen et al., 2004b). Nampt is an upstream regulator of SIRT1. Nampt is induced by 
stress or nutrient deprivation and increases cellular resistance to damage (Yang et al., 
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2006b). This indicated that long-term CNE does not work as CR mimicry like 
resveratrol, and the up-regulation of SIRT and its related genes by CR is perhaps due to 
a decrease in food consumption, but not in body weight. This supports the idea that these 
genes are up-regulated to protect against cellular stress such as food deprivation, and 
imply that long-term CNE does not produce significant cellular stress.  
Experiments have only been conducted to restrict caloric consumption for more 
than six months to observe an up regulation in brain SIRT1 expression. Six months of 
70% CR increases brain SIRT1 and non-amyloidogenic processing of amyloid precursor 
protein (Qin et al., 2006b). Rats with 60 % CR from weaning to 12 months old showed 
increased SIRT1 levels in the brain (Cohen et al., 2004b). However, CR has been proved 
to provide neuroprotection with a much shorter period of time. Nine months and even 
only 3 months of 70 % to 60 % CR provides neuroprotection to AD and PD mouse 
models (Duan and Mattson, 1999; Wang et al., 2005), and just 2 weeks of 60% CR in 
early adulthood can attenuate A-plaque deposition in mouse models of AD (Patel et al., 
2005). Our study provides the first evidence showing that 4 months of CR (70%) can 
increase brain SIRT1 mRNA levels.  
Nicotine by interacting with nAChRs could activate these cell defense factors 
through a yet unknown pathway. Nicotine decreases the levels of pro-apoptotic factors 
including caspase 3 and cytochrome c while SIRT1 deacetylates Ku70 and subsequently 
blocks activation of caspase 3 and cytochrome c (Garrido et al., 2001; Sawada et al., 
2003; Cohen et al., 2004a; Liu and Zhao, 2004), and down regulation of Nampt has been 
shown to increase caspase 3 cleavage and cytochrome c release (Hsu et al., 2009). In 
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addition, nicotine administration up regulates nerve growth factor (NGF) and its receptor 
TrkB in the hippocampus while SIRT1 activation promotes NGF-induced neurite 
outgrowth in the cells (French et al., 1999; Sugino et al., 2010). Now we know that there 
is not a direct molecular link between activation of nAChRs and SIRT1-related 
longevity genes. The neuroprotection provided by nAChRs and SIRT1 activation was 
through different mechanism. 
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CHAPTER VI 
CONCLUSIONS 
 
Nicotine and nAChR agonists share many similar effects with caloric restriction 
(CR) and SIRT1 activation. First, they both regulate metabolism by decreasing caloric 
consumption and body weight. Nicotine decreases appetite and increases energy 
expenditure, which correlate with the fact that cigarette smokers tend to have lower body 
weights than non-smokers. Second, they both show well-demonstrated neuroprotective 
effects in vitro and in vivo. The goal of this study was to find the possible correlation 
between nicotine’s effects and activation of SIRT1 and its related genes. Using mice that 
lacked high affinity nicotinic receptors, namely 2-/- mice, we first demonstrated that 
2* nAChRs do not directly regulate expression of survival genes. However, we found 
that loss of 2* nAChRs could result in augmented cellular stress, which indirectly 
increases expression of SIRT1, Nampt, and Ku70 as an adaptive response to provide 
protection against neurodegeneration (Chapter II). We also found that loss of 
endogenous activation of 2* nAChRs has less of an effect on synaptic connections but 
strongly impairs survival of hippocampal GABAergic neurons (Chapter III). To activate 
2* nAChRs, we administered nicotine through drinking water, first in a short-term 
study and then in a long-term study. In our short-term study, we determined the dose of 
nicotine to be used in mice, and found that short-term chronic nicotine treatment was 
anxiolytic, decreases caloric consumption, increases nAChR binding sites, and most 
importantly increases expression of SIRT1 and its related genes (Chapter IV). Next, we 
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compared long-term nicotine treatment with CR, which is a known regimen to up-
regulate SIRT1 and its related genes, in middle-aged mice to examine the effects of each 
of these treatments (CR and nicotine treatment) on various aspects of brain aging. Our 
results indicated that in mice long term CR and nicotine treatment both have a tendency 
to improve memory in aging mice, but appear to act through different mechanisms. CR 
treatment up-regulated SIRT1 expression but long-term nicotine did not (Chapter V).  
Cognitive improvement is one of the best established therapeutic effects of 
nicotine (Heishman et al., 2010). In human studies, memory improvement is seen in AD 
and mild cognitive impairment (MCI) subjects given nicotine (Newhouse et al., 1988; 
Jones et al., 1992; White and Levin, 1999; Newhouse et al., 2012). Because nicotine can 
be neurotoxic under certain situations, it is important to elucidate the mechanisms 
underlying nicotine’s neuroprotective effects for better potential therapies against 
neurodegenerative diseases. One proposed mechanism for nicotine to produce 
neuroprotective effects is via regulation of nAChR-containing circuits (Nashmi et al., 
2007; Xiao et al., 2009). In this case, chronic nicotine could regulate the firing rates of 
neurons through nAChRs upregulation and prevent neurons from experiencing bursts of 
firing that could lead to excitotoxic Ca
2+
 influx. At the very least, we demonstrated that 
long-term nicotine treatment does not cause cellular stress nor does it up regulate SIRT1.  
It is known that the effects of acute and chronic nicotine are not the same, and 
this is largely due to the unique phenomenon that the number of nicotine’s receptors 
(nAChRs) can be up-regulated after chronic nicotine treatment. This selective 
upregulation directly results in modified neuronal excitability and neuronal interactions. 
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Here we found that short-term and long-term nicotine treatment also can yield different 
effects in terms of anxiety levels, food consumption, and SIRT1 and its related gene’s 
expression. It would also be interesting to investigate how and why short- and long-term 
nicotine exposure cause different effects when both short- and long-term treatment cause 
an upregulation of nAChRs.  
Nicotinic systems can be manipulated to provide help for neural illnesses such as 
Parkinson's disease, cognitive decline, epilepsy, and schizophrenia. As research in this 
area progresses, we will elucidate the mechanisms of nicotine’s complex effects, 
understanding what pathway is being triggered and how this is accomplished. 
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